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ABSTRACT 
An individual's response to drug therapy is the result of complex 
interactions between environmental and genetic factors. The ability to 
characterise inter-individual variation in response to pharmaceutical intervention 
is of particular importance in a clinical setting, where variation in response can 
result in therapeutic failure or adverse effects in individuals or sub-populations of 
patients. Given the success of NMR-based techniques for metabolic profiling, this 
thesis focused on characterisation of the systems-wide endogenous metabolic 
response to isoniazid and gentamicin. Throughout this work, one-dimensional 1H 
and two-dimensional 1H NMR of biofluids and tissue was applied to generate 
metabolic profiles reflective of response to pharmaceutical intervention in the 
animal model, in conjunction with conventional clinical chemistry and 
histopathological assessment.  
Isoniazid is a widely prescribed anti-tubercular treatment that has toxic side 
effects: it is widely associated with both hepatotoxicity and peripheral 
neurotoxicity in the clinical setting. Here, a relationship was established between 
the post dose profile of drug metabolites and the severity of the adverse effect on 
the central nervous system. Further, the metabonomic approach resulted in the 
identification of pre-dose urinary markers of toxic outcome. 
The aminoglycoside antibiotic gentamicin is a known nephrotoxin. Clinical 
chemistry and histopathology identified clear differences in the degree of 
nephrotoxicity experienced by the rat relative to administration time. 
Complementary metabolic profiling techniques were then applied to the analysis 
of urine and kidney tissue, and identified clear metabolic differences in response 
3 
to treatment time. A final study then explored whether co-administration of a statin 
(atorvastatin) could reduce gentamicin-induced nephrotoxicity in the rat. 
Conventional toxicity assessments indicated that co-administration of gentamicin 
and atorvastatin was non-toxic, while metabonomic analysis of urine and kidney 
tissue indicated that there were metabolic differences, likely linked to the antibiotic 
effect of gentamicin. This work highlights the potential for beneficial drug-drug 
interactions to decrease a drugs toxic effect, as well as the importance of 
considering administration time when developing treatment regimens. 
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Chapter 1 INTRODUCTION 
The activity of any xenobiotic, such as a drug, can be considered in terms 
of its action on the body, i.e. pharmacodynamics, ranging from a therapeutic 
effect to a toxic event, and the action of the body on the xenobiotic, i.e. 
pharmacokinetics, which includes absorption, distribution, metabolism and 
elimination (collectively termed ADME). This thesis focuses on the metabolic 
effects in the animal model of two commonly prescribed therapeutic agents, 
isoniazid, an anti-tubercular drug, and gentamicin, an aminoglycoside antibiotic. 
1.1 DRUG TOXICITY AND ADVERSE DRUG REACTIONS 
The development of a new pharmaceutical is a costly and time-consuming 
process. Figures published in 2003, estimated the cost of getting a new 
compound from discovery to the point of marketing approval at US$802 million. 1 
By 2007, this figure was predicted to rise to US$1.3 billion, in a process that 
would take an estimated 16 years. 2 Many factors contribute to the high cost of 
development but a major problem is the rate of attrition of compounds at various 
stages of the development process: the further a compound gets along this 
developmental pathway before it is rejected, the higher the cost to the 
pharmaceutical company.  
Once a new compound of interest has been identified, it must undergo 
rigorous clinical trials before it can be approved for use. This is by far the most 
costly part of the development process. The trials involve a number of phases and 
possibly thousands of individuals to ensure the drug is both fit for purpose and 
safe to use. However, despite employing numerous in vitro experiments prior to 
these trials, over the ten year period between 1991-2000 almost 90% of all drug 
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candidates have failed during clinical trials, by which point the pharmaceutical 
company will already have invested much time and money into the compound. 3 
Safety issues with drugs are a significant element of this high level of attrition of 
development compounds. A more accurate understanding of the mechanisms of 
toxicity, and the underlying risk factors are necessary to improve both the 
development process and to reduce the incidents of toxicity, which accounted for 
more than 100,000 fatalities in the US in 1994, 4 as well as the withdrawal of 121 
pharmaceutical products between 1960 and 1999 due to post-marketing toxicity 
problems. 5 Ultimately, it is hoped that an improved understanding of the 
mechanisms of toxicity will enable better pre-clinical testing for safety signals, i.e. 
indications of possible adverse reactions, allowing the elimination of compounds 
with safety signals early from the development process. It is also possible that 
improved understanding of toxicity will enable patient stratification, paving the way 
for the development of personalised healthcare and individualised drug regimes. 
A major problem is that individuals vary greatly in their response to 
pharmaceutical intervention. In a clinical setting, this can result in therapeutic 
failure or adverse effects in individuals or sub-populations of patients. While many 
adverse drug reactions (ADRs) can be predicted from the known primary or 
secondary pharmacology of the drug or known metabolite, many ADRs are not 
readily predicted. A number of factors contribute to individual variability and may 
impact on the fate of xenobiotic compounds, including the development of 
toxicities. These factors include age, sex, disease state, drug interactions, and 
genetic factors.  
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1.2 ABSORPTION, DISTRIBUTION, METABOLISM, ELIMINATION 
(ADME) 
Drugs are administered by an enteral (e.g. oral, inhalation) or parenteral 
(e.g. injection) route. Following administration, the drug is absorbed into the 
systemic circulation and distributed throughout the body to its target site. The 
majority of xenobiotics will undergo metabolism, either to produce a 
pharmacologically active species or as a detoxification mechanism. The primary 
site of drug metabolism is the liver, although some metabolism may occur in 
extra-hepatic tissues. All metabolites and unchanged parent compound are then 
eliminated from the body, with the majority excreted in the urine (kidney) or 
faeces (biliary).  
1.2.1 METABOLISM 
Once a drug has entered the body, it will likely undergo a biotransformation 
that will alter both its physical properties and biological effects. In some cases, 
this is necessary for the therapeutic effect of the drug (e.g. isoniazid is a pro-drug 
that must be activated by the bacterial catalase katG). 6, 7 In general metabolism 
leads to loss of therapeutic effect and subsequent excretion, although certain 
biotransformations can lead to the formation of toxic metabolites. Metabolism of 
any xenobiotic can be considered to be a complex process involving interactions 
between mammalian and microbial metabolism. It can be divided into two phases, 
phase  and phase , although they are not necessarily sequential in nature. 
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1.2.1.1 Phase  Metabolism 
Phase  reactions are considered to be functionalisation reactions and 
consist of oxidation and reduction reactions, that alter and create new functional 
groups, and hydrolysis reactions, that cleave esters and amides to release 
masked functional groups, thus preparing the compound for subsequent phase  
reactions. Most phase  reactions are catalysed by cytochrome P450 enzymes, a 
family of haem-containing, mono-oxygenase enzymes, embedded in the smooth 
endoplasmic reticulum that are involved in the metabolism of a range of 
endogenous and exogenous compounds, including steroids hormones, thyroid 
hormones, fatty acids and prostaglandins. 8 Different P450 isoenzymes often 
have distinct, but overlapping, substrate specificity, and genetic polymorphisms 
are common. In humans, CYP2C9, CYP2D6, and CYP3A4 are most involved in 
drug metabolism, accounting for 60-70% of all phase  biotransformations. In 
addition to the cytochrome P450 enzymes, other enzymes may catalyse phase  
reactions. For example, ethanol is metabolised by both alcohol dehydrogenase 
and CYP2E1. Phase  reactions prepare compounds for subsequent phase  
reactions. Flavin-containing mono-oxygenases (FMOs) are another important 
family of enzymes. They catalyse chemical reactions via the bound co-factor 
flavin and oxygenate sulphur- and nitrogen-containing xenobiotics. To date, five 
mammalian forms of FMO have been identified (designated as FMO1 to 5). 
1.2.1.2 Phase  Metabolism 
Phase  reactions can be considered to be conjugation reactions, with the 
resulting conjugate usually pharmacologically inactive and less lipid soluble than 
its precursor. Reactions involve the formation of high energy intermediates via the 
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activation of endogenous metabolites or foreign compounds, and are catalysed by 
a wide range of enzymes, including sulphotransferase (sulphation), UDP-
glucuronyl transferase (glucuronidation) and acetyltransferase (acetylation). 
1.2.1.3 Factors Affecting Xenobiotic Metabolism  
As previously stated a number of factors impact on an individual’s 
susceptibility to idiosyncratic ADRs. The gastrointestinal (GI) tract is home to a 
diverse ecosystem of microbes, collectively known as the ‘microbiota’, 9 that plays 
a key role in metabolism of both endogenous and xenobiotic compounds. 10 This 
complex consortium of microbes (approximately 100 trillion microbes, 11 
encompassing thousands of bacterial phylotypes) is genetically diverse, with 
approximately 100-times as many genes as the human genome. 12 The role of the 
microbiota is diverse, but it is instrumental in energy metabolism and host 
immunity. In addition, it has been associated with the development of a number of 
conditions including obesity, 13, 14 diabetes, 15 inflammatory bowel disease, 16 and 
cancer. 17 Gut microbiota also play a role in drug metabolism, with numerous 
drugs identified as substrates. 18 The exact composition of the microbiota varies 
between individuals, and exerts a strong influence on the individuals metabolic 
phenotype. 19 This in turn can lead to variations in drug metabolism and toxicity; 
paracetamol-induced hepatotoxicity has been linked to gut microbiome 
composition in man. 20 Therefore, differences in microbial composition may be a 
factor in individual drug responses. 
An individual’s response to a pharmaceutical agent will also reflect their 
genetic make-up. The expression levels of a number of enzymes involved in 
xenobiotic metabolism are genetically determined, and genetic differences may 
cause a drug to be detoxified more rapidly or converted to a reactive/toxic 
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metabolite. A number of enzymes are polymorphic in nature, having two or more 
active forms. This can lead to marked inter-individual variation in response. 
Acetylation plays a key role in xenobiotic metabolism. It is catalysed by N-
acetyltransferases, and involves the transfer of the acetyl group from acetyl 
coenzyme A to the acceptor amines, leading to the formation of amides. The N-
acetylating capacity of an individual is genetically determined, resulting in ‘slow’, 
‘fast’, and ‘intermediate’ acetylators. In humans, slow and fast acetylators differ by 
a single autosomal gene. 21 Extensive studies have found that acetylator status 
varies widely between populations, for example, Asian populations have higher 
levels of fast acetylators than Caucasian populations. 22-25  
Genetic polymorphism of P450 enzymes is also extensive. The P450 
alleles carried by an individual will influence the success, or otherwise, of some 
drug therapies. For example, individuals that lack functional CYP2D6 genes will 
metabolise selective substrates at a lower rate, which is likely to be clinically 
important, given the key role played by CYP2D6 in xenobiotic metabolism in 
humans. For example, in the case of the anti-anginal agent perhexilene, poor 
metabolisers will generally have reduced clearance leading to hepatotoxicity and 
peripheral neuropathy. 26 
While there is clearly a genetic component to many idiosyncratic adverse 
reactions, the relationship between genotype and clinical phenotype is complex; it 
is believed that susceptibility to Type B reactions is a multi-factorial process with 
each predisposing gene neither necessary nor sufficient by itself to produce the 
ADR, rather each gene increases the risk of experiencing an ADR. 27 Further, 
there is likely an environmental contribution to the development of ADRs, 
including concomitant drug use, age, sex, and underlying disease state. 
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1.3 TOXINS 
The liver, the major site of drug metabolism, and the kidneys, responsible 
for elimination of the majority of compounds from the body, are both major sites of 
drug-induced toxicity. This thesis looks specifically at isoniazid, a known 
hepatotoxin and neurotoxin, and gentamicin, a known nephrotoxin (gentamicin is 
also ototoxic, i.e. can result in damage to the ear, but this adverse effect was not 
considered in this study). 
1.3.1 ISONIAZID 
Isoniazid (also known as isonicotinic acid hydrazide, isonicotinyl hydrazine 
or INH) is a front-line anti-tubercular drug (Figure 1-1). First synthesised in 1912 
by Meyer and Mally as part of a doctoral research project, 28 its anti-tubercular 
properties were not recognised until the early 1950’s. Despite the widespread use 
of INH, it is associated with a number of adverse effects, ranging from relatively 
mild reactions, such as skin rash, to more severe incidents of hepatotoxicity, 29 
peripheral neuropathy 30 and central nervous system (CNS) effects. 31, 32 
 
Figure 1-1 Isoniazid 
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1.3.1.1 Tuberculosis 
Tuberculosis (TB) is an infectious disease, caused by Mycobacterium 
tuberculosis. Pulmonary TB is the most common form, accounting for 
approximately 75% of cases. Pulmonary TB is characterised by a chronic cough 
with blood-tinged sputum, fever, night sweats and weight loss. Extra-pulmonary 
sites of infection include the pleura, skeleton, and central nervous system. There 
were an estimated 9.27 million incident cases of TB in 2007, increased from 8.3 
million in 2000. Of these 9.27 million cases, the majority were in Asia (55%) and 
Africa (31%), with 2.0 million cases recorded in India in 2007. 33  
1.3.1.2 Treatment 
Antibiotics, administered over a long period of time (typically 6 to 12 
months), are used to treat tuberculosis. In the case of latent TB, i.e. when the 
subject is infected with M. tuberculosis but does not have active TB, the standard 
treatment is isoniazid alone for a period of 6 to 9 months. For active TB, a 
combination treatment of rifampicin, ethambutol, pyrazinamide and isoniazid are 
administered for 2 months, followed by a further 4 to 7 months of isoniazid and 
rifampicin. Some second-line drugs are also available which may be used where 
the infection is likely to be resistant to the first-line agents, or where the use of 
first-line agents has to be abandoned due to unwanted side effects and toxicities. 
These second-line agents fall into 6 categories: aminoglycosides, polypeptides, 
fluoroquinolones, thioamides, cycloserines and -aminosalicylic acid. They are 
generally less effective and may have more severe side effects. The 
recommended dose of INH in man for the treatment of active TB is 5 mg/kg per 
day orally or via intra-muscular injection. 
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1.3.1.3 Resistance 
Mismanagement of anti-TB therapy can lead to the development of 
resistant forms of the infection, either because of poor compliance (due to side 
effects of treatment) or failure to complete the treatment program (symptoms may 
be alleviated within a few weeks, but before the infection has been fully dealt 
with). Resistant TB is generally classified as multi-drug resistant TB (MDR-TB) or 
extensively drug-resistant TB (XDR-TB). MDR-TB is considered to be TB that is 
resistant to at least isoniazid and rifampicin (the two primary drugs for treatment 
of TB), while XDR-TB displays additional resistance to any fluoroquinolone and at 
least one of three injectable second-line drugs (kanamycin, capreomycin or 
amikacin). XDR-TB is therefore resistant to both first- and second-line 
antibacterial agents, seriously limiting treatment options. The rate of MDR-TB 
occurrence varies worldwide but countries of the former Soviet Union, as well as 
some provinces of China, appear to show the highest prevalence of resistance – 
of all new TB cases reported between 1994 and 2007, more than 6% were MDR-
TB. 34 In 2007, there were an estimated 0.5 million cases of MDR-TB, and 26,000 
cases of XDR-TB worldwide. 33  
1.3.1.4 Impact of HIV/AIDS 
AIDS (Acquired Immune Deficiency Syndrome) is a viral disease that 
affects the immune system caused by Human Immunodeficiency Virus (HIV). HIV 
is transmitted through body fluids. The condition is managed through antiretroviral 
treatments which reduce the morbidity and mortality of the infection, and whilst, 
as yet, there is no vaccine or cure, the recent introduction of the CCR5 blocker 
Maraviroc TM from Pfizer has transformed the prognosis of patients with CCR5-
tropic virus. 35 HIV/AIDS compromises the immune system and leaves individuals 
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susceptible to opportunistic infections. One of the most common infections is TB. 
Of the 9.27 million incident cases in 2007, approximately 15% occurred in 
individuals that were HIV-positive, equivalent to 1.37 million cases, with 79% of 
these cases occurring in Africa. According to the World Health Organisation, TB 
co-infection is the single biggest cause of AIDS morbidity. 33 Co-infection of 
HIV/AIDS and TB forms a lethal combination, with each increasing the other’s 
progress. HIV/AIDS weakens the immune system, and consequently an individual 
who is HIV-positive and infected with TB bacilli is many times more likely to 
become sick with TB than someone who is infected but HIV-negative. It is a 
leading cause of death among individuals who are HIV-positive: in Africa, 
HIV/AIDS is the single most important factor contributing to the increase in TB 
incidence since 1990. In New York City, the re-emergence of TB in the 1980’s 
coincided with the emergence of HIV/AIDS, with individuals with AIDS 120 times 
more likely to develop TB than an immune-competent individual. 36 Co-infection 
with HIV/AIDS can also impact on the development of resistance, as individuals 
may not be able to absorb anti-TB drugs as well. 37 In addition, these individuals 
already have a compromised immune system which is unable to assist in fighting 
the infection.  
1.3.1.5 Mechanism of Action 
While the exact mode of action of INH is not fully understood, a number of 
possible mechanisms have been identified that may act additively or 
synergistically. INH enters the bacterial cell by passive diffusion. 6 INH itself is not 
toxic to the bacterial cell, rather it is a pro-drug that is activated by a bacterial 
catalase, katG, 6, 7 with mutations in the katG gene being a major cause of INH 
resistance. 7 katG activates INH by peroxidation to produce either an isonicotinyl 
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acyl anion 38 or an isonicotinyl acyl radical. 39 These INH-derived species couple 
covalently to a form of Nicotinamide Adenine Dinucleotide (NADH), and it is likely 
that this activated INH-NADH complex has a number of targets. The most likely 
target is the disruption of the mycolic acid synthesis pathway, leading to the 
production of a defective cell wall, resulting in the loss of further material from the 
cell and ultimately, bacterial cell death. 40 Earlier work has established that the 
INH-NADH complex is a powerful inhibitor of InhA, a 2-trans enoyl-acyl carrier 
protein reductase enzyme involved in mycolic acid synthesis. 41 Another possible 
mechanism of action includes the formation of reactive oxygen species resulting 
in damage to a number of intracellular macromolecules, including nucleic acids, 
contributing to cell death. 38 The role of free radicals is supported by the finding 
that a free radical scavenger can partially protect mycobacteria against INH. 42  
1.3.1.6 Metabolism 
The metabolic fate of INH in man has been well described and is 
presented in Figure 1-2. 43 Acetylisoniazid (AcINH) is the major urinary metabolite 
of INH, generated by hepatic acetylation of INH by the polymorphic enzyme N-
acetyltransferase 2 (NAT2). 43-45 AcINH is hydrolysed to acetylhydrazine (AcHz) 
and isonicotinic acid (INA), and AcHz undergoes further acetylation to 
diacetylhydrazine (DiAcHz). 29, 46 INA is also formed, along with hydrazine, via 
direct hydrolysis of INH. INA undergoes further metabolism, where it is 
conjugated with glycine by glycine transferase, a mitochondrial enzyme, resulting 
in the formation of isonicotinylglycine (INA-GLY). Individuals vary in their ability to 
conjugate glycine which is unrelated to acetylator phenotype. 46, 47 Rather, glycine 
conjugation is affected by variable expression of glycine transferase and 
availability of glycine, which becomes deficient in low protein diets and is depleted 
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by chronic exposure to toxins. INH also undergoes non-enzymatic reactions with 
the endogenous keto acids pyruvate and 2-oxoglutarate to form pyruvate 
isonicotinylhydrazone (INH-PA) and 2-oxoglutarate isonicotinylhydrazone (INH-
KA), respectively. 48 INH-PA is formed more readily than INH-KA, 49 but the extent 
of hydrazone formation is dependent on the availability of INH. 47 INH is also 
believed to from a Schiff base complex (isoniazidyl-pyridoxal complex, INH-PY) 
with pyridoxal-5-phosphate 50, 51 and conjugates with glucose to form glucose 
isonicotinylhydrazide (INH-GLC). 52 
 
 
 
 
 
 
 
30 
 
Figure 1-2 Scheme proposed for metabolism of INH in mammals including man. 
(Adapted from Timbrell et al. 43) 
Key: AcHz – acetylhydrazine; AcINH – acetylisoniazid; DiAcHz – diacetylhydrazine; INA 
– isonicotinic acid; INH – isoniazid; INH-GLC – glucose isonicotinylhydrazide; INA-GLY – 
isonicotinylglycine; INH-KA – 2-oxoglutarate isonicotinylhydrazone; INH-PA – pyruvate 
isonicotinylhydrazone; INH-PY – isoniazidyl-pyridoxal complex; NAT2 – N-
acetyltransferase 2. 
 
 Earlier studies have identified and quantified the major INH metabolites 
and have shown that in rats the principal metabolites present in urine, 24 hours 
after administration, are AcINH and INA. 43 Table 1-1 gives details of the 
metabolites observed in an earlier study 24 hours after the administration of a 
single low dose of [14C]-INH (100 mg/kg) to an animal cohort (n=3); quantitation 
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and identification of metabolites was carried out by scintillation counting and 
confirmed using reverse isotope dilution. 43 
 
Table 1-1 The metabolism and disposition of [14C]-isoniazid in rats. 
Results are mean values of three animals ± S.E.; INH (100 mg/kg) was given i.p. (From 
Timbrell JA et al. 43). 
Urinary Metabolites % Urinary Radioactivity (0-24 h) 
INH-KA 8.5 ± 1.3 
Isonicotinylglycine 8.8 ± 0.9 
Isonicotinic Acid 18.5 ± 0.4 
INH-PA 8.2 ± 1.2 
Isoniazid 2.1 ± 0.5 
Acetylisoniazid 45.6 ± 2.8  
Total 91.8 ± 1.1 
Key: INH-KA – 2-oxoglutarate isonicotinylhydrazone; INH-PA – pyruvate 
isonicotinylhydrazone. 
1.3.1.7 Adverse Effects  
Though widely used, INH administration in man may be accompanied by 
hepatic damage and peripheral neuropathy with standard therapeutic doses of 
INH. The two most likely causes of INH-induced hepatotoxicity are hydrazine and 
AcHz. Hydrazine, which is formed directly and indirectly following hydrolysis of 
INH and AcINH respectively, is widely used in industrial applications. It is a well-
studied model hepatotoxin and earlier work has shown that it causes fatty liver 53, 
54 and, in some cases, liver necrosis. 55 Hydrazine has been directly linked to the 
hepatotoxic effects of INH, likely due to its metabolism to free radicals capable of 
causing structural damage to liver cells. 56-59 Hydrazine undergoes mono- and di-
acetylation to form AcHz and DiAcHz. AcHz undergoes additional metabolism via 
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the cytochrome P450 microsomal enzyme system, specifically CYP2E1, 60 to 
produce a reactive acylating intermediate that covalently binds to hepatic proteins 
leading to hepatic necrosis in rat models and human populations. 43, 44  
Long-term exposure to INH has also been shown to result in peripheral 
neuropathy. 30 The most common symptoms are numbness and tingling of the 
feet, which may be accompanied by myalgias, weakness, and sensory ataxia. 61 
INH-induced peripheral neuropathy is dose related 61 and susceptibility is highest 
in chronic alcoholics and malnourished individuals, and ‘slow’ inactivators, i.e. 
slow acetylators (see section 3.1.8 for further details). 62 INH has been shown to 
form a complex with pyridoxal-5-phosphate, which is renally excreted, with this 
reaction ultimately depleting the cellular reserve of pyridoxal. 50 Therefore, in the 
clinic, pyridoxine (Vitamin B6) is co-administered with INH to counteract the INH 
depletion of the pyridoxal pool, particularly in the malnourished. 63, 64 
Consequently, peripheral neuropathy following INH treatment is now extremely 
rare.  
The primary site of acute INH-induced toxicity in human and animal models 
is the CNS. 31, 32, 65 Ingestion of 2 to 3 g of INH can cause acute neurotoxicity in 
adults, while ingestion of 10 to 15 g frequently results in death, if not correctly 
treated. 66, 67 Severe acute-INH induced neurotoxicity is characterised by a clinical 
triad of refractory seizures, metabolic acidosis with an elevated anion gap, and 
coma, with symptoms generally observed within 45 minutes and 2 hours post 
exposure. 32, 68 Other clinical signs associated with INH-induced neurotoxicity 
include hyperglycaemia, hypokalaemia, glucosuria, and ketonuria. 32, 69 While it is 
possible that hydrazine may play a role in the development of INH-induced 
neurotoxicity (it is known to cause CNS disturbances), 70 the development of INH-
induced neurotoxicity is most likely linked to the depletion of GABA levels in the 
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brain, as a result of depletion of the cellular reserve of pyridoxal. 50 GABA is an 
inhibitory neurotransmitter and a lack of it can cause seizures. Two enzymes are 
involved in the synthesis of GABA – glutamic acid decarboxylase (GAD) 
synthesises GABA from glutamate, and GABA transaminase (GABA-T) degrades 
GABA into succinate and semi-aldehyde – and both enzymes require the 
presence of the co-enzyme pyridoxal-5-phosphate (the physiologically active form 
of pyridoxal). As previously stated, INH sequesters pyridoxal-5-phosphate, 
reducing the cellular reserve. This in turn reduces the activity of the enzymes 
GAD and GABA-T. Following administration of INH, GAD activity is rapidly 
decreased, reducing the body’s ability to synthesis GABA and leading to a 
reduction in GABA levels. At the same time, there is a fall in GABA-T activity, but 
as this is a more gradual process, it has the net effect of degrading GABA faster 
than it is being synthesised. 71 The overall effect is a depletion of GABA in the 
brain, which leads to excessive CNS stimulation and seizures. 50, 71 The 
importance of pyridoxal in the prevention of INH-induced neurotoxicity has been 
demonstrated in a rat model of vitamin B6-deficient rats that were more 
susceptible to INH-induced neurotoxicity. 72  
1.3.1.8 Acetylator Status and INH-Induced Toxicity 
N-acetylation is an important pathway in the metabolic conversion of a 
number of compounds, including amines, hydrazine, and sulphonamides. Genetic 
polymorphisms have been identified in the genes for the two N-acetyltransferase 
enzymes, NAT1 and NAT2. 73, 74 These enzymes possess differential but 
overlapping substrate specificities, with INH predominantly acetylated by NAT2. 
Genetic polymorphism of NAT2 in man has been shown to give rise to slow, 
intermediate and fast acetylators. 75 Numerous studies have looked at the ratios 
34 
of acetylator phenotypes in different populations: for example, the Japanese 
population was found to have a rapid acetylator ratio of 88% 22 compared to 
approximately 40% in a study of a German population. 25 In contrast, Sprague-
Dawley rats, as used in this study, exhibit a monomorphic acetylation phenotype. 
76, 77 Acetylation of INH is dose related in rat models, and has been shown to be 
saturable in man and rat models after a therapeutic dose. 43, 46, 47, 78 Therefore, 
increasing the dose would be expected to result in a decrease in acetylation and 
an increase in the excretion of unchanged INH and its hydrazones. 
Acetylator status has been implicated in the development of INH-induced 
peripheral neuropathy, 30, 79, 80 with slow acetylators at greatest risk of toxicity. It is 
also believed that slow acetylators are at greatest risk of developing INH-induced 
hepatotoxicity due to their relative inability to detoxify AcHz to DiAcHz. This is 
supported by numerous population studies that have identified a higher incidence 
of INH-induced hepatotoxicity in slow acetylators. 22, 25, 80 Early work on INH 
however suggested that rapid acetylators were at a greater risk of developing 
hepatotoxicity due to rapid formation of AcHz. 29, 81, 82 These studies relied on 
classifying acetylator status using biochemical techniques – for example, 
following administration of sulphadimidine, the concentrations of acetylated and 
free sulphadimidine were determined in urine and blood and if the proportion of 
free acetylated sulphadimidine was less than 25% in blood or less than 70% in 
urine, the individual was classified as a slow acetylator 83 – rather than 
genotyping. Acetylation has also been implicated in the development of acute 
INH-induced neurotoxicity with non-acetylating species, such as dogs, subject to 
more severe toxicity. 84 No human studies have explicitly linked INH-induced 
neurotoxicity to acetylator status. 
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1.3.2 GENTAMICIN 
Gentamicin is an aminoglycoside antibiotic synthesised by 
Micromonospora purpurea. It was first reported in 1963. 85 It is a 4,6-disubstituted 
2-deoxystreptamine (2-DOS) that is administered therapeutically as a group of 
three structurally similar variants, termed C1, C1A and C2 (Figure 1-3). Clinically, 
gentamicin is used in the treatment of meningitis, pneumonia, and sepsis. While 
individual risk factors may contribute to the development of gentamicin-induced 
toxicity, the major factor contributing to organ damage is elevated peak and 
trough serum drug concentrations. Gentamicin-induced nephrotoxicity is related 
to the duration for which the trough serum concentration, i.e. the minimum serum 
concentration, exceeds 2 g/ml, while the risk of developing either ototoxicity or 
vestibular toxicity is highly correlated with elevated peak serum concentration (in 
excess of 10 g/ml). 86 Therapeutically, in patients with normal renal function, 
gentamicin is administered at a dose of 2 to 5 mg/kg daily. 
   
C1    C1A    C2 
Figure 1-3 Structure of gentamicin.  
Gentamicin is administered therapeutically as a combination of three structurally similar 
compounds, C1, C1A and C2. 
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Aminoglycoside antibiotics are a widely prescribed and highly effective 
class of drugs. The first example, streptomycin, was isolated from a strain of soil 
bacteria Streptomyces griseus in 1944. 87 Most aminoglycosides are naturally 
occurring substances produced by actinomycetes of either the genus 
Streptomyces or Micromonospora. Those compounds derived from bacteria of the 
Streptomyces genus (i.e. streptomycin, neomycin, kanamycin etc.) are named 
with the suffix –mycin, where as those that are derived from Micromonospora (i.e. 
gentamicin, amikacin, netilmicin etc.) are named with the suffix –micin.  
1.3.2.1 Structure 
Aminoglycoside antibiotics consist of an amino-cyclitol ring, saturated with 
amine and hydroxyl substituents. In most clinically important compounds, this 
amino-cyclitol moiety is streptamine or 2-DOS; the exception is streptomycin 
which possesses a streptidine molecule. The amino-cyclitol nucleus is connected 
to various amino sugars via glycosidic linkages. The position of these glycosidic 
bonds forms the basis for the structural classification of aminoglycosides. The 
three structural types are the 4,6-disubstituted 2-DOS derivatives, which include 
most of the clinically important aminoglycosides (i.e. gentamicin, tobramycin, 
amikacin and netilmicin), the 4,5-disubstituted 2-DOS derivatives (i.e. neomycin 
and paromomycin), and others (streptomycin) (Figure 1-4). Aminoglycosides are 
basic, strongly polar compounds that are cationic. They are highly soluble in 
water, relatively insoluble in lipids, and have enhanced antimicrobial activity in 
alkaline environments compared to acidic ones. The cationic nature of 
aminoglycosides means they are minimally absorbed from the gut and penetrate 
the blood brain barrier poorly. They cannot be administered orally and must be 
given parenterally. They are metabolically stable compounds that are excreted 
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unchanged in the urine. The major limitations of aminoglycosides include a 
relatively low therapeutic index, lack of oral absorption, and the risk of both 
nephrotoxicity and ototoxicity.  
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Streptomycin     Hygromycin B 
 
 
  
 
 
 R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 
Kanamycin A H H OH OH OH H H H OH CH2OH 
Kanamycin B H H OH OH NH2 H H H OH CH2OH 
Tobramycin H H OH H NH2 H H H OH CH2OH 
Gentamicin C1 CH3 CH3 H H NH2 H CH3 OH CH3 H 
Gentamicin C2 CH3 H H H NH2 H CH3 OH CH3 H 
Gentamicin 
C1A 
H H H H NH2 H CH3 OH CH3 H 
Amikacin H H OH OH OH 
 
H H OH CH2OH 
Figure 1-4 Structural families of aminoglycoside antibiotics. The 2-DOS scaffold is 
highlighted in blue. 88  
 R 
Paromomycin 
 
OH 
Neomycin B NH2 
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1.3.2.2 Mode of Action 
Aminoglycosides are bactericidal due to inhibition of protein synthesis and 
subsequent loss of bacterial cell membrane integrity. This binding does not inhibit 
the formation of the initiation complex of peptide synthesis, rather it impairs the 
proof-reading process controlling translational fidelity, and hence perturbs 
elongation of the peptide chain. The impact is compounded by the secondary 
effects of accumulation of erroneous proteins, i.e. accumulation of these 
truncated and mis-folded proteins in the bacterial cell membrane leads to 
increased cellular permeability. This triggers marked acceleration of intracellular 
accumulation of drug and subsequent cell death. Aminoglycosides are active 
primarily against aerobic Gram-negative bacilli. Table 1-2 lists the major clinical 
uses for aminoglycosides. 89 Aminoglycosides display a concentration-dependent 
bactericidal effect. They also exhibit a post-antibiotic effect, i.e. the persistent 
suppression of bacterial growth after a brief exposure (1 or 2 h) of bacteria to an 
antibiotic. 90, 91 Aminoglycosides are able to produce a synergistic bactericidal 
effect when co-administered with antimicrobial agents that inhibit cell wall 
biosynthesis, such as -lactam antibiotics.  
 
Table 1-2 Clinical uses of aminoglycosides 89 
Aminoglycoside Application 
Streptomycin Tularaemia, tuberculosis and plague 
Gentamicin, amikacin, netilmicin Meningitis, pneumonia, sepsis 
Paromomycin Amoebic dysentery 
Spectinomycin Gonorrhoea 
Neomycin Burns, wounds, ulcers, dermatitis 
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1.3.2.3 Resistance 
Aminoglycoside resistance is mediated by three distinct mechanisms of 
resistance: target site alteration; reduced intracellular drug concentration; 92, 93 
and deactivation by aminoglycoside-modifying enzymes. 94-96 These mechanisms 
may occur in combination. 
Modification of the target site can occur through methylation of the 
aminoglycoside-binding site. Resistance can also be conferred by mutation of the 
ribosomal target, although this is only clinically relevant for streptomycin treatment 
of M. tuberculosis: Mycobacterium is the only genus of eubacteria that contain a 
single copy of the ribosomal operon. Consequently, a single mutation can confer 
resistance. 97 
Reduced intracellular drug concentration due to energy-dependent efflux is 
a major cause of antibiotic resistance, and aminoglycosides have been shown to 
be substrates for a variety of multidrug efflux pumps. 98-100 Intracellular 
concentration can also be affected by mutations in the components of the 
transmembrane transport systems, leading to membrane impermeability.  
The major mechanism of aminoglycoside resistance is via enzymatic 
modification of the amino or hydroxyl groups, resulting in diminished affinity for 
the ribosomal A-site target, and reduced uptake via energy-dependent phase  
(EDP-). 101 More than 20 aminoglycoside-modifying enzymes have been 
identified, falling into three general classes of co-factor dependent enzymes: 
aminoglycoside O-phosphotransferases (APH), aminoglycoside O-
nucleotidyltransferases (ANT), and aminoglycoside N-acetyltransferases (AAC). 
Each class of enzyme is further sub-divided according to site of enzymatic 
modification. 
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1.3.2.4 Toxicity 
The most clinically important adverse effects associated with 
aminoglycoside administration are nephrotoxicity and ototoxicity, observed in man 
and animal models. Aminoglycoside-induced ototoxicity can affect both the 
cochlear and vestibular systems, and individual aminoglycosides differ in their 
ability to cause vestibular versus cochlear damage: streptomycin and gentamicin 
predominantly cause vestibular damage, whereas neomycin and amikacin mostly 
affect hearing. Tobramycin affects both equally. 102 Cochlear damage manifests 
as permanent, bi-lateral high-frequency sensorineural hearing loss, while 
vestibular damage leads to disequilibrium and oscillopsia (i.e. loss of vestibular 
ocular-reflex). Aminoglycoside-induced ototoxicity is believed to be due to the 
generation of reactive oxygen species, which promote apoptotic and necrotic cell 
death. The generation of these species involves the formation of an 
aminoglycoside-iron complex. Several studies support this theory: gentamicin-
induced ototoxicity is inhibited by the use of iron-chelators, 103, 104 while the 
addition of supplemental iron enhances the ototoxic effect of aminoglycosides. 105 
Patient susceptibility to aminoglycoside-induced ototoxicity has been linked to 
genetic predisposition, specifically to an inheritable mutation in the 12S ribosomal 
RNA. To date, five different homoplasmic mutations in the mitochondrial gene 
encoding this region have been found to predispose individuals to irreversible 
aminoglycoside-induced hearing loss. 106-110 It has been suggested that mutation 
increases affinity for aminoglycosides, leading to toxicity in the eukaryotic cell. 
Ototoxicity is potentiated by the concomitant use of other ototoxic drugs, such as 
loop diuretics.111  
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Aminoglycoside-induced nephrotoxicity presents as non-oliguric renal 
failure with varying degrees of tubular dysfunction. 112, 113 It is accompanied by a 
slow rise in serum creatinine and a hyperosmolar urinary output after several 
days of treatment. Aminoglycosides are excreted almost entirely by glomerular 
filtration; approximately 80% of the systemic dose is excreted within 24 hours. 
However, a small proportion (approximately 5-10%) is retained in the tubular 
epithelium of the S1 and S2 segment of the proximal tubules. 114 Aminoglycosides 
are then internalised by endosomes and subsequently transferred to lysosomes, 
where they accumulate and cause phospholipidosis. This ultimately causes the 
lysosome to rupture, releasing acid hydrolases and high concentrations of 
aminoglycosides into the cytoplasm, resulting in disruption to cellular structure 
and function. As aminoglycoside elimination is almost entirely renal, the 
nephrotoxic effect of aminoglycosides can further impair their excretion. A number 
of risk factors have been identified including choice of aminoglycoside and 
duration of therapy, administration time, hypotension, volume depletion, pre-
existing liver disease, and concomitant use of other nephrotoxic agents. 115 
A number of strategies have been employed in order to reduce 
aminoglycoside-induced nephrotoxicity. Renal damage is dependent on uptake 
and accumulation of the drug within the kidney cells, and subsequent 
phospholipidosis. Therefore, reducing accumulation of aminoglycosides by the 
kidney, or reducing lysosomal phospholipidosis once the aminoglycoside has 
been internalised may in turn reduce toxicity.  
Megalin plays a key role in aminoglycoside-induced nephrotoxicity. Also 
known as low-density lipoprotein-related protein 2 or LRP2, megalin is an 
endocytic receptor expressed in the apical surface of the proximal tubular 
epithelium and is responsible for the uptake of aminoglycosides into the 
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endosomes. Therefore, interfering with the activity of megalin should prevent 
accumulation of aminoglycosides, and the resultant toxicity. It has previously 
been shown that gentamicin and other polybasic drugs bind to purified megalin, 
and that a megalin antagonist can inhibit uptake. 116 This is supported by in vivo 
work that found increased urinary excretion of vitamin D binding protein and 
calcium following gentamicin administration, both of which are ligands of megalin, 
suggesting competitive inhibition of megalin binding. 117 Further, co-administration 
of gentamicin and megalin substrates, including cytochrome c, reduced renal 
accumulation of gentamicin, whilest also reducing gentamicin-induced 
nephrotoxicity. 118 In addition, megalin-deficient mice are protected from renal 
aminoglycoside accumulation. 119 
The mevalonate pathway is crucial to megalin function. This pathway is an 
important cellular metabolic pathway found in all higher eukaryotes and many 
bacteria. It produces isoprenoids which are vital for a range of diverse cellular 
functions including growth control and cholesterol synthesis. These isoprenoids, 
such as geranyl-geranyl-pyrophosphate and farnesyl pyrophosphate, are used for 
the modification of GTP-binding proteins. Once modified, and therefore activated, 
these proteins facilitate uptake of aminoglycosides via receptor-mediated 
endocytosis by megalin. The mevalonate pathway is shown in Figure 1-5. 
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Figure 1-5 The mevalonate pathway.  
The bulk product of mevalonate metabolism is cholesterol. Mevalonate is also involved in 
receptor-mediated endocytosis – it is a precursor to geranyl-geranyl-pyrophosphate 
which is necessary for megalin function. (Adapted from Goldstein and Brown. 120)  
 
It has been proposed that co-administration of gentamicin and statins may 
offer protection against gentamicin-induced nephrotoxicity, due to interference 
with the mevalonate pathway. 121 Statins are an important class of drug used to 
lower plasma cholesterol levels. They act by inhibiting the enzyme 3-hydroxy-3-
methylglutaryl co-enzyme A (HMG-CoA) reductase, a rate-limiting step in the 
mevalonate pathway. As well as lowering cholesterol levels, statins also offer a 
potential strategy to prevent aminoglycoside-induced nephrotoxicity in man by 
preventing uptake and accumulation of aminoglycosides in tubular cells. A recent 
in vivo study, showed that gentamicin-induced cell death could be prevented with 
non-toxic doses of a range of statins. The same study also found that co-
incubation with mevalonate reversed this inhibitory effect. 121 
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1.3.2.5 Toxicity and Administration Time – Effect of Circadian Rhythm 
Administration time has a significant impact on the severity of renal 
damage observed following gentamicin administration, with the greatest toxicity in 
the rat model expected following a morning administration time. 122, 123 The 
temporal variation in toxicity has been linked to a subjects food consumption: 
aminoglycosides have been found to be less toxic when administered during the 
period of food intake (which corresponds to the activity period). 124 For laboratory 
animals, the activity period occurs at night, therefore they are more protected 
from gentamicin-induced toxicity when injected in the evening, indicating that the 
presence of food reduces the absorption of the drug. A possible contributing 
factor to the temporal variation observed in aminoglycoside-induced toxicity is 
melatonin. Melatonin (N-acetyl-5-methoxytryptamine) is a naturally occurring 
compound that controls the circadian rhythm of many biological functions. 
Produced by the pineal gland, circulating levels vary throughout the day: it is 
secreted in darkness, and production is inhibited by light. In addition to its role in 
circadian rhythms, melatonin has also been identified as a potent scavenger of 
free radicals and a number of studies have reported that administration of 
melatonin attenuates both the nephrotoxic 125-127 and ototoxic 128, 129 effects of 
gentamicin exposure. 
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1.4 BIOMARKERS OF TOXICITY 
Toxicity is assessed using a number of biomarkers, where a biomarker is 
defined as a ‘characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or pharmacologic 
responses to a therapeutic agent’. 130 Examples of hepatic biomarkers commonly 
measured in clinical chemistry screening include alanine transaminase (ALT), 
aspartate transaminase (AST), alkaline phosphatase (ALP) and total bilirubin. 
These enzymes are all physiologically important and catalyse a number of 
reactions, for example, ALT catalyses the reversible inter-conversion of alanine 
and 2-oxoglutarate (2-OG) to pyruvate and glutamate, while AST catalyses the 
conversion of aspartate and 2-OG to oxaloacetate and glutamate. Cellular 
damage and death results in elevated blood levels of these enzymes due to 
leakage of cellular contents into the bloodstream, for example, elevated levels of 
ALT and AST may indicate hepatocellular necrosis, while elevated levels of ALP 
may indicate cholestatic injury. However, it is worth noting that these markers are 
not mechanism specific, i.e. elevated levels of AST and ALT may be indicative of 
myocardial or muscle damage, or exercise. Although ALT remains the ‘gold 
standard’ biomarker for assessing hepatotoxicity, total bilirubin is also used as a 
marker of hepatic injury, especially choleostasis and biliary effects, though it may 
also be increased by non-hepatic causes such as haemolysis. 131 
Routinely used measures of renal function include blood urea nitrogen 
(BUN) and serum creatinine, both of which are affected by glomerular filtration 
rate. However, they are not region-specific and they increase significantly only 
after substantial kidney damage has occurred. Therefore, earlier and more 
sensitive biomarkers of nephrotoxicity are needed. Proteomic and genomic 
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approaches have lead to the identification of a number of possible biomarkers of 
renal damage. These include kidney injury molecule-1 (designated as Kim-1 in 
rodents and KIM-1 in humans), neutrophil gelatinase-associated lipocalin (NGAL 
or lipocalin-2), N-acetyl--glucosaminidase (NAG), clusterin, and cystatin-C. The 
relative advantage and disadvantages of each are summarised in Table 1-3. 
 
Table 1-3 Potential biomarkers of kidney injury (Adapted from Vaidya et al. 132) 
Biomarker Comments Species 
Kidney injury 
molecule 1  
(KIM-1) 132, 133 
Type-1 cell membrane glycoprotein containing a six 
cysteine immunoglobulin-like domain and a mucin 
domain in its extracellular domain; up-regulated in 
dedifferentiated proximal tubule epithelial cells. 
Advantages: 
Elevated urinary levels are highly sensitive and specific 
for acute kidney injury (AKI). 
Earlier diagnostic indicator of kidney injury, compared 
to conventional markers (30-fold increase reported 
after 3 daily doses of gentamicin; no significant 
changes in BUN or serum creatinine 133) 
Up-regulated following various models of preclinical 
and clinical AKI, fibrosis, renal cell carcinoma, and 
polycystic kidney disease. 
Zebra-
fish, 
mouse, 
rat, dog, 
monkey, 
human. 
Neutrophil 
gelatinase-
associated 
lipocalin, 
lipocalin-2 
(NGAL) 132, 134 
25kDa protein, initially identified bound to gelatinase in 
specific granules of the neutrophil. 
Advantages: 
Sensitive – expression up-regulated following ischemic 
or cisplatin induced renal damage. 
Early indicator of AKI following cardiopulmonary 
bypass. 
Disadvantages: 
Specificity to sepsis needs to be established. 
Mouse, 
rat, 
human 
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N-Acetyl--
glucosaminidase 
(NAG) 132 
Proximal tubule lysosomal enzyme. 
Advantages: 
Sensitive – elevated following subtle alterations in 
epithelial cells of brush border of proximal tubules; 
amount of enzyme can be directly correlated to tubular 
injury. 
Extensive preclinical and clinical data available under a 
variety of conditions. 
Disadvantages: 
Activity may be inhibited by endogenous urea, some 
nephrotoxicants and heavy metals. 
Non-specific – elevated levels reported in absence of 
clinically significant AKI (e.g. rheumatoid arthritis). 
Mouse, 
rat, 
human 
Clusterin 132, 135 Multi-faceted glycoprotein. Induced in kidney and urine 
after various forms of preclinical AKI; expressed in 
dedifferentiated tubular epithelial cells. 
Advantages: 
Elevated kidney and urinary levels are very sensitive 
for AKI in preclinical models. 
Up-regulated in various rodent models of AKI, fibrosis, 
renal cell carcinoma, and polycystic kidney disease. 
Disadvantages: 
No clinical study demonstrating use. 
Mouse, 
rat, dog, 
monkey, 
human 
Cystatin-C  
(Cys-C) 132, 134 
13kDa protein; extracellular inhibitor of cysteine 
proteinases. 
Advantages: 
Sensitive serum marker of glomerular filtration rate – 
strong predictor of death and cardiovascular events in 
older patients. 
Serum concentrations appear to be independent of 
age, sex, muscle mass. 
Mouse, 
rat, 
human 
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Despite extensive work, the value of current biomarkers when considered 
in isolation is limited. Many lack specificity and in terms of detecting changes in 
the levels of these biomarkers, timing is critical: unless the toxicological insult is 
very severe (in which case there may be other signs to indicate damage), the 
enzyme levels may, over time, return to normal. Therefore, a more specific and 
less invasive technique for identifying biomarkers is needed, and the biomarker 
itself must be detectable before any gross morphological or functional change 
takes place. Ideally the biomarker should occur at an early stage in the 
development of toxicity so it can be predictive, or enable therapy to be terminated 
before irreversible damage has occurred. 
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1.5 METABONOMICS AND TOXICITY 
Recently the focus has shifted towards identifying potential metabonomic 
biomarkers of toxicity. Metabonomics is defined as ‘the quantitative measurement 
of the dynamic multi-parametric metabolic response of living systems to 
pathophysiological stimuli or genetic modification’. 136, 137 Metabolic profiles of 
biofluids and tissues present a means of visualising the complex relationship 
between genetic background, environmental factors, such as diet, nutritional 
status, and lifestyle, and extra-genomic influences such as gut microfloral 
composition. 136, 138 Metabonomic investigations generally utilise high resolution 
nuclear magnetic resonance (NMR) spectroscopy, as in this current work, or 
employ a liquid chromatography mass spectrometry (LC-MS) based analytical 
strategy. For the purpose of this current work, an NMR-based approach was 
employed because it facilities rapid, simultaneous characterisation of endogenous 
and drug-related metabolites. Metabolic profiling can be applied to a range of 
biological fluids, intact tissues, and tissue and cell extracts; urine and serum are 
most commonly used. Interpretation of metabolic profiles is facilitated by the 
application of an array of multivariate statistical modelling techniques, which 
reduce complexity and increase ease of interpretation.  
Metabonomic methods offer a complementary approach to conventional 
methods of toxicological assessment. Any change in either the physiological or 
external conditions to which an individual is subjected will result in a change in 
their metabolic profile as the organism attempts to compensate. The change may 
be significant, i.e. the appearance of a previously unseen metabolite, or more 
subtle, i.e. a change in the relative concentration of metabolites. 139 While a dose-
related change in the levels of drug metabolites can in general, be predicted, 
51 
perturbation of endogenous metabolite levels may be indicative of both the target 
and the nature of the toxic insult, for example, renal papillary damage is 
accompanied by a combination of changes in the urinary levels of trimethylamine-
N-oxide, N,N-dimethylglycine, dimethylamine and succinate. 140, 141 Studies 
involving high resolution spectroscopic techniques combined with multi-variate 
statistics have been shown to be useful in the elucidation of mechanisms of 
toxicity, 142, 143 and the identification of outliers. 144, 145 In addition, the application 
of metabonomic techniques enables metabolic changes to be followed across 
time, showing the onset, progression, and, where applicable, recovery from toxic 
insult, while identifying differential rates of response to pharmaceutical 
intervention. 144, 146 
As the main site of xenobiotic metabolism, much emphasis has been 
placed on the characterisation and identification of metabonomic biomarkers of 
hepatotoxicity. Previous metabonomic studies have characterised the metabolic 
impact of a range of model hepatotoxins, including hydrazine, 147-149 
acetaminophen, 150 galactosamine, 141, 142, 145 and 1-naphthylisothiocyanate. 151 
One such study looked at different classes of hepatotoxin including steatotic, 
cholestatic, and necrotic, and classified then according to their metabolic profiles. 
A single administration of INH at 110 mg/kg (male Wistar rats, n=5) resulted in the 
detection of decreased urinary levels of succinate, dimethylamine, 2-oxoglutarate, 
and hippurate via NMR spectroscopy, although there was no significant change in 
plasma levels of ALT and AST and histopathological examination identified only 
moderate hepatocellular rarefaction. 152 Unfortunately a number of other possible 
biomarkers of INH-induced toxicity were unassigned in this study. Recent work by 
Sumner et al. applied NMR-based metabonomic techniques to the identification of 
a non-invasive biomarker of microvesicular lipid accumulation (MVLA) in the liver 
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following INH administration at 10 and 300 mg/kg/day for up to 8 days. 153 
Perturbations in levels of serum enzymes (ALT, AST, sorbitol dehydrogenase) did 
not correlate with histopathological assessment of MVLA, but NMR analysis of 
urine and kidney extracts showed significant perturbations in a number of 
metabolic pathways. MVLA was characterised by changes in amino acid and 
pyrimidine metabolism and in biochemical energy pathways (TCA cycle, 
glycolysis). Further work is needed to fully elucidate the metabolic impact of INH. 
Besides the liver, the kidney is the major site of drug-induced toxicity, and 
there have been numerous studies focused on nephrotoxicity. Early efforts have 
successfully classified renal damage as proximal tubular or medullary in nature 
for a range of nephrotoxins. 154 In each case, a reproducible and distinct pattern 
of metabolites was observed using 1H NMR urinalysis, although this study did not 
include any aminoglycosides. Specifically, initial increases in levels of 
trimethylamine-N-oxide (TMAO) and dimethylamine, followed by elevated levels 
of acetate, succinate, lactate, and alanine were found to be reflective of proximal 
tubular injury. 154 Following gentamicin exposure at 40 mg/kg over a period of up 
to 28 days, the earliest metabolic change seen was aminoaciduria, with significant 
increases in urinary amino acids after a single dose. 155 The same study also 
detected a significant increase in the excretion of polyamines after a single dose 
which decreased gradually at later time points. Analysis of kidney tissue using 
LC-MS revealed reductions in nucleosides, with the effect becoming more severe 
as dosing continued. Other metabolites identified as potential early biomarkers of 
gentamicin toxicity were myo-inositol, 3-hydroxybutyrate (both significantly 
increased after a single dose; the increase persisted for duration of exposure), 
phosphate (significantly increased after single dose only), and 5-
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methyltetrahydrofolate (significantly decreased in kidney tissue up to 5 days post 
dose). 155 
A recent study by Sieber et al. looked at the relative benefits of renal 
biomarkers, such as KIM-1 and NGAL, compared with metabolic profiling for the 
assessment of gentamicin-induced nephrotoxicity. 156 Although they observed a 
clear time- and dose-dependent separation of gentamicin treated animals from 
controls using principal component analysis (PCA; separation was based on 
reduced levels of citrate, hippurate, N-methylnicotinic acid, and 3-indoxylsulphate 
and increased lactate, glucose and N,N-dimethylglycine), they highlighted the 
need for accurate metabolite identification and mechanistic interpretation. On this 
basis, they favoured the use of KIM-1 and NGAL as biomarkers of renal damage: 
they were detected prior to significant clinical changes, offered good sensitivity 
and were mechanistically anchored.  
The study protocol used by Sieber et al. 156employed a combined 1H NMR 
and gas chromatography mass spectrometry (GC-MS) methodology to assess 
chronic toxicity in the male Wistar rat, and was based on an earlier study 
conducted by Lenz et al., which utilised 1H NMR and LC-MS. 157 The key 
metabolic changes noted in the earlier study by Lenz et al. were increases in 
urinary levels of TCA cycle intermediates (i.e. citrate, 2-oxoglutarate), and 
dimethylglycine, and reduced levels of TMAO and betaine after 3 days. By day 9, 
the gentamicin treated animals displayed marked glucosuria, increased excretion 
of N-acetyl glycoprotein, citrate and lactate, coupled with reduced urinary 
excretion of TMAO and betaine. In addition, they noted the presence of elevated 
levels of an unidentified singlet at  1.39 in the day 9 urine sample. 157 The 
metabolic changes observed in response to gentamicin administration in these 
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studies can be considered to reflect both the pharmacological, i.e. antibiotic, and 
toxicological activity of gentamicin.  
1.5.1 PHARMACOMETABONOMICS –  PREDICTING TOXICITY 
While metabonomics may enable the early detection of a toxic event, the 
ultimate goal is to avoid toxicity. This offers advantages for both pharmaceutical 
development and clinical use; those individuals with an intrinsic risk of developing 
toxicity can be excluded from the testing process or prescribed a more 
appropriate pharmaceutical agent. Consequently, metabonomics has been 
applied to the prediction of toxic outcome. Termed ‘pharmacometabonomics’ (the 
prediction of the outcome of a drug or xenobiotic intervention in an individual 
based on a mathematical model of pre-intervention metabolite signatures), it 
takes into account both genetic variation and the environmental factors that 
impact on an individual’s response to a drug. 20, 158-162 The 
pharmacometabonomic approach has been successfully applied to the prediction 
of individual response to paracetamol, in rat and human models. 20, 158, 160 
Paracetamol is detoxified in the liver, via sulphation, to paracetamol sulphate, and 
via glucuronidation, to paracetamol glucuronide. The parent compound also 
undergoes metabolism to form the toxic metabolite N-acetyl-p-benzoquinone 
imine (NAPQI), which is subsequently detoxified via conjugation with glutathione. 
Paracetamol toxicity can occur due to overdose of paracetamol which this 
saturates the detoxification pathways, lack of glutathione as observed in chronic 
alcoholics, or increased production of NAPQI. Depletion of glutathione combined 
with direct mitochondrial damage due to NAPQI and covalent binding of NAPQI to 
hepatic protein, leads to cell necrosis and death. Following administration of a 
single toxic-threshold dose of paracetamol to an animal cohort (n=65), two pre-
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dose models were developed with respect to classification of pre-dose profiles. 
One showed an association between the pre-dose spectra and the 
histopathological necrosis severity score after paracetamol exposure, while the 
second predicted the ratio of post dose paracetamol to paracetamol glucuronide 
(one of the major metabolites of paracetamol) from pre-dose urinary spectra. 158 
The pharmacometabonomic approach has also been applied to the investigation 
of paracetamol metabolism in humans. 20 A clear association was identified 
between an individual's pre-dose urinary metabolic profile and the post-dose 
profile of paracetamol metabolites, specifically that individuals with high pre-dose 
levels of -cresol sulphate had low post-dose ratios of paracetamol sulphate to 
paracetamol glucuronide. -Cresol sulphate is derived from -cresol by sulphation 
using the same sulphotransferases as paracetamol. -Cresol is not a human 
molecule rather it is derived from gut bacteria, specifically Clostridium species. 
Excess -cresol depletes sulphation capacity. Researches concluded that those 
individuals with high levels of bacterial -cresol would have depleted sulphonation 
capacity and potentially be at greater risk of developing paracetamol-induced 
toxicity. 20 Winnike et al. demonstrated a correlation between pre-dose levels of 
glycine, a component of glutathione, and development of post dose paracetamol-
induced hepatotoxicity. 160 All three studies suggested that it may be possible to 
predict an individual's response to paracetamol exposure based on their pre-dose 
metabolic profile. 20, 158, 160 
Recently, pharmacometabonomics has been utilised in the clinical 
oncology setting. 161, 162 Chemotherapy-induced toxicities limit the ability to deliver 
effective treatment and a recent pharmacometabonomic study has enabled the 
successful prediction of toxic responses to cancer therapy. Through the 
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application of high resolution NMR-based methodology, researchers were able to 
identify a metabolic signature associated with capecitabine-induced toxicity. 162 
Furthermore, they identified a gradation of this profile that correlated with the 
severity of toxicity experienced. 162 Pharmacometabonomics has also been used 
to predict the efficacy of anti-cancer treatment in breast cancer patients. 161 
Stebbing et al. identified an association between sera levels of lactate, glucose 
(both elevated) and alanine (reduced) and disease progression in 
postmenopausal women undergoing chemotherapy. 161 
Metabonomics can therefore offer a means of gaining a better 
understanding of the mechanisms of different types of toxicity as well as 
identifying those individuals at greatest risk of developing these types of toxicity, 
prior to pharmaceutical intervention. Many drugs are known to have toxic side 
effects, but are still used as they offer the best, and sometimes only, treatment for 
particular conditions. Identifying those individuals at greatest risk of experiencing 
drug-related toxicity could allow judgements to be made based on the ratio of risk 
to benefit. 
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Chapter 2 ANALYTICAL STRATEGIES 
Throughout this work, an NMR-based metabolic profiling strategy has been 
applied to interrogate and understand the aetiology of toxic responses to isoniazid 
and gentamicin, through the analysis of a range of biofluids, including urine, 
serum and intact tissue. NMR spectroscopic profiling enables simultaneous 
characterisation of metabolites from many classes. The metabolic changes can 
be further characterised through the application of pattern recognition (PR) 
techniques.  
2.1 NUCLEAR MAGNETIC RESONANCE 
2.1.1 GENERAL PRINCIPLES OF NMR 
NMR is a powerful analytical tool, which results from the interaction 
between the intrinsic angular momentum of a nucleus (its spin) and an external 
magnetic field. The spin quantum number of a nucleus is dependent upon the 
number of protons and neutrons present, and is the fundamental determinant of 
whether a particular nuclei will exhibit magnetic resonance phenomena. Nuclei 
with even numbers of protons and neutrons possess a spin quantum number of 0, 
so are NMR inactive. Nuclei with odd numbers of protons and/or neutrons 
possess spin and are therefore detectable in NMR. The rules for determining the 
spin quantum number are: 
 Nuclei with even numbers of protons and even number of neutrons have a 
spin of zero, e.g. 12C, 16O and 32S. 
 Nuclei with odd numbers of protons and odd numbers of neutrons have spin 
values of 1, 2, 3 etc. Examples include 2H and 14N. 
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 Nuclei where the number of protons plus the number of neutrons is odd 
possess half-integral spin values of 1/2, 3/2, 5/2 etc. Examples include 1H, 
13C, 15N and 19F. 
The most commonly studied nuclei in biological systems are 1H and 13C, 
which have a natural abundance of 99.9% and 1.11%, respectively, and both 
possess spin of ½. Other nuclei commonly studied by NMR include 19F and 31P.  
 When an external magnetic field (Bo) is applied, nuclei that possess spin 
½ will adopt one of two spin states: parallel (-state, lower energy) or anti-parallel 
(-state, higher energy) to the applied magnetic field. Therefore a nucleus with a 
spin of ½, will adopt a spin state of either +½ or –½. The population of each spin 
state is described using the Boltzmann distribution: 
Nα / Nβ = e
ΔE / KT 
where Nα and Nβ are populations of the α and β states, K is the Boltzmann 
constant, T is the temperature in Kelvin and ΔE is the difference in energy 
between the two spin states α and β. The parallel orientation () has the lower 
energy level and consequently will have slightly more nuclei than the higher 
energy level. ΔE is small, and the population difference between the two spin 
states is correspondingly small. Therefore, NMR is relatively insensitive. 
Once aligned with the applied magnetic field, the nuclei precess in the 
same direction about the axis of the applied field (Figure 2-1), in what is termed 
the Larmor precession.  
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Figure 2-1 In an external magnetic field (Bo), nuclei with a spin of ½ can precess 
either parallel or anti-parallel to the field. 163  
 
The rate of precession, i.e. the Larmor frequency of a nuclei (), is defined as:  
 =  B0 / 2π 
where  is the gyromagnetic ratio (also known as magnetogyric ratio), and 
Bo is the applied magnetic field. NMR spectroscopy manipulates the orientation of 
the nuclei through the application of an additional magnetic field, i.e. the NMR 
pulse that forces some of the nuclei in the low energy state to adopt a higher 
energy level. The frequency of this transition energy matches that of the Larmor 
frequency of a specific nuclei. Therefore the energy required to change spin 
states is: 
E = h = h .  B0 / 2 
where h is Plancks constant,  is the Larmor frequency, B0 is the applied 
magnetic field and  is the gyromagnetic ratio. When the applied radiofrequency 
energy is removed, the nuclei relax back to their original energy state. It is this 
period of relaxation, termed the free induction delay or FID that is measured 
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during the acquisition of a NMR spectrum. The FID consists of two independent 
components characteristic of nuclear relaxation: the longitudinal or spin-lattice 
relaxation time (T1) and the transversal relaxation time (T2). The longitudinal 
relaxation time is the time constraint for the recovery of the magnetisation along 
the direction of B0, and the transversal relaxation time is the time constraint for 
decay of magnetisation in the x-y plane. The decay of T2 occurs approximately 5-
10 times more rapidly than T1 recovery, and these relaxation times are dictated by 
the speed of molecular rotation and its size. 
Nuclei in different chemical environments experience different values of B0 
due a phenomenon termed chemical shielding, which is mediated by the 
electrons in a molecule. Chemical shielding is influenced by a number of factors 
including the inductive effects of electromagnetic groups, the magnetic anisotropy 
of -systems, and hydrogen bonding. Typical chemical shift values for common 
organic functional groups are presented in Figure 2-2.  
 
 
Figure 2-2 Typical 1H chemical shift values for some common organic functional 
groups. 164 
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Additional spectral information is provided by the splitting pattern of the 
signals, which occurs due to the interaction between neighbouring groups. 
Splitting offers a detailed insight into the connectivity of atoms within a molecule. 
Active nuclei that are close to one another exert an influence on each other's 
effective magnetic field. If the neighbouring active nuclei are non-equivalent, the 
effect is observable in the resultant NMR spectrum. This is termed spin-spin 
coupling or J-coupling and is mediated by the electrons in the bonds that link the 
coupling nuclei. The complexity of the splitting pattern is directly related to the 
number of neighbouring nuclei. The multiplicity of splitting follows the general rule 
of n + 1, determined by the number of protons (n) on the adjacent atoms. For 
example, a nucleus with two neighbouring chemically equivalent protons gives a 
resonance signal with a triplet form. The distance between two peaks in a 
multiplet is termed the J-constant, and is independent of the applied magnetic 
field (i.e. not field strength dependent). This is an example of “First-Order” 
splitting, and assumes that the spin-coupled nuclei have very different chemical 
shifts. If the chemical shift difference between the spin-coupled nuclei decreases, 
then the splitting pattern may be distorted. This is termed “Second-Order” 
splitting. Second-order effects decrease as the frequency difference between the 
multiplets increases, therefore NMR spectra display less distortion at higher 
frequency.  
It is also possible to determine the number of 1H nuclei contributing to an 
individual signal (or peaks, in the case of a multiplet), as the signal area is directly 
proportional to the number of 1H nuclei responsible for that signal. Hence NMR is 
inherently quantitative. 163 Absolute and relative concentrations can be 
determined from the intensities of signals relative to the intensity of an internal 
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standard of known concentration, e.g. TSP, or to other endogenous signals, 
respectively, providing that all signals of interest are fully or equivalently relaxed. 
2.1.2 ONE AND TWO DIMENSIONAL NMR  EXPERIMENTS 
Throughout this study a number of one-dimensional (1D) and two-
dimensional (2D) homo- and hetero-nuclear sequences were utilised. 163 The 
main features of each are summarised below. 
1D pulse programs were used extensively in this study. The simplest 1D 
pulse program consists of a radiofrequency pulse, followed by acquisition of the 
FID. The radio frequency pulse is repeated multiple times to improve the signal to 
noise ratio, and subsequent interpretation of the spectra. Throughout this study, 
1D spectra were acquired using the first increment of a 2D Nuclear Overhauser 
Effect Spectroscopy (NOESY) pulse. 165 This pulse sequence with solvent 
suppression has the form [-relaxation delay-90o pulse-3 s delay-90o pulse-tm-90
o 
pulse-acquire FID-], where tm is the mixing time. 
165 Water is present at high 
concentrations in biofluids (typically 110 M for 1H NMR), and results in an 
extremely large NMR signal that is likely to obscure other spectral information as 
analytes of interest are typically present at micromolar concentrations. Therefore, 
pre-saturation of the water resonance occurs during the relaxation delay of the 
NOESY sequence.  
High molecular weight molecules typically display broader resonances than 
smaller ones as they possess shorter T2 spin relaxation times due to the limited 
rotational and translational motion of large molecules. The Carr-Purcell-Meiboom-
Gill (CPMG) 166 spin-echo pulse sequence enables T2-spectral editing. The pulse 
sequence, [-relaxation delay-90o pulse-(t-180o pulse-t)n-acquire FID-] where t is 
the spin echo delay and n represents the number of loops, reduces the broad 
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resonances from these macromolecules, facilitating the observation of low 
molecular weight compounds. This pulse sequence is widely utilised for the 
analysis of plasma samples, due to their high lipid and protein content.  
2D NMR spectroscopic techniques provide useful information for structural 
elucidation, and have been employed throughout this work. The 2D 1H- 1H J-
resolved experiment (or JRES) provides information on the multiplicity and 
coupling patterns of resonances. 167 Further examples of 2D homonuclear pulse 
sequences include correlation spectroscopy (COSY) 168 and total correlation 
spectroscopy (TOCSY), 169 which provide spin-spin coupling connectivities. 
COSY identifies correlations between directly coupled protons, whilst TOCSY 
establishes correlations between protons that reside within the same spin system. 
In addition to homonuclear 2D experiments, 13C can be used in 
heteronuclear correlation experiments such as 1H-13C heteronuclear single 
quantum coherence spectroscopy (HSQC) 170 and 1H-13C heteronuclear multiple 
bond coherence spectroscopy (HMBC). 171 HSQC identifies directly coupled 
nuclei while HMBC is used to establish long-range correlations, typically over two 
or three bonds, thereby providing a wealth of information on the molecular 
skeleton.  
2.1.3 SOLID STATE NMR  –  MAGIC ANGLE SPINNING-NMR  
(MAS-NMR) 
The development of high resolution 1H magic angle spinning (MAS) NMR 
enables the acquisition of high resolution NMR data from intact tissues with no 
pre-treatment. 172, 173 A small sample (typically 10 – 20 mg), is spun rapidly 
(typically at 5 kHz) at the magic angle () of 54.7o relative to the applied magnetic 
field. MAS-NMR eliminates many of the line broadening effects due to sample 
64 
heterogeneity, dipolar couplings, and chemical shift anisotropy, resulting in sharp, 
well-resolved spectral lines. All common pulse programs (as described above) 
can be used with MAS-NMR to study metabolic changes and assist in structural 
elucidation. 
2.1.4 PROCESSING OF NMR SPECTRAL DATA 
Prior to the application of suitable PR techniques, data must be pre-
processed. The FID is Fourier transformed to convert the time domain signal to 
the frequency domain, producing the NMR spectrum. The resulting spectrum 
consists of a series of signals with different multiplicities and chemical shift values 
(), reported relative to a reference value. In this work, deuterated 3-trimethylsilyl-
[2,2,3,3-2H4]-propionic acid sodium salt (TSP,  = 0.0) was used as a reference. 
Spectra are phased and subject to polynomial baseline correction. Finally, 
spectral regions that contain noise or offer no diagnostic value are removed. 
Typically this includes the TSP resonance ( -0.2 to 0.2), water (typically from  
4.5 to 5.0) and, where present, the urea resonance ( 5.5 to 6.1).  
Once NMR spectral data has been suitably processed and redundant 
regions have been removed, spectra must be aligned. A number of factors may 
potentially impact on chemical shift differences resulting in uncontrollable 
variation in peak positions between samples. These include instrumental 
imperfections, such as temperature variation and inhomogeneity in the applied 
magnetic field, and pH shifts arising from small differences in the amount of either 
the molecule itself or components of the surrounding matrix. Differences in ionic 
strength can also impact on peak position; this is especially relevant for the 
analysis of urine samples where there is likely to be considerable inter-subject 
variation in both sample dilution and content. Variation in peak position can result 
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in spurious groupings of samples in multivariate models, therefore a number of 
strategies exist to address the issue of variable peak position across multiple 
spectra. Throughout this work the recursive segment-wise peak alignment 
(RSPA) method was employed, 174 to account for chemical shift variation between 
the samples. 
Next, the data is normalised. Normalisation is a mathematical correction 
applied to experimental data to make all samples directly comparable with each 
other by correcting for variations in volume and concentration. Throughout this 
study, data was normalised using probabilistic quotient normalisation. 175 
Probabilistic quotient normalisation assumes that changes in the concentrations 
of single analytes only influence parts of the spectra, whilst changes in the overall 
concentration of a sample influence the complete spectrum. It has been 
demonstrated that probabilistic quotient normalisation is not hampered by 
extreme levels of metabolites, i.e. drug metabolites, and is sensitive to samples 
with low levels of metabolic variation. 175 Other commonly applied techniques 
include normalisation to total area, whereby the total spectral area of each 
spectrum is set to unity and the intensities of all data points are expressed relative 
to this, and normalisation relative to a specific peak (such as TSP or creatinine).  
Scaling is performed on the columns of data, i.e. on each spectral intensity 
across all samples. 176 A number of scaling methods are commonly used. Data is 
first mean centred to improve interpretability. Mean-centring removes the offset 
from the data by calculating the average value of each variable, which is then 
subtracted from the data. This technique is particularly good for identifying large 
metabolite differences but it may mask discrete metabolite changes. Autoscaling, 
also called unit or unit variance scaling, is commonly applied to metabonomic 
data and was employed throughout this study. Each variable is divided by its 
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standard deviation so all variables have a standard deviation of one, and are 
equally important. A full review of pre-treatment methods has been published by 
van den Berg et al. 176 
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2.2 CHEMOMETRICS 
Spectral data sets are complex and a number of PR techniques are used 
to reduce the dimensionality of complex data sets to allow inherent patterns to be 
rapidly visualised and enable the identification of discriminatory metabolites. 177 
PR techniques are divided into ‘unsupervised’, such as Principal Component 
Analysis (PCA) and ‘supervised’ such as Partial Least Squares Discriminant 
Analysis (PLS-DA), PLS-Regression Analysis, Orthogonal Partial Least Squares 
Discriminant Analysis (O-PLS-DA) and O-PLS-Regression Analysis methods. 
Both methods were employed extensively in this work.  
2.2.1 PRINCIPAL COMPONENT ANALYSIS (PCA) 
PCA is a common ‘unsupervised’ technique used to establish if there is any 
structure in a data set related to the experimental design without the use of any a 
priori knowledge. PCA involves a mathematical procedure in which a number of 
variables, in this case spectral data points, are transformed into a smaller number 
of components called principal components or PC, which are a linear combination 
of variables. 178 The first PC (PC1) accounts for the direction in the 
multidimensional space explaining as much of the variance in the data as 
possible, with each subsequent orthogonal PC accounting for as much of the 
remaining variance as possible. The PCs are plotted to give a low dimensionality 
representation of the data set. The plot will show any inherent clustering due to 
the major sources of variation influencing the samples, e.g. the action of a drug or 
toxin, and the position of a sample is entirely independent of any knowledge of 
class membership, hence the model cannot be over fitted. The results of PCA are 
presented as scores (t) and loadings (p) plots. A scores plot allows visualisation 
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of the data in, typically two or three PC dimensions, and summarises the 
similarities and differences between the spectra, with each sample represented 
by a single data point; two widely spaced data points indicate a high degree of 
variation between the metabolic profiles. Figure 2-2 details how PCA scores are 
calculated. The corresponding loadings plot will describe the original variables 
importance to each PC.  
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Figure 2-3 PCA Scores (from reference Tsang) 179.  
(a) Principal Component 1 (PC1) is the vector that best accounts for the variation in the 
data. (b) The second principal component (PC2) is orthogonal to PC1, to account for the 
next most amount of variation in the data. Each subsequent component is orthogonal to 
the previous component. (c) The observations are visualised in a lower dimensional 
plane, the scores plot. (d) Each observation (i) is projected onto the PC and a new 
coordinate value is obtained; ti1 is the distance of observation to PC1. 
179 
2.2.2 PARTIAL LEAST SQUARES (PLS)-BASED TECHNIQUES 
Partial Least Squares (PLS) relates a matrix containing variables from 
samples (for example, spectral data, the X matrix), to a second matrix containing 
outcome variables (for example, toxicity scores, the Y matrix). PLS aims to 
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construct a model that ‘maximises the co-variation between the measured data 
(X), e.g. the spectral data, and the response variable (Y)’. 139 PLS has been 
successfully used for multiple regression where Y contains continuous data. PLS 
can be combined with discriminant analysis, termed PLS-DA, to maximise the 
discrimination between the two classes by using a dummy Y matrix to enable the 
data to be modelled according to class, enabling sample classification. PLS-DA is 
considered to be a supervised pattern recognition technique because it uses prior 
information about classes to compute its components. PLS-DA can be extended 
with the use of built-in orthogonal signal correction (OSC) in what is termed 
orthogonal PLS-DA (O-PLS-DA). O-PLS-DA pre-filters classification irrelevant 
orthogonal variation from the data and can greatly improve the interpretation of 
spectral variation between classes. 178, 180 O-PLS-DA gives rise to differential 
regression coefficients. The differential regression coefficients corresponds to the 
plot of the covariance upon which the correlation is plotted with a colour code. 
The size and direction of the peak represents covariance and peaks are colour-
coded according to their correlation coefficient value to indicate which peaks are 
most discriminatory. 181 This plot is often called a differential metabogram in a 
metabolic profiling context. 182 
2.2.3 INTERPRETATION AND VALIDATION 
With any multivariate regression model it is important to consider both its fit 
and its predictive ability. A number of parameters have been used throughout this 
work to assess the fit of each model and to prevent over-fitting. To test the validity 
of all discriminant models in this study, 7-fold cross-validation was used, whereby 
a seventh of the data was left out and then predicted back into the model, 
repeating the process until all the data have been excluded at least once. A 
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number of key parameters can also be calculated, including the cross-validated 
percent of Y variance explained by the model, i.e. the predictive ability of the 
model, (Q2Y), and the percent of X variance explained by the model (R2X). In 
addition, permutation tests can be used to test the robustness of the model: the Y 
vector is permutated, typically 1000 times, and the probability of the predictive 
Q2Y being obtained by chance is calculated.  
2.2.4 STATISTICAL TOTAL CORRELATION SPECTROSCOPY 
(STOCSY) 
The development of statistical techniques such as Statistical Total 
Correlation Spectroscopy (STOCSY) has enhanced information recovery from 
complex data sets, such as NMR spectral data of biofluids obtained in 
metabonomic studies. 183 STOCSY utilises the co-linearity that exists between 
variables of differing intensities in a set of spectra to generate connectivities 
between resonances from molecules present at different concentrations in each 
sample. In contrast to traditional 2D spectroscopic techniques, STOCSY is not 
constrained by parameters such as lack of J couplings and extended distances. 
Additional information can be extracted from the data set by lowering the 
correlation coefficient and looking at additional correlations to highlight metabolic 
pathway linkages, between two or more molecules. The technique can be applied 
to the construction of virtual 2D heteronuclear correlation spectra to aid in 
metabolic assignment in what is termed heteronuclear-STOCSY (HET-STOCSY). 
HET-STOCSY has been successfully applied to correlate 1H and 31P MAS-NMR 
spectra obtained from intact liver tissue, 184 and to correlate 1H and 19F spectra 
from human urine samples. 185 
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In addition to the traditional STOCSY approach, an extended version called 
STOCSY-editing or STOCSY-E can be used. STOCSY-E enhances information 
recovery from complex NMR data sets. By identifying strongly correlated 
resonances, for example drug metabolite resonances, these resonances can be 
subtracted from the original data set, enabling the construction of a new matrix 
comprising endogenous metabolites only. This has been found to improve 
statistical analysis and ultimately enhance the detection of endogenous 
biomarkers, as the presence of drug metabolites can skew the models being 
constructed. 186 
2.2.5 METABOLITE ASSIGNMENT  
Throughout this work, metabolites were assigned using a combination of 
methods. Those metabolites most commonly encountered in biological samples 
were assigned using literature values. Drug-associated resonances were 
assigned, wherever possible, using standard compounds. In the case of INH, a 
number of drug-related resonances were observed that have never previously 
been assigned using NMR. The identification and assignment of these 
resonances formed a significant part of the INH study. For other metabolites, 2D 
NMR was employed to obtain structural information based on cross-peaks and 
splitting patterns. STOCSY was also employed to identify structural information, 
as well as identification of related metabolites. This information was then used to 
enable a targeted search of metabolite databases. Once potential metabolites 
had been identified, final assignment was then made where possible through the 
use of 'spike-in' experiments. 
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Chapter 3  ISONIAZID 
AIMS AND OBJECTIVES 
 Assessment of the response to a single dose of isoniazid (INH) using 
traditional clinical chemistry and histopathological assessments of toxicity, 
alongside complementary high resolution nuclear magnetic resonance 
spectroscopic methods. 
 Identification and quantification of urinary metabolites of INH in the rat 
model using high resolution nuclear magnetic resonance spectroscopic 
methods. 
 Exploration of inter-individual variation in response to INH administration 
through characterisation of the endogenous and xenobiotic metabolic 
profile. 
 Construction of pre-dose classification models of INH-induced adverse 
CNS effects – application of pharmacometabonomics. 
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3.1 METHODS 
3.1.1 ANIMAL HANDLING AND SAMPLE COLLECTION 
All animal manipulations were conducted by Pfizer Global R&D, Amboise 
France, in accordance with the relevant national requirements and local 
guidelines. Male Sprague-Dawley (SD) rats (7 weeks of age, approximately 250g, 
n=30, from Charles River, France) were allocated randomly to three dose groups 
(n=10 per group) and administered via intra-peritoneal (i.p.) injection, a single 
dose of vehicle (0.9% saline, Control) or INH in vehicle at 200 mg/kg (Low Dose) 
or 400 mg/kg (High Dose) (dose volume 10 mL/kg). Animals were housed in 
individual metabolism cages with free access to water and a standardised diet 
(diet A04C, Usine d’Alimentation Rationnelle, Villemoisoon-sur-Orge, France). 
Temperature (20 ± 2 oC) and relative humidity (60 ± 20%) were maintained, with a 
12 hour light/dark cycle throughout the study. The planned protocol was that half 
of the animals from each group were euthanized via CO2 anaesthesia at 48 h 
post-treatment, and the remainder at 168 h post-treatment for removal of target 
organs for histopathological examination. 
Urine samples were collected into ice-cooled vessels containing 0.1 mL 
sodium azide (100 mg/mL) over the following time periods: -48 to -41 h; -24 to -17 
h; 0 to 7 h; 7 to 24 h; 24 to 31 h; 48 to 55 h; 72 to 79 h; 96 to 103 h; 120 to 127 h; 
144 to 151 h. All urine samples were centrifuged at 9447 g for 10 minutes at room 
temperature to remove particulate matter, divided into aliquots and stored at -
20oC. Blood was sampled prior to animals being placed in the metabolic cages, 
and prior to planned termination, i.e. at 24 and 168 h post-dose, into commercially 
available plastic tubes containing lithium heparin as an anti-coagulant, from which 
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plasma samples were isolated by centrifugation. Clinical observations were 
carried out once a day over the period -48 to 0 hours, and 48 to 168 hours, and 
twice daily over the period 0 to 48 hours. Four animals in the high dose group 
displayed clinical signs of adverse CNS effects at approximately 2 hours post-
treatment and were euthanized. Post-dose urine was collected from 3 of these 4 
individuals that developed an adverse response, whilst post-dose plasma 
samples were not collected from these individuals.  
3.1.2 CLINICAL CHEMISTRY AND HISTOPATHOLOGY 
Urine parameters (total volume, pH, bilirubin, ketone substances, glucose, 
haemoglobin and protein concentration) were recorded using an automatic test-
strip reader (Clinitek 200, Bayer Diagnostics). Plasma was analysed for urea, 
creatinine, glucose, cholesterol, triglycerides, albumin, total protein, total bilirubin, 
alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), 5´-nucleotidase (5-NU), -glutamyl transferase (GGT) 
and bile acids using an AU600 multiparametric clinical analyser (Olympus) 
following the standard operating procedures of the laboratory. Significant changes 
from control levels were determined using a Student’s two-tailed t-test (with a 
significance threshold of p < 0.05). Tissue from the left lobe of the liver, kidney 
and brain were sampled at termination (scheduled at 48 hours and 168 hours 
post-treatment; the CNS responders were sampled within 2 hours of dosing as 
they were found dead or sacrificed as moribund) and fixed in a 10% formalin 
solution. Representative samples were processed routinely in an automatic tissue 
processor, embedded in paraffin, sectioned at 4-6 m, stained with haematoxylin 
and eosin (H&E), and examined histologically using light microscopy. Periodic 
acid Schiff staining was performed on additional samples of the left liver lobe to 
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further characterise hepatic glycogen content. All clinical chemistry and 
histopathological toxicity assessments were carried out by Pfizer Global R&D, 
Amboise France. 
3.1.3 NMR  SPECTROSCOPIC ANALYSIS OF URINE SAMPLES 
Urine samples were thawed, vortexed, and allowed to stand for 10 minutes 
at room temperature prior to mixing (400 L) with phosphate buffer (200 L, 0.2 M 
in 90:10 H2O/D2O, pH 7.4, containing 3 mM 3-trimethylsilyl-[2,2,3,3-
2H4]-propionic 
acid sodium salt (TSP, Sigma Aldrich) and 3 mM sodium azide (Sigma Aldrich)). 
The urine-buffer mixtures were centrifuged at 9447 g for 10 minutes at room 
temperature. Supernatants (550 L) were transferred to 5 mm NMR tubes (Norell 
Standard Series, HP507) for NMR analysis. The D2O provided a field frequency 
lock and TSP a chemical shift reference (1H,  0.0). 
One-dimensional (1D) 1H NMR spectra were acquired on a Bruker Avance 
DRX 600 MHz Spectrometer (Bruker BioSpin, Rheinstetten, Germany), operating 
at 14.1 T (600.13 MHz 1H frequency) and at a temperature of 300 K, using a 
standard 1D solvent suppression pulse sequence of the form [relaxation delay-
90o pulse-3 s delay-90o pulse-mixing time-90o pulse-acquire FID]. 165 For each 
sample, 196 transients were collected into 64 K data points, using a sweep width 
of 12019.2 Hz, with a relaxation delay of 4 s, an acquisition time of 2.72 s and a 
mixing time of 100 ms. Pre-saturation of the water signal was applied during the 
relaxation delay and mixing time. A line-broadening factor of 0.3 Hz was applied 
to all spectra prior to Fourier transformation (FT).  
77 
3.1.4 DATA PROCESSING 
The 1H NMR spectra were manually phased, baseline corrected and 
referenced to TSP ( 0.0). Full resolution 1H NMR spectra were imported into 
MATLAB (version 7.6, The MathWorks, Natick, USA) using MetaSpectra 4.1.1 (an 
in-house routine written by Dr O. Cloarec). The regions corresponding to water ( 
4.70 to 4.85), TSP ( -0.20 to 0.20), and urea ( 5.50 to 6.10) were removed. The 
spectra were aligned using the recursive segment-wise peak alignment (RSPA) 
method 174 to account for any chemical shift variations induced by differences in 
pH between samples. The urinary spectral regions containing drug-related 
resonances ( 2.14 to 2.24, 2.37 to 2.39, 2.47 to 2.52, 2.78 to 2.92, 4.24 to 4.29, 
7.67 to 7.95, and 8.60 to 8.82) were separated from the remaining spectral 
regions to form a xenobiotic spectral data set (Figure 3-1a). The remaining urinary 
spectral regions represented an endogenous metabolic data set (Figure 3-1a). 
The xenobiotic and endogenous metabolic spectral data sets were modelled 
separately to reflect the metabolic fate of INH and its endogenous consequences. 
This approach is summarised in Figure 3-1.  
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Figure 3-1 A scheme summarising the approach of separating the 1H NMR 
spectral profiles of rat urine into both endogenous and xenobiotic metabolic 
profiles (From Cunningham et al. 187). 
 These metabotypes are treated separately for subsequent normalisation and multivariate 
statistical modelling. 
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Both data sets were normalised separately using probabilistic quotient 
normalisation 175 to partially correct for variations in urinary volume and 
concentration. Multivariate statistical analysis (PCA, PLS-DA and O-PLS-DA) was 
carried out in MATLAB. 178, 180, 181 PCA models were computed using scaling to 
unit variance for the separate endogenous and xenobiotic metabolic profiles 
(Figure 3-1b). Metabolic trajectory plots were calculated using the mean PCA 
score (PC1 and PC2) values of the control, low and high dose urinary spectra at 
each time point, for each data set separately (Figure 3-1b). Relative 
concentrations of key endogenous and xenobiotic metabolites, as identified as 
discriminatory from loadings plots, were calculated by integration of their NMR 
spectral resonances, with integrals corrected for the number of protons giving rise 
to a resonance. Pair-wise O-PLS-DA models were computed between the control 
and sub-categories of high dose animals (i.e. CNS responders and CNS non-
responders) to identify the specific metabolic impact of INH administration in 
responders and non-responders, where controls were classed as group 1 and 
treated samples were classed as group 0. To test the validity of all O-PLS-DA 
models, 7-fold cross-validation was used, whereby a seventh of the data was left 
out of the model and then predicted back into the model, repeating the process 
until all of the data have been excluded at least once to calculate the Q2Y value (a 
measure of the cross-validated predictive ability). A permutation test was also 
performed to test the robustness of the models: the null hypothesis was simulated 
by 1000 random permutations of the Y vector. The permutation p-value was then 
obtained by ranking the actual Q2Y within the permuted Q2Y calculated by the 
simulation.   
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3.1.5 ASSIGNMENT OF INH METABOLITES 
The NMR resonance of INH-related metabolites were assigned using 1D 
and 2D NMR spectra of standard compounds and incubations of standards. 5 mM 
solutions of INH (Sigma Aldrich), isonicotinic acid (INA; Sigma Aldrich) 
acetylhydrazine (AcHz; Sigma Aldrich), acetylisoniazid (AcINH; synthesised by 
Pfizer Global R & D), and diacetylhydrazine (DiAcHz; Lancaster Synthesis), were 
prepared in 0.2 M phosphate buffer (as above) and analysed by 1D 1H NMR 
using the standard 1D 1H NMR solvent suppression sequence described above. 
165 Typically, 128 transients were collected into 64 K data points using a sweep 
width of 12019.2 Hz, and a relaxation delay of 2 s. A line-broadening factor of 0.3 
Hz was applied to all spectra prior to FT.  
Additional solutions of pyruvate (Sigma Aldrich), 2-oxoglutarate (Sigma 
Aldrich), pyridoxal (Sigma Aldrich), pyridoxal-5-phosphate (Sigma Aldrich), 
glycine (Sigma Aldrich) and glucose (Sigma Aldrich), were prepared. 24 hour 
incubations at 37oC of INH (500 L, 5 mM in 0.2 M phosphate buffer, as above) 
with pyridoxal, pyridoxal-5-phosphate, pyruvate, glycine, glucose, and 2-
oxoglutarate (all 500 L, 5 mM in 0.2 M phosphate buffer, as above) were carried 
out, and all reaction products (5 mm NMR tube, 600 L volume) analysed using 
the standard 1D 1H NMR solvent suppression sequence described above. 165 -
Glucosyl isonicotinylhydrazide (INH-GLC) was prepared as described previously 
188 by heating equivalent amounts of INH and glucose (both 5 mM solutions in 
methanol, 5 mL of each) at 90oC degrees for approximately 2 hours, at which 
point the methanol has evaporated off. The product was reconstituted in 
phosphate buffer and characterised by 1D 1H NMR as described above. 
Additional time-course incubation reactions were carried out to follow the 
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formation of INH hydrazone and hydrazide metabolites: an initial spectrum of INH 
(500 L, 5 mM) in urine and/or buffer was acquired, the second compound (100 
L, 5 mM in 0.2 M phosphate buffer, as above) added, and a series of spectra 
acquired over a period of approximately 6 hours (acquisition parameters as 
above; incubation time subject to variation). Visual comparisons and ‘spike-in’ 
experiments were carried out to identify and confirm the presence of reaction 
products in the post-treatment urinary spectra.  
Additional 2D homonuclear and heteronuclear spectra were acquired as 
necessary to confirm peak assignment, using an NMR spectrometer, operating at 
14.1 T (600.13 MHz 1H frequency) and a temperature of 300 K. For 1H- 1H 
correlation spectroscopy (COSY) 168 and total correlation spectroscopy (TOCSY) 
169 experiments, 64 scans (8 dummy scans) per increment were collected into 256 
increments at a spectral resolution of 8 K. 2D 1H J-resolved (JRES) spectra were 
acquired using the standard pulse sequence. 167 Typically, 128 transients (8 
dummy scans) per increment were acquired into 128 increments at a resolution of 
64 K. The sweep width was 12019.2 Hz in F2 and 50 Hz in F1 and water pre-
saturation was employed during a relaxation delay of 4 s. Spectra were 
processed using a SINE window function along the F1 and F2 axes, with SSB = 0 
and a resolution of 64 K (in F2) and 512 (F1) data points. The peaks were 
subsequently tilted by 45o and symmetrised. 
 Two dimensional heteronuclear multiple bond correlation (HMBC) 1H- 13C 
spectra 171 were acquired with 512 scans (32 dummy scans) collected into 152 
transients at a spectral resolution of 8 K in F2 across a sweep width of 6203.5 Hz 
and 33523.1 Hz for the 1H and 12C axes respectively, with an acquisition time of 
0.568 s and a relaxation delay of 1.5 s. Heteronuclear single quantum coherence 
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(HSQC) 170 1H- 13C echo-anti-echo spectra were acquired using 512 transients 
(and 32 dummy scans), collected into 8 K data points per increment for 128 
increments. A sweep width of 7211.5 Hz in the F1 dimension (13C) and 30187.8 
Hz in the F2 dimension (1H) were used with a relaxation time of 0.284 s and an 
acquisition time of 1.5 s.  
3.1.6 IDENTIFICATION OF PRE-DOSE METABOLITES OF 
TOXICITY 
O-PLS-based models were constructed to investigate the statistical 
relationship between the pre-dose NMR spectral data (X) and selected post-dose 
response variables, i.e. the development of INH-induced adverse CNS effects (Y, 
with those animals exhibiting overt signs of CNS disturbances classed as group 1; 
all other animals were classed as group 0), and the ratio of AcINH/pyruvate 
isonicotinyl hydrazone (INH-PA; Y). The statistical validity and robustness of each 
model was assessed using 7-fold cross validation and permutation test (details as 
above).  
A series of 2D homo- and heteronuclear NMR spectroscopic techniques 
were applied to enable the structural elucidation of the discriminatory metabolites 
highlighted in these models. COSY, 168 TOSCY, 169 JRES, 167 HSQC 171 and 
HMBC 170 spectra were acquired for the pooled pre-dose urine samples, using the 
acquisition parameters detailed above.  
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3.2 RESULTS  
3.2.1 IDENTIFICATION OF URINARY INH METABOLITES AND 
ASSIGNMENT OF THEIR NMR  SPECTRA 
NMR spectroscopic profiling enabled simultaneous characterisation of 
urinary INH-related metabolites and endogenous INH-induced metabolic 
changes. A representative 600 MHz 1H NMR spectrum of urine collected 0-7 
hours after administration of 400 mg/kg INH is shown in Figure 3-2 to highlight the 
simultaneous assignment of diverse urinary INH-derived metabolites and 
endogenous metabolites from many chemical classes.  
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Figure 3-2 Representative 600 MHz 1D 1H NMR spectrum of rat urine collected 0-
7 hours after administration of 400 mg/kg of isoniazid. 
 Two areas have been expanded to show the regions of the spectrum containing NMR 
spectral resonances due to INH-derived metabolites. 
Key: DMA – dimethylamine; DMG – dimethylglycine; TMAO – trimethylamine-N-oxide. 
 
The use of authentic compounds enabled the assignment of resonances 
due to INH, AcINH (the acetylated metabolite of INH), and INA (derived from 
hydrolysis of INH and AcINH). Further INH-related metabolites were identified 
through the use of incubation reactions. INH undergoes non-enzymatic reactions 
with the endogenous keto-acids, pyruvate and 2-oxoglutarate, to form INH-PA 
and 2-oxoglutarate isonicotinylhydrazone (INH-KA), respectively. Spectroscopic 
characterisation of the incubation solution of INH with pyruvate (Figure 3-3), and 
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of INH with 2-oxoglutarate (Figure 3-4) led to the identification of the syn and anti 
isomers of these metabolites. 43, 48 Both forms were detectable in the post-dose 
urine.  
 
 
Figure 3-3 Formation of pyruvate isonicotinylhydrazone (INH-PA) via reaction of 
INH with pyruvate over time in phosphate buffer at 37oC. 
Standard spectra of the parent compounds (INH and pyruvate) are shown, along with the 
progression of INH-PA formation at approximately 15 and 135 minutes post incubation.  
Key: INH – isoniazid; INH-PA – pyruvate isonicotinylhydrazone. A and B refer to the two 
forms of INH-PA (i.e. syn and anti forms).  
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Figure 3-4 Formation of 2-oxoglutarate isonicotinylhydrazone (INH-KA) via 
reaction of INH with 2-oxoglutarate over time in phosphate buffer at 37oC. 
Standard spectra of the parent compounds (INH and 2-oxoglutarate) are shown, along 
with the progression of INH-KA formation at approximately 65 and 210 minutes post 
incubation.  
Key: 2-OG – 2-oxoglutarate; INH – isoniazid; INH-KA – 2-oxoglutarate 
isonicotinylhydrazone. A and B refer to the two forms of INH-KA (i.e. syn and anti forms). 
 
Variable-temperature NMR experiments revealed the coalescence of the 
resonances from the syn and anti isomers of INH-PA and INH-KA with increasing 
temperature, indicative of rapid exchange between the isomers (Figure 3-5). 
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Figure 3-5 Effect of temperature on 1H NMR spectra. 
(a) 600 MHz 1H NMR spectra of standard solution of INH-KA showing the region  8.85 
to 8.62. (b) 600 MHz 1H NMR spectra of urine collected 0-7 hours after administration of 
INH at 400 mg/kg showing the region of  2.13 to 2.24.  
Spectra were acquired at 290 K, 300 K, 310 K and 330 K.  
Key: AcINH – acetylisoniazid; INH – isoniazid; INH-KA – 2-oxoglutarate 
isonicotinylhydrazone; INH-PA – pyruvate isonicotinylhydrazone. 
  
The ratio of the syn and anti isomers of both INH-PA and INH-KA was 
approximately 2:1, as determined from the relative ratio of the integral for the 
respective NMR resonances in the post-dose urinary spectra, where A referred to 
the major form and B to the minor form of the compound.  
1D and 2D spectroscopic analysis of the reaction products of INH and 
glucose enabled characterisation of the corresponding urinary metabolites as 
INH-GLC (Figure 3-6). These resonances were consistent with literature values 
for INH-GLC. 189 It was not possible to measure accurate J-coupling constants for 
all the protons due to a significant degree of peak overlap.  
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Figure 3-6 Formation of -glucosyl isonicotinylhydrazide (INH-GLC) via reaction 
of INH with glucose over time in methanol. 
Standard spectra of the parent compounds (INH and glucose) are shown, along with the 
results of the reaction between these compounds at 90oC for 120 minutes.  
Key: GLC – glucose; INH – isoniazid; INH-GLC – -glucosyl isonicotinylhydrazide. 
 
 Spectroscopic analysis of the products of the incubation of INH with glycine 
detected resonances assigned to isonicotinylglycine (INA-GLY, Figure 3-7), which 
were also observed in the 0-7 hour post-dose urinary spectra. 
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Figure 3-7 Formation of isonicotinylglycine (INA-GLY), via reaction of INH with 
glycine in phosphate buffer at 37 oC.  
Standard spectra of the parent compounds (INH and glycine) are shown, along with the 
results of the reaction between these compounds at approximately 12 hours post 
incubation. The aliphatic region showing the end-products of the reaction has been 
magnified 3 times. 
Key: INA – isonicotinic acid; INH – isoniazid; INA-GLY – isonicotinylglycine. 
 
Characterisation of the products from the reaction of pyridoxal and 
pyridoxal-5-phosphate with INH indicated that the isoniazidyl-pyridoxal complex 
(Schiff base) was not detected in the post-dose urine by NMR spectroscopy; this 
was consistent with earlier reports on the urinary metabolites of INH in a rat 
model. 43 As a consequence of the above analysis, INH-related metabolites were 
assigned as shown in Figure 3-8. Full spectral assignment details for INH and its 
related metabolites are provided in Table 3-1. 
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Figure 3-8 Representative 600 MHz 1H NMR spectrum of rat urine collected 0-7 
hours after administration of 400 mg/kg isoniazid, showing assignment of 
endogenous and exogenous metabolites. 
Full details of INH-related metabolites are given in Table 3-1. 
Key: AcINH – acetylisoniazid; DMA – dimethylamine; DMG – dimethylglycine; INA – 
isonicotinic acid; INH-GLC – -glucosyl isonicotinylhydrazide; INH-KA – 2-oxoglutarate 
isonicotinylhydrazone; INH-PA – pyruvate isonicotinylhydrazone; INA-GLY – 
isonicotinylglycine; MA – methylamine; TMAO – trimethylamine-N-oxide; U1/2 – 
unassigned INH-related metabolites. A/B refer to the syn/anti isomers of INH-PA and 
INH-KA 
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Table 3-1 Full assignment of INH and related metabolites. 
Metabolite 1H shift 
Isoniazid (INH) 
 
8.685 (d, 2H, H2 + H6, J = 6.2 Hz) 
7.705 (d, 2H, H3 + H5, J = 6.2 Hz)  
 
Isonicotinic acid (INA) 
 
8.619 (d, 2H, H2 + H6, J = 6.1 Hz) 
7.748 (d, 2H, H3 + H5, J = 6.1 Hz) 
 
Acetylisoniazid (AcINH) 
 
8.733 (d, 2H, H2 + H6, J = 6.3 Hz) 
7.812 (d, 2H, H3 + H5, J = 6.3 Hz) 
2.150 (s, COCH3) 
 
Pyruvate isonicotinylhydrazone A 
(INH-PA A) 
 
8.751 (d, 2H, H2 + H6, J = 6.2 Hz) 
7.803 (d, 2H, H3 + H5, J = 6.2 Hz) 
2.194 (s, CH3) 
 
Pyruvate isonicotinylhydrazone B 
(INH-PA B) 
 
8.741 (d, 2H, H2 + H6, J = 6.1 Hz) 
7.813 (d, 2H, H3 + H5, J = 6.1 Hz) 
2.220 (s, CH3) 
 
2-Oxoglutarate 
isonicotinylhydrazone A (INH-KA A) 
 
8.751 (d, 2H, H2 + H6, J = 5.8 Hz) 
7.804 (d, 2H, H3 + H5, J = 5.8 Hz) 
2.813 (t, 2H, CH2, J = 7.6 Hz) 
2.494 (t, 2H, CH2, J = 7.6 Hz) 
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2-Oxoglutarate 
isonicotinylhydrazone B (INH-KA B) 
 
8.762 (d, 2H, H2 + H6, J = 5.8 Hz) 
7.908 (d, 2H, H3 + H5, J = 5.8 Hz) 
2.887 (t, 2H, J = 6.2 Hz) 
2.559 (t, 2H, J = 6.2 Hz) 
 
-Glucosyl isonicotinylhydrazide 
(INH-GLC) 
 
8.693 (d, 2H, H2 + H6, J = 6.0 Hz) 
7.723 (d, 2H, H3 + H5, J = 6.0 Hz) 
4.263 (d, 1H, H1’, J = 8.9 Hz) 
3.409 (dd, 1H, H2’)  
3.575 (t, 1H, H3’) 
3.467 (dd, 1H, H4’)  
3.744 (dd, 1H, H5’) 
3.925 (dd, 2H, H6’) 
Accurate J-coupling constants were 
not available for H2’ – H6’ due to 
peak overlap. 
 
Isonicotinylglycine (INA-GLY) 
 
8.689 (d, 2H, H2 + H6, J = 6.1 Hz) 
7.791 (d, 2H, H3 + H5, J = 6.1 Hz) 
3.983 (s, 2H, CH2) 
 
Acetylhydrazine (AcHz) 
 
1.96 (s, COCH3) 
 
Diacetylhydrazine (DiAcHz) 
 
2.07 (s, COCH3) 
  
Key: A/B refer to the syn/anti isomers of INH-PA and INH-KA, although the structures 
shown are for illustrative purposes only. It has not been possible at present to assign 
syn/anti isomers. AcHz and DiAcHz were not detected in post-dose urine. 
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3.2.2 INTER-INDIVIDUAL VARIATION IN RESPONSE TO INH  
EXPOSURE 
Clinical observations of adverse CNS effects following administration of the 
high dose of INH enabled classification of "CNS responders" (4 of 10 rats). The 
remainder of the high dose cohort displayed no clinical signs of INH-induced CNS 
effects (6 of 10 rats) and were therefore classified as "CNS non-responders". 
Statistically significant reductions in the plasma activity of AST and ALT were 
reported at 24 hours post-dose in the high dose CNS non-responders (and the 
low dose cohort), relative to control activity (Figure 3-9). No clinical chemistry data 
was available for the high dose CNS responders. Histopathological assessment 
of the liver revealed hepatocellular glycogen depletion in 3 of the 4 CNS 
responders (representing a sampling point within 2 hours post-dosing) and in one 
CNS non-responder (later classified as CNS non-responder B; see below for 
further details). There was no histopathological evidence to suggest the presence 
of a hepatic necrotic lesion in the CNS non-responders at 48 hours or 168 hours 
post-treatment. In addition, histopathological assessment of brain and kidney 
tissues revealed no microscopic abnormalities.  
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Figure 3-9 INH-induced changes in plasma levels of clinical chemistry parameters. 
A significant change in ALT levels relative to control was observed at (a) 24 hours and (b) 
168 hours post-dose. A significant change in AST levels relative to control was observed 
at (c) 24 hours post-dose. Values are expressed as mean ± S.D. Each point represents 
an individual animal. Individual values are identified with black dots. The work was 
conducted by Dr Claude Charuel and the technical staff at Pfizer Global R&D, Amboise 
France. 
Key: Control (n=5; ); low dose (200 mg/kg, n=5; ); high dose CNS non-responders 
(400 mg/kg, n=3; ); ALT – alanine aminotransferase; AST – aspartate 
aminotransferase. (*) p < 0.05. (***) p < 0.001. 
  
The variability in response to INH and the existence of sub-populations 
within the high dose group was characterised via PCA analysis of post-dose 
urinary NMR spectra following separation of the NMR spectral profiles into distinct 
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endogenous and xenobiotic metabolic data sets as illustrated by the scheme in 
Figure 3-1. PCA analysis of the 1H NMR spectra of urine from both low dose and 
high dose animals, and the computation of a metabolic trajectory from the mean 
PC1 and PC2 score values enabled visualisation of INH-induced perturbations in 
the endogenous (Figure 3-10a) and xenobiotic (Figure 3-10b) data sets across 
time (from 24 hours pre-dose to 55 hours post-dose). The low dose endogenous 
metabolic trajectory showed clear deviation from the control endogenous 
metabolic space over the collection period 0-7 hours post-dose, followed by a 
return towards the control endogenous space over the collection period 7-31 
hours post-dose (Figure 3-10a). The endogenous metabolic trajectory was 
indicative of INH-induced homeostatic perturbation, which was most marked over 
the period 0-7 hours post-dose, followed by recovery of metabolic homeostasis by 
31 hours post-dose. In comparison, the movement observed in the low dose 
xenobiotic trajectory reflected the presence of INH and its metabolites at 0-7 and 
7-24 hours post-treatment, followed by complete clearance of INH-related 
metabolites from 24 hours onwards (Figure 3-9b).  
The high dose CNS non-responders exhibited a similar trajectory to the low 
dose animals but experienced a greater displacement from the control 
endogenous metabolic space at 0-7 hours post-dose with recovery over the 
period 24-31 h post-dose (Figure 3-10a). The PCA trajectory representing the 
xenobiotic metabolic profile for the high dose CNS non-responders exhibited a 
more prolonged perturbation relative to the low dose cohort (Figure 3-10b).  
 The endogenous and xenobiotic metabolic trajectories for the high dose 
CNS responders exhibited greater displacement compared to the high dose CNS 
non-responders (Figure 3-10a and -10b) 
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Figure 3-10 PCA analysis of 1H NMR spectra.  
PC1 vs PC2 scores trajectory plot showing the mean points of the individual PC scores 
for control, low and high dose urinary NMR spectra across the time course from 24 hours 
pre-dose to 55 hours post-dose for (a) endogenous metabolic data set and (b) xenobiotic 
metabolic data set. The high dose animals were sub-divided according to the severity of 
the observed CNS response and classified as CNS responders and CNS non-
responders. The numbers refer to the sampling time. The error bars indicate the standard 
deviation.  
Key: ( ) – control; ( ) – low dose; ( ) – high dose CNS non-responders;  
( ) – high dose CNS responders. 
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The differential metabotypes of the high dose CNS responders and non-
responders were further explored through PCA analysis of the endogenous and 
xenobiotic data sets at the 0-7 hours post-treatment time-point. The PC1 vs PC2 
scores plot from PCA analysis of the 0-7 hours post-dose urinary xenobiotic 
metabolic data set showed separation of the high dose CNS responders and non-
responders along PC1 (Figure 3-11a). The corresponding PCA loadings plot 
indicated that elevated levels of INH-PA and INH-GLC, coupled with low levels of 
AcINH were seen in the urinary spectra of CNS responders in comparison to CNS 
non-responders (Figure 3-11b). One animal displayed no clinical signs of toxicity, 
i.e. was classified as a CNS non-responder, but was clustered with the metabolic 
profiles of the responders on the PCA scores plot (non-responder B). The urinary 
spectrum from this animal showed high post-dose levels of INH-PA and INH-GLC, 
but no significant reduction in urinary levels of AcINH as was seen in the 
remaining animals classified as CNS responders, which partially explains its 
anomalous position in the PCA scores plot.  
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Figure 3-11 PCA analysis of 1H NMR spectra. 
PC1 vs PC2 scores plot derived from urinary spectra collected 0-7 hours after 
administration of high dose INH (400 mg/kg) for drug-related resonances only. (a) PC1 vs 
PC2 scores plot. (b) PCA loadings plot corresponding to the first principal component for 
this model. Individuals have been colour-coded on the basis of response to INH.  
Key: ( ) – CNS non-responders; ( ) – CNS responders; ( ) – CNS non-responder 
B*; AcINH – acetylisoniazid; INA – isonicotinic acid; INH – isoniazid; INH-GLC – -
glucosyl isonicotinylhydrazide; INH-KA – 2-oxoglutarate isonicotinylhydrazone; INH-PA – 
pyruvate isonicotinylhydrazone. 
(* This individual exhibited no overt clinical signs of an adverse CNS effect but shared 
some of the metabolic features of the CNS responders). 
 
To further characterise the CNS responder and CNS non-responder 
metabolic phenotypes with respect to the metabolic fate of INH, integrals of the 
INH metabolite spectral resonances were calculated from the 1H NMR post-dose 
urinary spectra (Table 7-1, Appendix I). A number of peak ratios were calculated 
to express the relative urinary excretion of the key INH metabolites (Table 3-2). 
CNS non-responder B was excluded from the CNS non-responder group and 
considered separately. Within the high dose group, the CNS responders excreted 
significantly lower ratios of AcINH relative to the parent INH (a ratio of 0.37 
compared to 0.70, p < 0.05) over the period 0-7 hours post-dose, compared to the 
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CNS non-responders. The post-dose ratio of INH-PA to AcINH was significantly 
elevated in the CNS responders relative to the CNS non-responders (a ratio of 
3.26 compared to 0.65 respectively, p < 0.01). In addition, the post-dose ratio of 
INH-GLC to AcINH was significantly elevated in the CNS responders relative to 
the CNS non-responders (a ratio of 5.75 compared to 0.31 respectively, p <0.05). 
The increase in the ratio of INH-GLC to AcINH (p < 0.05) in the CNS responders 
was less statistically significant than that of INH-PA to AcINH (p < 0.01), due to 
the high degree of inter-individual variation in urinary levels of INH-GLC. 
Therefore, the ratio of INH-PA to AcINH was considered a more robust marker of 
the responder phenotype and the development of an adverse CNS effect. Full 
integral values for INH and its metabolites for both low and high dose cohorts at 
0-7 hours and 7-24 hours post-dose are presented in Appendix I, Table 7-1. It 
was notable that the urinary levels of AcINH over the period 0-7 hours post-dose 
were comparable in the low dose cohort (200 mg/kg) and high dose CNS non-
responders (400 mg/kg).  
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Table 3-2 Quantification of INH-related metabolites. 
 AcINH:INH INH-PA:INH INH-GLC:INH 
INH-PA 
:AcINH 
INH-GLC: 
AcINH 
Low dose 0.97 ± 0.74 0.57 ± 0.22 0.31 ± 0.22 0.80 ± 0.35 0.36 ± 0.10 
High dose CNS 
non-responders 
0.70 ± 0.11 0.45 ± 0.10 0.22 ± 0.05 0.65 ± 0.15 0.31 ± 0.05 
High dose CNS 
responders 
0.37 ± 0.13 * 1.21 ± 0.44  2.25 ± 1.17 3.26 ± 0.41 ** 5.75 ± 1.53 * 
High dose CNS 
non-responder B 
0.55 1.18 1.56 2.15 2.85 
Ratios of AcINH, INH-PA and INH-GLC to INH, and of INH-PA and INH-GLC to AcINH 
present in the spectra of urine collected 0-7 hours after administration of INH at 400 
mg/kg. Ratios were calculated for individual animals and the mean ± standard deviation 
calculated for each group. Significant changes in the ratios observed in the high dose 
CNS responders relative to CNS non-responders were determined using a Student’s two-
tailed t-test. Full integral values are presented in Appendix I Table 7-1. 
Key: AcINH – acetylisoniazid; INA – isonicotinic acid; INH – isoniazid; INH-GLC – -
glucosyl isonicotinylhydrazide; INH-KA – 2-oxoglutarate isonicotinylhydrazone; INH-PA – 
pyruvate isonicotinylhydrazone. (*) p < 0.05. (**) p < 0.01. 
 
The endogenous metabolic phenotype reflective of differential CNS 
response to INH was assessed through PCA analysis of the endogenous 
metabolic data set for CNS responders and CNS non-responders at 0-7 hours 
post-treatment (Figure 3-12). A PCA scores plot of PC1 vs PC2 revealed the 
separation of CNS responders and CNS non-responders along PC1 (Figure 3-
12a) with significant inter-individual variation in INH-induced endogenous 
metabolic response between the CNS responders. The corresponding loadings 
plot indicated the presence of elevated levels of glucose and lactate, coupled with 
low levels of creatinine in the urine of CNS responders relative to CNS non-
responders (Figure 3-12b). CNS non-responder B, the individual that displayed a 
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unique INH metabolite profile i.e. elevated urinary levels of INH-PA and INH-GLC, 
compared to the remaining non-responders, was positioned between the CNS 
non-responder cluster and the CNS responders on the basis of the PCA scores 
plot of the endogenous data set. The corresponding loadings plot showed that 
this individual had elevated post-dose urinary levels of glucose relative to the 
CNS non-responders, but no increase in urinary levels of lactate was observed.  
 
 
Figure 3-12 PCA analysis of 1H NMR spectra. 
PC1 vs PC2 scores plot derived from urinary spectra collected 0-7 hours after 
administration of high dose INH (400 mg/kg) for endogenous resonances only. (a) PC1 
vs PC2 scores plot. (b) PCA loadings plot corresponding to the first principal component 
for this model. The metabolites responsible for separation were assigned from standard 
spectra and literature values. Individuals have been colour-coded on the basis of 
response to INH.  
Key: ( ) – CNS non-responders; ( ) – CNS responders; ( ) – CNS non-responder 
B*; CRN – creatinine.  
(* This individual exhibited no overt clinical signs of an adverse CNS effect but shared 
some of the metabolic features of the CNS responders). 
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To provide an interpretation of the urinary metabolic signature changes 
reflective of non-toxic exposure to INH, the supervised discriminant analysis 
technique O-PLS-DA was employed to maximise the discrimination between the 
control and treated groups. Pair-wise models were computed for the high dose 
CNS non-responders versus the control animals at 0-7 hours post-dose, and for 
the CNS responders versus the control animals at the same collection point, for 
the endogenous metabolic data set alone (Figures 3-13 and 3-14). For the 
purpose of this analysis, the outlying CNS non-responder identified in the earlier 
PCA analysis (CNS non-responder B) was excluded as it was established that its 
endogenous metabolic profile was distinct from the remaining CNS non-
responders. There was significant discrimination between the control and treated 
individuals, as denoted by the robust model statistics (high Q2Y and R2Y values 
and significant permutation p-values, see individual figures for full details). The O-
PLS-DA loadings plot for the urinary collection period 0-7 hours post dose 
showed that 3-IS and dimethylglycine were present at lower levels in high dose 
CNS non-responders relative to controls (Figure 3-13). The loadings plot also 
revealed that high dose CNS non-responders excreted lower levels of the TCA 
cycle intermediates, 2-oxoglutarate and citrate, over the same period. Further 
significant discriminators at 0-7 hours post-dose were elevated levels of 
methylamine, acetate, creatine, and creatinine in the urine collected from high 
dose CNS non-responders. 
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Figure 3-13 O-PLS-DA model derived from 1H NMR spectra of control (n=10) and 
INH-treated CNS non-responding (n=5) animals 0-7 hours following 
administration of INH at 400 mg/kg. 
(a) O-PLS-DA scores plot (cross-validated scores, Tcv, vs class) showing separation 
between the groups. Control ( ); INH-treated ( ). (b) O-PLS-DA loadings coefficient 
plot, using univariance scaling, showing endogenous metabolites responsible for 
separation between control (top) and treated (bottom) animals. The metabolites 
responsible for separation were assigned from standard spectra, literature values and 
'spike-in' experiments. 
Model Statistics: Q2Y 0.87; R2Y 0.98; p 0.001. 
Key: 2-OG – 2-oxoglutarate; 3-IS – 3-indoxylsulfate; CIT – citrate; CRE – creatine; CRN 
– creatinine; DMG – dimethylglycine; MA – methylamine. 
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A second O-PLS-DA model was computed to illustrate the endogenous 
metabolites responsible for discrimination between the control and high dose 
CNS responders at 0-7 hours post-dose (Figure 3-14). Discrimination between 
the groups was primarily due to reduced urinary levels of 3-IS, 
phenylacetylglycine (PAG), 3-hydroxyphenylpropionate (3-HPPA), 4-
hydroxyphenylpropionate (4-HPPA), 2-oxoglutarate, citrate, dimethylglycine, and 
succinate, along with elevated levels of acetate, lactate, dimethylamine and 
glucose in the urine of high dose CNS responders relative to control levels.  
 
 
 
 
 
 
105 
Figure 3-14 O-PLS-DA model derived from 1H NMR spectra of control animals 
(n=10) and INH-treated CNS responders (n=3) 0-7 hours following administration 
of INH at 400 mg/kg. 
(a) O-PLS-DA scores plot (cross-validated scores, Tcv, vs class) showing separation 
between the groups. Control ( ); INH-treated CNS responders ( ). (b) O-PLS-DA 
loadings coefficient plot, using univariance scaling, showing endogenous metabolites 
responsible for separation between control (top) and treated (bottom) animals. The 
metabolites responsible for separation were assigned from standard spectra, literature 
values and 'spike-in' experiments. 
Model Statistics: Q2Y 0.83; R2Y 0.96; p 0.004. 
Key: 2-OG – 2-oxoglutarate; 3-HPPA – 3-hydroxyphenylpropionic acid; 3-IS – 3-
indoxylsulfate; 4-HPPA – 4-hydroxyphenylpropionic acid; DMA – dimethylamine; DMG – 
dimethylglycine; PAG – phenylacetylglycine. 
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 The dominant endogenous metabolic changes reflective of high dose (400 
mg/kg) INH exposure in CNS responders and non-responders are presented in 
Table 3-3.  
 
Table 3-3 Metabolic perturbations following INH exposure at 400 mg/kg, relative to 
control urinary spectra, in CNS responder and non-responders at 0-7 hours post-dose.  
Metabolites were increased () or decreased () in treated urine, relative to control 
urinary spectra at each defined time-point. The scale of change (as indicated by the first 
value in brackets) has been expressed as the median log fold change of the metabolite 
resonance in the treated urinary cohort relative to the median metabolite resonance in 
the control cohort. The O-PLS-DA model coefficient of determination values (r2) indicate 
which metabolites were most discriminatory. The resonance integrated for each 
metabolite is underlined. Metabolites were assigned via a combined application of 
literature values, 'spike-in' experiments and STOCSY.  
Metabolite 
 
1H Chemical Shift + 
Multiplicity 
 
CNS Non-
responders 
CNS 
Responders 
2-Oxoglutarate 
 
2.45 (t), 3.01 (t)  (-0.48; r2 = 0.83)  (-0.47; r2 = 0.69) 
3-Hydroxyphenyl-
propionate 
 
2.48 (t), 2.84 (t), 6.76 (d), 
6.80 (s), 6.92 (dd), 7.27 (t) 
-  (-0.42; r2 = 0.86) 
3-Indoxylsulfate 
 
 
7.21 (dd), 7.28 (dd), 7.36 
(s), 7.51 (d), 7.71 (d) 
 (-0.23; r2 = 0.95)  (-0.57; r2 = 0.85) 
4-Hydroxyphenyl-
propionate 
 
2.45 (t), 2.81 (t), 6.85 (d), 
7.18 (d) 
-  (-0.29; r2 = 0.83) 
Acetate 
 
1.94 (s)  (0.21; r2 = 0.79)  (0.33; r2 = 0.82) 
Citrate 
 
2.56 (d), 2.72 (d)  (-0.17; r2 = 0.97)  (-0.18; r2 = 0.87) 
Creatinine 
 
3.05 (s), 4.05 (s)  (0.08; r2 = 0.85) - 
Dimethylamine 
 
2.73 (s) -  (0.83; r2 = 0.88) 
Dimethylglycine 
 
2.93 (s)  (-0.47; r2 = 0.91)  (-0.46; r2 = 0.81) 
Glucose 
 
3.2 – 3.9, 4.65 (d), 5.22 (d) -  (1.58; r2 = 0.76) 
Lactate 
 
1.33 (d), 4.11 (q) -  (1.26; r2 = 0.89) 
Methylamine 
 
2.61 (s)  (0.30; r2 = 0.91) - 
Phenylacetyl-
glycine 
 
3.69 (s), 3.74 (d), 7.35 
(m), 7.38 (m), 7.41 (s)  
-  (-0.38; r2 = 0.85) 
Succinate 2.41 (s) -  (-0.18; r2 = 0.81) 
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3.2.3 PRE-DOSE CLASSIFICATION OF POST-DOSE 
VARIABILITY IN RESPONSE TO INH 
O-PLS-based pattern recognition methods were used to identify 
relationships between the pre-dose metabolic profiles and post-dose outcome 
with respect to an adverse CNS effect following high dose INH exposure (400 
mg/kg). An O-PLS-DA model was constructed to explore discrimination of the pre-
dose urinary spectral profiles of CNS responders and CNS non-responders (with 
CNS non-responder B excluded). The cross-validated scores plot for this model, 
which was characterised by a Q2Y of 0.34, and R2Y of 0.76, showed clear 
separation between the pre-dose urinary spectra derived from the high dose CNS 
responders and CNS non-responders (Figure 3-15a). The corresponding loadings 
plot indicated that the discrimination was due to elevated levels of a number of 
urinary spectral resonances in the CNS responders, specifically resonances at  
5.11 (d, 7.6 Hz), 6.65 (dd) and 6.72 (s) (Figures 3-15b and 3-15d). Visual 
comparison confirmed increased intensities of these resonances in the pre-dose 
urinary spectra of CNS responders (Figures 3-15c and 3-15e). 
 
 
 
 
 
 
 
 
108 
 
Figure 3-15 O-PLS-DA model derived from 1H NMR spectra of animals that 
developed INH-induced CNS effects (n=4) and those that did not (n=5), collected 
prior to administration of INH at 400 mg/kg.  
(a) Cross validated scores versus Y response: CNS non-responder ( ); CNS responder 
( ). (b, d) Loadings coefficient plot showing metabolites responsible for discrimination 
between individuals that developed CNS effects (top) and those that did not (bottom). (c, 
e) Corresponding 1H spectral regions colour coded according to severity of post-dose 
response (red, CNS responders; blue, CNS non-responders). Animal 206 was excluded. 
Model Statistics: Q2Y 0.34; R2Y 0.76; p 0.14. 
 
 Having established the existence of a relationship between the 
development of CNS adverse effects and the ratio of post-dose excretion of INH-
PA:AcINH, an O-PLS-regression model was constructed using the post-dose ratio 
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of INH-PA to AcINH (Figure 3-16). The resulting scores plot showed moderate 
separation between the differential response phenotypes, whilst the loadings plot 
indicated the same discriminatory spectral resonances. (Figure 3-16) 
Figure 3-16 O-PLS-regression model derived from 1H NMR spectra collected prior 
to administration of 400 mg/kg INH, comparing pre-dose metabolic profile with 
post-dose ratio of pyruvate isonicotinylhydrazone (INH-PA) and acetylisoniazid 
(AcINH). 
(a) O-PLS-regression scores plot of cross-validated scores (Tcv) versus ratio of INH-
PA:AcINH showing separation between the groups. (b, c) Regions of O-PLS-regression 
loadings coefficient plot, showing metabolites responsible for discrimination on the basis 
of post-dose ratio of INH-PA to AcINH. The upper section of the plot represents 
metabolites that were elevated in pre-dose urine from individuals with low post-dose 
levels of AcINH relative to INH-PA.  
Key: ( ) – CNS non-responders; ( ) – CNS responders. 
Model Statistics: Q2Y 0.71; R2Y 0.95; p 0.02. 
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Variable intensities of these signals were also observed in the pre-dose 
urinary spectra of the low dose cohort (Figure 3-17). Interestingly, the highest 
levels of these pre-dose signals corresponded with those individuals with the 
lowest levels of AcINH in the 0-7 hour post-dose urine following the low-dose INH 
treatment. 
 
Figure 3-17 Expanded regions of 600 MHz 1D 1H NMR spectra of rat urines 
collected 24 hours prior to administration of 200 mg/kg INH. 
Spectra have been colour coded to highlight those spectra with elevated levels of the 
resonances of interest. (c) Table detailing corresponding post-dose levels of AcINH; 
values have been colour coded corresponding to pre-dose spectra: everything below 3.0 
x 108, red; everything above 3.0 x 108, blue. Integrals were calculated for the AcINH 
resonance at  2.15. 
Key: AcINH – acetylisoniazid. 
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3.2.4 NMR  ANALYSIS OF UNKNOWN URINARY METABOLITES 
IN PRE-DOSE URINE OF CNS  RESPONDERS. 
A range of 2D NMR spectroscopic experiments were applied to the 
structural identification of the pre-treatment urinary spectral resonances identified 
as discriminatory in Section 2.3 above. From the statistical models and from 
observation of the 1H NMR spectra, it was determined that the metabolite(s) of 
interest were present at very low concentrations. Therefore, pre-dose urine was 
pooled from a number of samples (n=7) to increase the concentration of the 
metabolite(s) of interest and enhance the resultant 2D spectra. 1H-1H TOCSY 
showed the aromatic resonances at  6.65, and 6.72 were coupled to a 
resonance at  7.26 (Figure 3-18); this pattern is typical of a 1,2,4-trisubstituted 
phenolic moiety. In addition, the resonance at  5.11 was found to be coupled to a 
resonance at  3.61 and is typical of an ether glucuronide moiety, or more 
specifically an axial anomeric proton in a glucuronide (Figure 3-16). These NMR 
signals have therefore been tentatively assigned to a phenolic ether-glucuronide, 
although further experiments are necessary to fully elucidate and confirm an 
exact molecular structure.  
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Figure 3-18 2D 600 MHz 1H- 1H TOCSY of pooled urine from 10 rats collected 24 
hours prior to administration of 400 mg/kg isoniazid and subsequent development 
of clinical signs of toxicity. 
The regions  6.4 – 7.8 and  3.4 – 5.2 have been expanded. Cross-peaks are 
highlighted in red and red lines have been added to show intersections. 
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3.3 DISCUSSION 
Although widely used to treat tuberculosis, INH is associated with adverse 
toxic effects when administered in isolation or in combination therapies, though 
the reported incidence vary. INH has been shown to induce an increase in plasma 
ALT levels in up to 2% of patients, with over hepatotoxicity identified in up to 1% 
of patients, with a variable and often lengthy delay before the onset of 
hepatotoxicity. 190 In a study with a cohort of 519 subjects, 7% of subjects 
exhibited severe hepatotoxicity (i.e. necessitating termination of therapy) following 
a standard dose of 5 mg/kg/day, although this rate varies considerably between 
studies; Nolan et al. reported an incidence of less than 1%. 191-194 INH has also 
been reported to cause peripheral neuropathy 30 and neurotoxicity in humans, 194 
although the administration of INH with pyridoxine to combat peripheral 
neuropathy is recommended as standard clinical practice. 63 Further, while 
chronic INH-induce toxicity manifests as hepatotoxicity or peripheral neuropathy, 
neurotoxicity has been widely reported following acute INH exposure. 31, 32, 69 
Here, a dual metabonomic and pharmacometabonomic strategy for 
exploration of INH-induced toxicity in the rat model was applied by considering 
the systemic response to INH through analysis of distinct xenobiotic and 
endogenous metabolic phenotypes, or metabotypes. This led to the classification 
of CNS responders (40% of cohort) and CNS non-responders (60% of cohort) 
based on the presence or absence of unexpected adverse neuropathic effects. 
Histopathological assessment revealed hepatic glycogen depletion in 3 of 4 CNS 
responders which suggested a rapid utilisation of hepatic glycogen stores in 
response to INH-induced CNS toxicity. There was no histopathological evidence 
of hepatic necrosis or a hepatic lesion in CNS non-responders. Reductions in 
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plasma activity of ALT and AST were observed in the low dose and high dose 
CNS non-responders at 24 hours post-treatment, which supports previous 
findings. 153, 195 Both enzymes require the co-factor pyridoxal-5-phosphate, which 
is known to be sequestered by INH, 31, 32 and by hydrazine, a known metabolite of 
INH. 196, 197  
1H NMR spectroscopic analysis enabled the simultaneous identification 
and assignment of numerous endogenous metabolites and INH-related urinary 
metabolites, including AcINH, INA, INH-KA (syn and anti isomers), INH-PA (syn 
and anti isomers), INH-GLC, INA-GLY and unchanged INH. This represents the 
first example of the application of 1H NMR spectroscopy to identify simultaneously 
multiple INH urinary metabolites, an outcome with clear translational potential to 
the clinic. PCA analysis of the urinary NMR spectral profiles enabled 
discrimination of both the endogenous and xenobiotic metabolic profiles of CNS 
responders and CNS non-responders following INH administration. INH-induced 
CNS responder effects were characterised by statistically significantly elevated 
urinary levels of the INH metabolites INH-PA and INH-GLC, accompanied by low 
levels of AcINH, a metabolite produced via acetylation of INH. Acetylation has 
been identified as a contributing factor in the development of INH-induced 
hepatotoxicity 22, 25, 80 and peripheral neuropathy. 30 Further, acetylation of INH 
has been shown to be saturated at high doses of INH in both human and rat 
models. 43, 46, 47, 78 In the current study, saturation of acetylation was observed 
following administration of INH at 200 mg/kg as comparable urinary levels of 
AcINH were excreted by both the low dose animals and the high dose CNS non-
responders. In contrast, the high dose CNS responders excreted significantly 
lower levels of AcINH than the high dose CNS non-responders suggesting that 
acetylation capacity was lower in those individuals that experienced INH-induced 
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effects on the CNS. As a direct consequence of the lower acetylation capacity of 
CNS responders, a greater proportion of INH would be thus be expected to be 
metabolised via other routes. Evidence to support this was provided from the 
observation that significantly elevated levels of the INH hydrazones and 
hydrazides (i.e. INH-PA, INH-GLC) were excreted by the CNS responders 
suggesting enhanced metabolism of INH via conjugation with pyruvate and 
glucose. The application of a metabonomic platform has thus enabled the 
determination of unique INH metabotypes representing differential metabolic fate 
of INH of relevance to differential neuropathic outcome. 
In humans, severe acute INH-induced neurotoxicity is characterised by a 
clinical triad of refractory seizures, metabolic acidosis with an elevated anion gap, 
and coma, with symptoms generally observed between 45 minutes and 2 hours 
post exposure. 32 This neurotoxicity latency period is consistent with previous 
animals studies, 65 and with the clinical signs of an adverse CNS effect observed 
at 2 hours post-treatment in this study. INH-induced neurotoxicity in man has also 
been associated with hyperglycaemia, hypokalaemia, glucosuria, and ketonuria. 
32, 69 Discrimination of high dose CNS responders from CNS non-responders was 
also determined from modelling of the distinct metabolic profiles representing the 
endogenous metabolic complement. The CNS responders excreted significantly 
elevated urinary levels of glucose and lactate. Metabolic acidosis following INH-
induced neurotoxicity in man is associated with elevated urinary lactate, which 
was apparent in those animals that displayed overt clinical signs of CNS effects, 
i.e. CNS responders. Though the exact mechanism of INH-induced metabolic 
acidosis is unknown, the most likely causes are tissue hypoxia, induced by 
seizures, and inhibition of lactate dehydrogenase, responsible for the conversion 
of lactate to pyruvate. 32, 68, 69, 198 It is worth noting that the primary site of lactate 
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dehydrogenase activity is the liver, suggesting a degree of hepatic dysfunction in 
the responders. Glucosuria, as observed in the high dose CNS responders, has 
also been associated with INH-induced neurotoxicity in man. 69 Reduced urinary 
levels of creatinine were observed in the CNS responders relative to the CNS 
non-responders. While creatinine is generally used as a measure of glomerular 
filtration rate and therefore renal function, here it likely reflects a generalised state 
of homeostatic perturbation. 
The endogenous metabolic effects of a non-neuropathic response to INH 
was also considered through multivariate modelling of the urinary spectra 
representing animals that did not display marked effects on the CNS, i.e. the high 
dose CNS non-responders. O-PLS-DA models indicated that urinary levels of a 
number of metabolites, specifically 3-IS, dimethylglycine, and methylamine, were 
perturbed in the high dose CNS non-responders 0-7 hours after INH 
administration. Perturbation in levels of 3-IS are reflective of impaired bacterial 
catabolism of tryptophan, 199 while dimethylglycine and methylamine are all 
implicated in bacterial-mediated choline metabolism 200 and may collectively 
indicate an impact on the gut microbiota. Although excretion of INH is largely via 
urine, with up to 95% of INH and its metabolites being renally excreted within 24 
hours, 43 a small proportion is reabsorbed into the bile, and subsequently 
excreted in the faeces, where it may directly alter the gut microbial composition.  
Elevated creatinine was observed in the high dose CNS non-responders, 
relative to control levels at 0-7 hours post-dose. Creatinine is generally 
considered a marker of renal function. Here it is believed to indicate a generalised 
state of homeostatic perturbation. 
Transient perturbations in 2-oxoglutarate and citrate were also observed in 
the high dose CNS non-responders at 0-7 hours post-dose suggestive of 
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mitochondrial metabolic perturbation. Earlier work on INH-induced hepatotoxicity 
reported similar reductions in urinary levels of 2-oxoglutarate in response to INH 
administration. 152 Reductions in urinary levels of 2-oxoglutarate at both dose 
levels were also a likely consequence of the formation of the metabonate 138 INH-
KA, via non-enzymatic reaction of INH with 2-oxoglutarate.  
Pharmacometabonomics has proved beneficial in the prediction of inter-
individual variation in animal and human models of xenobiotic interventions, 20, 158, 
159, 162, 201 and was applied here to classify toxic outcome on the basis of pre-dose 
urinary metabolic profiles. An O-PLS-DA model identified a positive relationship 
between the pre-dose levels of urinary metabolite(s) and the development of INH-
induced adverse effects on the CNS, providing further support for the value of the 
pharmacometabonomic concept. 20, 158, 159 A second model, albeit a less 
statistically significant one, also identified a positive correlation between the post-
dose ratio of AcINH to INH-PA and the pre-dose metabolic profile. In addition, an 
elevation in this pre-dose metabolic signature was detected in 3 of 10 individuals 
administered a low dose of INH, corresponding to those individuals with the 
lowest post-dose levels of AcINH. It was therefore hypothesised that this pre-dose 
metabolic signature may be predictive of the capacity for acetylation of INH in this 
pre-clinical model. On the basis of a range of 2D NMR experiments, this 
metabolite was tentatively assigned as a phenolic glucuronide moiety.  
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3.4 CONCLUSION 
Here, the xenobiotic and endogenous metabolic phenotypes associated 
with inter-individual variability in toxicity outcomes for a pre-clinical model of INH 
treatment in rats have been characterised. NMR spectroscopic analysis was 
applied to characterise the urinary metabolic fate of INH, which was seen to differ 
with respect to acetylation capacity and production of hydrazone and hydrazide 
metabonates in responders that developed adverse effects on the CNS. The 
endogenous consequences of INH administration were also identified, 
highlighting the power of this multivariate approach for the assessment of a 
systems level response to a toxin. The application of pharmacometabonomics 
enabled identification of a pre-treatment metabolic signature that was reflective of 
the differential metabolic fate of INH and the subsequent development of INH-
induced adverse CNS effects. Such an approach is widely applicable to the 
clinical setting to explore the relationship between adverse drug reactions, the 
metabolic fate of pharmaceuticals and their impact on metabolic homeostasis. 
This metabonomic strategy may lead to novel means of determining the metabolic 
basis for adverse drug reactions and ultimately enable the prediction of 
susceptibility to adverse drug reactions. 
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Chapter 4 GENTAMICIN  
AIMS AND OBJECTIVES 
The aim of this work was to employ an integrated approach to characterise 
the metabolic impact of gentamicin exposure in the rat model through the 
integration of traditional toxicity assessment (histopathological assessment, 
measurement of kidney injury molecule 1, N-acetyl--glucosaminidase, and total 
protein) with high resolution NMR spectroscopy of urine, serum, and intact kidney 
and liver. The relationship between gentamicin-induced nephrotoxicity and 
administration time was further explored to determine if the severity of 
gentamicin-induced nephrotoxicity was linked to administration time and whether 
this relationship was reflected in differential metabolic profiles. 
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4.1 METHODS 
The following study was carried out collaboratively with Dr Antoine and 
Prof Park at the MRC Centre for Drug Safety Science at the University of 
Liverpool, who designed the study. All animal manipulations were conducted by 
the MRC Centre for Drug Safety Science at the University of Liverpool. 
4.1.1 ANIMAL HANDLING AND SAMPLE COLLECTION  
 
Male SD rats (approximately 250-330g, n=16) were randomly allocated to 
four dose groups (n=4): control (AM), control (PM), gentamicin (AM), and 
gentamicin (PM). Animals were dosed once daily for nine days via intra-peritoneal 
(i.p.) injection with control vehicle (0.9% saline), or gentamicin (200 mg/kg in 0.9% 
saline). “AM” dose was administered daily at 10am; “PM” dose was administered 
daily at 10pm. Full details are given in Table 4-1. 
 
Table 4-1 Dosing procedure and group assignments. 
Treatment Group Animal Numbers Dosing Time 
Gentamicin 1, 2, 3, 4 PM (22.00) 
Gentamicin 5, 6, 7, 8 AM (10.00) 
Control 9, 10 11, 12 AM (10.00) 
Control 13, 14, 15, 16 PM (22.00) 
 
Urine was collected over a period of 24 hours following administration of 
the final dose, and blood collected at termination via cardiac puncture. Liver (right 
lateral lobe) and kidney tissue (left kidney section including papilla, cortex and 
medulla) samples were collected at termination. Three aliquots were snap frozen 
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pending further analysis, and the remainder frozen in 10% formalin. The 
experimental timeline is outlined in Figure 4-1. 
 
 
Figure 4-1 Experimental timeline. 
Gentamicin or control vehicle were administered daily at 10.00 (AM group) or 22.00 (PM 
group) for nine days, as indicated by the green lines. Urine was collected over a period of 
24 hours (hatched black area) and serum and tissue sampled at termination (red line). 
Key: Gen – gentamicin. 
 
4.1.2 CLINICAL CHEMISTRY AND HISTOPATHOLOGY 
Urinary N-acetyl--glucosaminidase (NAG) was measured 
spectrophotometrically as described by Horak et al. 202 and urinary kidney injury 
molecule 1 (KIM-1) was measured using the xMAP Luminex technology. 203 Other 
urinary parameters were measured using a Roche Modular Analyser. Serum 
creatinine was measured using a standard clinical chemistry analyser (Roche-
Modular). This work was conducted by Dr Antoine at the Vaidya/Bonventre 
laboratory, Harvard Medical School. Significant changes in these parameters from 
control levels were assessed using a Students two-tailed t-test. The liver and 
kidney were sampled and fixed in a 10% formalin solution. Representative 
samples were processed routinely in an automatic tissue processor, embedded in 
paraffin, sectioned at 4-6 m, stained with haematoxylin and eosin, and examined 
histologically using light microscopy to determine the extent of macroscopic 
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damage. This work was conducted in Professor Park’s laboratory at the University 
of Liverpool. 
4.1.3 1H NMR  SPECTROSCOPY OF URINE 
Urine samples were prepared and 600 MHz 1H spectra were acquired 
using a standard 1D solvent suppression pulse, as described previously (Chapter 
3, section 1.3). For each sample, 256 transients were collected into 64 K data 
points, using a sweep width of 12019.2 Hz with a relaxation delay of 4 s, an 
acquisition time of 2.72 s, and a mixing time of 100 ms. Pre-saturation of the 
water resonance occurred during the relaxation delay and the mixing time. A line-
broadening factor of 0.3 Hz was applied to all spectra prior to FT.  
4.1.4 1H NMR  SPECTROSCOPY OF SERUM 
Serum (200 L) was mixed with 400 L of saline, containing 20% D2O; no 
sample was available for animal number 4 (gentamicin, PM). Samples were 
centrifuged at 9447 g for 10 minutes and supernatants (550 L) transferred to 5 
mm NMR tubes (Norell Standard Series 507) for NMR analysis. 1D 1H NMR 
spectra were acquired on an NMR spectrometer (Bruker Biospin, Rheinstetten, 
Germany) operating at 14.1 T (600.13 MHz 1H frequency) at a temperature of 300 
K, using the standard 1D solvent suppression pulse sequence, as described 
above, 165 in which 128 transients were collected into 64 K data points, with a 
sweep width of 12019.2 Hz, a relaxation delay of 4 s, an acquisition time of 2.72 s 
and a mixing time of 100 ms. In addition, the Carr-Purcell-Meiboom-Gill (CPMG) 
166 spin-echo pulse sequence with a fixed spin-spin relaxation delay (2n) of 64 
ms was applied to attenuate broad resonances from high molecular weight 
compounds. For each sample, 512 transients were collected into 64 K data points 
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with a sweep width of 12019.2 Hz, a relaxation delay of 4 s, and an acquisition 
time of 2.73 s. A line-broadening factor of 0.3 Hz was applied to all spectra prior 
to FT. 
4.1.5 1H MAS-NMR  SPECTROSCOPY OF INTACT K IDNEY AND 
L IVER SAMPLES 
Kidney (single sample of cortex) and liver tissue samples (approx. sample 
weight of 10 mg) were rinsed with D2O and placed in a 4 mm zirconium oxide 
rotor with an insert to ensure a spherical cavity, and spun in air at the magic angle 
( = 54.7o) at a spin rate of 5 kHz using a Bruker DRX-600 spectrometer (Bruker 
Biospin, Rheinstetten, Germany) operating at 14.1 T (600.13 MHz 1H frequency). 
The MAS-NMR spectra were acquired at 283 K, using the CPMG 166 spin-echo 
pulse sequence described above. Typically, 128 transients were collected into 64 
K data points over a sweep width of 12019.2 Hz with a relaxation delay of 4 s and 
an acquisition time of 2.73 s. A line-broadening factor of 0.3 Hz was applied to all 
spectra prior to FT. 
4.1.6 NMR  SPECTRAL DATA PROCESSING 
The 1H NMR spectra were manually phased, baseline corrected and 
referenced to TSP ( 0.0) for urinary spectra, -glucose ( 5.233) for serum 
spectra, and lactate ( 1.33) for tissue samples. Full resolution NMR spectra were 
imported into MATLAB (version 7.6, The MathWorks, Natick, USA) using 
MetaSpectra 4.1.1 (an in-house routine written by Dr O. Cloarec). The regions 
corresponding to water ( 4.73 to 4.90), and, where present, TSP ( -0.20 to 0.20) 
were removed. In addition, the region containing the urea resonance ( 5.50 to 
6.10) was removed from urinary spectra. The spectra were aligned using the 
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RSPA method, 174 and the data normalised using probabilistic quotient 
normalisation. 175 
Multivariate statistical analysis (PCA, PLS-DA, and O-PLS-DA) was carried 
out in MATLAB using univariance scaling. 178, 180, 181 To test the validity of all PLS-
DA and O-PLS-DA models, 7-fold cross-validation was used, and the Q2Y value 
(a measure of the cross-validated predictive ability) calculated. A permutation test 
was performed to test the robustness of the models. Metabolites were assigned 
via a combined application of literature values and 'spike-in' experiments. To 
assist in the assignment of metabolite signals, homonuclear 1H-1H STOCSY 
analysis was performed as necessary. 183 Relative concentrations of key 
endogenous metabolites, as identified from O-PLS-DA loadings plots, were 
calculated by integration of specific NMR spectral resonances, with integrals 
corrected for the number of protons giving rise to spectral resonances. The scale 
of metabolic perturbation was assessed from calculation of the log (base 10) of 
the median fold change of integrals of resonances of the discriminatory 
metabolites, relative to median control levels. 
 
125 
4.2 RESULTS 
4.2.1 CLINICAL CHEMISTRY AND HISTOPATHOLOGY 
The effects of gentamicin were assessed using a range of conventional 
clinical chemistry analyses, including histopathological examination of the kidneys 
and urinary levels of KIM-1, NAG and total protein (Figure 4-2). A once daily PM 
administration of gentamicin induced mild nephrotoxicity in 3 out of 4 rats 
(severity score of 1), characterised by tubular protein casts and focal cortical 
interstitial mononuclear infiltrate with mild fibrosis; one individual in this treatment 
group exhibited no significant microscopic changes. The nephrotoxic effect of 
gentamicin was more marked following an AM administration, with all rats (n=4) 
experiencing moderate to severe toxicity (severity score of 2 or 3). This was 
characterised by tubular protein casts, focal interstitial mononuclear infiltrates, 
dilation of cortical tubuli and evidence of necrotic epithelial cells, and evidence of 
vascular leukocyte recruitment. No microscopic changes were observed in kidney 
tissue from control animals. 
Urinary levels of KIM-1, NAG and total protein were measured for all 
animals at termination (Figures 4-2b, 4-2c, and 4-2d). All values relate to relative 
urinary levels, rather than absolute excretion and are expressed relative to 
creatinine. NAG and total protein levels were significantly elevated (p < 0.05) 
following gentamicin administration at both administration times, relative to 
corresponding control levels (Figures 4-2c and 4-2d). KIM-1 levels were 
significantly elevated (p < 0.05) following AM administration of gentamicin, 
relative to the corresponding control animals and relative to PM administration of 
gentamicin (Figure 4-2b). However, all three parameters showed a high degree of 
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variability in response to gentamicin administration. This inter-individual variation 
was most notable in the AM treatment group.  
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Figure 4-2 Clinical chemistry parameters and histopathology scores following 
treatment with gentamicin for (a) histopathology severity score of nephrotoxic 
damage; (b) KIM-1 (nanograms); (c) NAG (milligrams); (d) total protein 
(milligrams). 
Individual values are identified with black dots and the bar represents the mean of each 
group of samples. Error bars represent standard deviation. All kidneys were scored from 
0 (= no necrosis) to 4 (= severe necrosis). Urinary protein biomarker results were 
corrected for urinary creatinine levels. Analysis of KIM-1, NAG and total protein was 
conducted by Dr Antoine at the Vaidya/Bonventre laboratory, Harvard Medical School, 
while histopathological assessment was conducted in Prof Park’s laboratory at the 
University of Liverpool. 
Key: KIM-1 – kidney injury molecule 1; NAG – N-acetyl--glucosaminidase. (*) p < 0.05; 
(**) p < 0.01.  
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4.2.2 REPRESENTATIVE NMR  SPECTRA 
NMR spectra from biofluids and tissues are comprised of signals from 
metabolites representing numerous metabolic pathways. Representative urinary 
and kidney spectra from control and gentamicin-treated rats (AM administration 
time), specifically median spectra for each group, are presented in Figures 4-3 
and 4-4.  
 
 
Figure 4-3 600 MHz 1H NMR spectra of urine from (a) control rats and (b) 
gentamicin treated rats (AM administration time). 
Key: 2-OG – 2-oxoglutarate; 3-IS – 3-indoxylsulfate; DMG – dimethylglycine; HIP – 
hippurate; NMNA – N-methylnicotinic acid; NMND – N-methylnicotinamide; PAG – 
phenylacetylglycine; TMAO – trimethylamine-N-oxide. 
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Figure 4-4 600 MHz 1H MAS-NMR spectra of kidney from (a) control rats and (b) 
gentamicin treated rats (AM administration time). 
Key: PC – phosphocholine; TMAO – trimethylamine-N-oxide. 
  
Examination of the urinary and kidney spectra identified a number of 
outliers. Specifically, the urinary spectrum from subject 6 (gentamicin, AM) 
contained significantly higher levels of glucose, lactate, alanine, taurine, and 
trimethylamine-N-oxide (TMAO), coupled with lower levels of citrate and 2-
oxoglutarate compared to the other individuals in this treatment group. This 
individual exhibited only mild histopathological damage (severity score of 2) 
characterised by tubular protein casts, focal interstitial mononuclear infiltrates, 
dilation of cortical tubuli, and excreted the lowest levels of urinary total protein, 
relative to creatinine, compared to the other individuals in this treatment group. 
The 1H MAS-NMR spectrum from subject 1 (gentamicin, PM) had higher levels of 
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a number of amino acids, specifically valine, leucine, isoleucine, and 
phenylalanine, compared to the other individuals in the group. There were no 
gentamicin-related histopathological changes observed in the kidney tissue from 
this individual (severity score of 0). The 1H MAS-NMR spectrum from subject 12 
(control, AM) was found to contain elevated levels of isovalerate, and acetyl 
tyrosine, compared to the other individuals in this treatment group. These 
subjects were excluded from subsequent analysis. To aid comparison, all models 
were therefore computed with three individuals in the gentamicin (AM) group, 
three in the gentamicin (PM) group, and three in the control (AM) group. 
4.2.3 METABOLIC IMPACT OF GENTAMICIN EXPOSURE –  
URINE 
The PCA scores plot of PC1 vs PC2 for the urinary spectra of the control 
and gentamicin-treated animals, for both administration times, is presented in 
Figure 4-5. PCA analysis of the 1H NMR urinary spectra showed clear 
segregation of the control animals and the gentamicin-treated animals into three 
separate clusters: control, gentamicin, AM, and gentamicin, PM (Figure 4-6). The 
PCA scores plot of PC1 vs PC2 showed discrimination between control and 
treated animals, and between the treated samples according to administration 
time in the first component, which accounted for 31% of the total variance in the 
data. The gentamicin, AM, treated individuals were further from control space 
along PC1, compared to the PM treated individuals. The PM treated group 
exhibited a high degree of variability along PC2. 
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Figure 4-5 PCA scores plot of PC1 vs PC2 obtained from 1H NMR urinary spectra 
of control and gentamicin-treated animals, for both administration times. 
Key: ( ) – control, AM; ( ) – control, PM; ( ) – gentamicin, AM; ( ) – gentamicin, 
PM. 
 
The supervised discriminant analysis technique, O-PLS-DA, was then 
employed to maximise the discrimination between the control and treated groups 
and provide an interpretation of the metabolic signature changes characteristic of 
administration of gentamicin at different administration times. Pair-wise models 
were computed for the treated versus control animals following both 
administration times. An O-PLS-DA model, using a single orthogonal component, 
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was computed to illustrate the metabolites responsible for discrimination between 
control and gentamicin-treated animals following an AM administration of 
gentamicin (Figure 4-6). The major urinary metabolic changes contributing to the 
separation between control and AM treated individuals, as identified from the 
corresponding loadings plots, were reduced levels of 3-IS, phenylacetylglycine 
(PAG), and hippurate, and higher urinary levels of taurine, alanine and lactate, 
relative to control levels (Figure 4-6).  
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 Figure 4-6 O-PLS-DA model derived from 1H NMR urinary spectra of control 
(n=3) and gentamicin-treated animals (n=3), following AM administration. 
(a) Cross validated scores (Tcv1) versus Y response. Control ( ); gentamicin-treated (
). (b) Loadings coefficients plot showing metabolites responsible for discrimination 
between control (top) and gentamicin treated (bottom) animals. Metabolites were 
assigned using standard spectra, literature values, and 'spike-in' experiments (3-IS. 
PAG). 
Model Statistics: Q2Y 0.85; R2Y 0.94; p 0.07. 
Key: 3-IS – 3-indoxylsulfate; PAG – phenylacetylglycine.  
 
A second cross-validated O-PLS-DA model for PM administration of 
gentamicin was computed to compare the treated group to the corresponding 
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control group and is shown in Figure 4-7. The major urinary metabolic changes 
contributing to separation between control and PM treated individuals were 
reduced levels of hippurate and 3-IS, and an increase in urinary taurine, as with 
AM administration. In addition, PM administration of gentamicin resulted in 
significant reductions in urinary levels of 2-oxoglutarate, citrate and succinate.  
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 Figure 4-7 O-PLS-DA model derived from 1H NMR spectra of control (n=4) and 
gentamicin-treated animals (n=3), following PM administration. 
(a) Cross validated scores (Tcv1) versus Y response. Control ( ); gentamicin-treated (
). (b) Loadings coefficients plot showing metabolites responsible for discrimination 
between control (top) and gentamicin treated (bottom) animals. Metabolites were 
assigned using standard spectra, literature values, and 'spike-in' experiments (3-IS). 
Model Statistics: Q2Y 0.78; R2Y 0.99; p 0.04. 
Key: 2-OG – 2-oxoglutarate; 3-IS – 3-indoxylsulfate; PAG – phenylacetylglycine.  
 
A further model was computed to explore the impact of administration time 
on urinary metabolic profiles. An O-PLS-DA pair-wise model was built comparing 
the gentamicin treated animals at both administration times (Figure 4-8). The 
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scores plot showed clear separation between the treated animals on the basis of 
administration time, and the dominant metabolic changes responsible for 
separation were identified from the corresponding loadings plot as low urinary 
levels of 3-IS, and PAG, coupled with elevated levels of alanine, valine, leucine, 
and lactate following an AM administration of gentamicin.  
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Figure 4-8 O-PLS-DA model derived from 1H NMR urinary spectra following AM 
(n=3) and PM administration (n=3) of gentamicin. 
(a) Cross validated scores (Tcv1) versus Y response. AM ( ); PM ( ). (b) Loadings 
coefficients plot showing metabolites responsible for discrimination between PM (top) 
and AM (bottom) administration time. Metabolites were assigned using standard spectra, 
and literature values. 
Model Statistics: Q2Y 0.78; R2Y 0.96; p 0.05. 
Key: 3-IS – 3-indoxylsulfate; PAG – phenylacetylglycine. 
 
A summary of the dominant urinary metabolic changes in response to 
gentamicin administration at AM or PM, as determined by the O-PLS-DA loadings 
coefficient, is presented in Table 4-2.  
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Table 4-2 Summary of metabolites responsible for discrimination between control 
and gentamicin-treated individuals, following administration of gentamicin. 
Metabolites are elevated () or reduced () in spectra of treated individuals relative to 
control. The scale of change (the first value in brackets) has been expressed as the log 
fold change of the metabolite resonance in the treated urine relative to the median control 
urine over the same collection period. For each metabolite, the coefficient of 
determination (r2) was measured at the peak underlined. Incidents of metabolic 
perturbations is indicated, i.e. occurrence/total number of individuals. Metabolites were 
assigned using standard spectra, literature values, and 'spike-in' experiments (3-IS. 
PAG). 
 
Metabolite 
 
1H Chemical Shift + 
Multiplicity 
 
Administration Time 
AM PM 
U1 1.66  (0.12; r2 = 0.99; 3/3)  (0.10; r2 = 0.98; 3/3) 
 
2-Oxoglutarate 2.47 (t), 3.03 (t)   (-0.10; r2 = 0.88; 3/3) 
 
3-Indoxylsulfate 7.21 (dd), 7.28 (dd), 7.36 
(s), 7.51 (d), 7.71 (d) 
 
 (-0.28; r2 = 0.97; 3/3)  (-0.21; r2 = 0.96; 3/3) 
 
Alanine 1.48 (d), 3.79 (q) 
 
 (0.08; r2 = 0.97; 3/3)  
 
Citrate 2.55 (d), 2.69 (d) 
 
  (-0.13; r2 = 0.94; 2/3) 
 
Hippurate 3.97 (d), 7.55 (t), 7.64 (t), 
7.83 (d) 
 
 (-0.74; r2 = 0.99; 3/3)  (-0.54; r2 = 0.91; 3/3)  
 
Lactate 1.33 (d). 4.11 (q) 
 
 (0.08; r2 = 0.97; 3/3)  
Phenylacetyl-
glycine 
3.69 (s), 3.74 (d), 7.35 
(m), 7.38 (m), 7.41 (s)  
 
 (-0.20; r2 = 0.95; 3/3)  
Succinate 2.41 (s) 
 
  (-0.14; r2 = 0.97; 3/3) 
Taurine 3.27 (t), 3.43 (t) 
 
 (0.29; r2 = 0.98; 3/3)  (0.32; r2 = 0.93; 3/3) 
Key: U1 – unassigned urinary metabolite. 
 
A number of metabolic commonalities were identified from the O-PLS-DA 
loadings plots in response to both an AM and PM administration of gentamicin, 
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specifically a reduction in urinary levels of 3-IS and hippurate, and in increase in 
urinary levels of taurine and an unassigned multiplet at  1.66 (U1).  
There were also clear differences in the urinary metabolic profiles of the 
treated individuals at each treatment time relative to the corresponding control 
animals. An AM administration of gentamicin resulted in an increase in urinary 
levels of alanine and lactate, while the same treated individuals excreted lower 
levels of PAG, relative to control levels. In contrast, levels of these metabolites 
were not significantly perturbed following a PM administration of gentamicin 
based on the O-PLS-DA loadings plot. The O-PLS-DA model of control versus 
gentamicin following a PM administration identified a reduction in urinary levels of 
a number of TCA cycle intermediates (i.e. 2-oxoglutarate, succinate and citrate) in 
response to gentamicin; these metabolites did not contribute to the separation 
observed between the AM treated animals and the corresponding control group.  
The O-PLS-DA loadings plot of AM versus PM gentamicin treated rats 
identified a number of additional metabolites that contributed to separation 
between the treated groups, specifically lactate, valine, leucine and isoleucine (all 
elevated in the AM treated group), and PAG and 3-IS (all reduced in the AM 
treated groups).  
4.2.4 METABOLIC IMPACT OF GENTAMICIN EXPOSURE –  
K IDNEY 
This analytical approach was replicated for the kidney 1H MAS-NMR 
spectra. PCA analysis of the 1H MAS-NMR kidney spectra showed a degree of 
separation between the treated individuals and the corresponding control animals: 
the scores plot of PC1 vs PC2 (where PC1 and PC2 explained 35% of the total 
variance in the data) showed separation in the first component between control 
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and treated for both AM and PM administration times, and between the treated 
animals in the second component (Figure 4-9). 
 
 
Figure 4-9 PCA scores plot of PC1 vs PC2 obtained from 1H MAS-NMR kidney 
spectra from control or gentamicin-treated animals. 
Key: ( ) – control, AM; ( ) – control, PM; ( ) – gentamicin, AM; ( ) – gentamicin, 
PM. 
 
To provide a clearer interpretation of the metabolic signature changes 
reflective of gentamicin exposure in the kidney, pair-wise O-PLS-DA models were 
constructed for the treated animals versus the control group, at each 
administration time. O-PLS-DA models were computed to illustrate the 
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metabolites responsible for discrimination between control and gentamicin-treated 
animals, following an AM administration (Figure 4-10) and a PM administration 
(Figure 4-11). In both instances, the O-PLS-DA scores plots showed clear 
separation between the control and treated spectra. The corresponding O-PLS-
DA loading coefficient plots indicated that discrimination between AM control and 
gentamicin treated individuals was primarily due to low levels of amino acids (i.e. 
alanine, leucine, isoleucine, phenylalanine), tyrosine, and betaine, coupled with 
high levels of choline, phosphocholine, lactate, myo-inositol (MI), glycine, and 
creatine, in kidney tissue collected from gentamicin-treated individuals (Figure 4-
10). 
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Figure 4-10 O-PLS-DA model derived from 1H MAS-NMR kidney spectra of 
control (n=3) and gentamicin-treated animals (n=3), following AM administration. 
(a) Cross validated scores (Tcv1) versus Y response. Control ( ); gentamicin-treated (
). (b) Loadings coefficients plot showing metabolites responsible for discrimination 
between control (top) and gentamicin treated (bottom) animals. Metabolites were 
assigned using standard spectra, and literature values, while STOCSY was employed to 
identify correlated peaks.  
Model Statistics: Q2Y 0.75; R2Y 0.97; p 0.09. 
Key: CRE – creatine; MI – myo-inositol; PC – phosphocholine.  
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Figure 4-11 identified a reduction in kidney levels of leucine, and alanine 
and an increase in creatine, choline and phosphocholine following a PM 
administration of gentamicin relative to control levels.  
 
 
Figure 4-11 O-PLS-DA model derived from 1H MAS-NMR kidney spectra of 
control (n=4) and gentamicin-treated animals (n=3), following PM administration. 
(a) Cross validated scores (Tcv1) versus Y response. Control ( ); gentamicin-treated (
). (b) Loadings coefficients plot showing metabolites responsible for discrimination 
between control (top) and gentamicin treated (bottom) animals. Metabolites were 
assigned using standard spectra, and literature values, while STOCSY was employed to 
identify correlated peaks. 
Model Statistics: Q2Y 0.71; R2Y 0.99; p 0.03. 
Key: CRE – creatine; PC – phosphocholine.  
 
A further O-PLS-DA model was computed to specifically investigate the 
impact of administration time on gentamicin metabolism in the kidney (Figure 4-
144 
12). This pair-wise model, constructed using univariance scaling, compared the 
kidney 1H MAS-NMR spectra obtained following daily AM and PM administration 
of gentamicin. The O-PLS-DA scores plot showed clear separation of the 
gentamicin-treated animals on the basis of administration time. The 
corresponding loadings coefficient plot indicated that the major metabolites 
contributing to this separation were lactate, creatine, choline, and MI (all 
elevated), and amino acids (i.e. leucine, valine, alanine, etc.), tyrosine, histidine, 
and phenylalanine (all reduced) following daily AM administration of gentamicin. 
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Figure 4-12 O-PLS-DA model derived from 1H MAS-NMR kidney spectra 
following AM (n=3) and PM administration (n=3) of gentamicin. 
(a) Cross validated scores (Tcv1) versus Y response. AM ( ); PM ( ). (b) Loadings 
coefficients plot showing metabolites responsible for discrimination between PM (top) 
and AM (bottom) administration time. Metabolites were assigned using standard spectra, 
and literature values, while STOCSY was employed to identify correlated peaks. 
Model Statistics: Q2Y 0.73; R2Y 0.95; p 0.07. 
Key: CRE – creatine; MI – myo-inositol.  
 
A summary of the dominant endogenous metabolic changes observed in 
the kidney reflective of gentamicin administration at both administration times, as 
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determined from the O-PLS-DA loadings coefficient plots, is presented in Table 4-
3. 
 
Table 4-3 Summary of metabolites responsible for discrimination between control 
and gentamicin-treated individuals, following administration of gentamicin. 
Metabolites are elevated () or reduced () in spectra of treated individuals relative to 
control. The scale of change (as indicated by the first value in brackets) has been 
expressed as the median log fold change of the metabolite resonance in the treated urine 
relative to the median control urine over the same collection period. For each metabolite, 
the coefficient of determination (r2) was measured at the peak underlined. Incidents of 
metabolic perturbations is indicated, i.e. occurrence/total number of individuals. 
 
Metabolite 
 
1H Chemical Shift + 
Multiplicity 
 
Administration Time 
AM PM 
Alanine 1.48 (d), 3.79 (q) 
 
 (-0.32; r2 = 0.98; 
3/3) 
 
 (-0.10; r2 = 0.91; 
3/3) 
Betaine 3.27 (s), 3.90 (s) 
 
 (-0.14; r2 = 0.90; 
2/3) 
 
 
Choline 3.20 (s), 3.51 (t), 3.51 (t) 
 
 (0.08; r2 = 0.80; 
3/3) 
 
 (0.02; r2 = 0.96; 
2/3) 
Creatine 3.04 (s), 3.94 (s) 
 
 (0.14; r2 = 0.95; 
3/3) 
 
 (0.05; r2 = 0.88; 
2/3) 
Fumarate 6.53 (s) 
 
 (0.96; r2 = 0.97; 
2/3) 
 
 
Glycine 3.57 (s) 
 
 (0.10; r2 = 0.82; 
2/3) 
 
 
Isoleucine 0.94 (t), 1.01 (d), 1.26 
(m), 1.48 (m), 1.96 (m), 
3.68 (d) 
 
 (r2 = 0.96; 3/3)  
Lactate 1.33 (d). 4.11 (q) 
 
 (0.27; r2 = 0.91; 
3/3) 
 
 
Leucine 0.96 (t), 1.71 (m), 3.73 t) 
 
 (-0.27; r2 = 0.95; 
3/3) 
 
 (-0.10; r2 = 0.92; 
3/3) 
Myo-inositol 3.27 (t), 3.53 (dd), 3.62 
(t), 4.05 (t) 
 
 (0.07; r2 = 0.98; 
3/3) 
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Phenylalanine 3.13 (d), 3.28 (dd), 4.00 
(dd), 7.33 (m), 7.39 (t), 
7.43 (m) 
 
 (-0.27; r2 = 0.98; 
3/3) 
 
Phosphocholine 3.22 (s), 3.62 (t) 4.18 
(dd) 
 
 (0.25; r2 = 0.94; 
3/3) 
 
 (0.19; r2 = 0.92; 
3/3) 
Tyrosine 3.06 (dd), 3.20 (dd), 
3.94 (dd), 6.91 (d), 7.20 
(d) 
 
 (-0.25; r2 = 0.98; 
3/3) 
 
Valine 0.99 (d), 1.04 (d), 2.28 
(d), 3.62 (d) 
 
 (-0.43; r2 = 0.97; 
3/3) 
 
It was not possible to determine the scale of change of isoleucine due to peak overlap. 
 
Administration of gentamicin, at either administration time, was 
characterised by lowered urinary levels of alanine and leucine, and elevated 
urinary levels of choline, creatine, and phosphocholine relative to control levels. In 
addition, an AM administration of gentamicin was characterised by a number of 
unique metabolic changes, as described previously.  
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4.3 DISCUSSION 
An NMR-based metabolic profiling strategy in conjunction with 
measurement of urinary biomarkers and histopathology was applied to interrogate 
and understand the metabolic basis of gentamicin-induced nephrotoxicity. 
Metabolic perturbations following gentamicin administration were detected using 
solution and solid state NMR spectroscopy of urine, serum, kidney and liver from 
rats. There were no significant changes noted in either the serum or liver 
metabolic profiles following gentamicin administration at either treatment time, 
relative to the corresponding controls. Unlike many drugs, gentamicin is not 
metabolised in the liver but is excreted unchanged in the urine, accounting for the 
lack of metabolic impact on the liver samples. Analysis therefore focused on the 
metabolic changes observed in the urine and kidney. Pattern recognition methods 
were applied to the identification of discriminatory metabolites in response to 
differential treatments. 
4.3.1 METABOLIC IMPACT OF GENTAMICIN 
Conventional histopathological analysis was performed on kidney tissue 
collected from all animals at termination. No vehicle-related microscopic changes 
were observed in the kidney tissue. Gentamicin administration resulted in clear 
microscopic damage, reflective of the nephrotoxic effect of gentamicin. In this 
study, the microscopic damage observed was most severe in the AM treated 
group, indicating a greater degree of toxicity, consistent with earlier studies. 122, 123 
It was noted that the PM administration time resulted in a high degree of inter-
individual variation on the basis of histopathology severity scores. 
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Kidney damage proceeds via a number of reversible steps, depending on 
the degree of toxic insult. The conventional biomarkers of kidney injury (i.e. serum 
creatinine, blood urea nitrogen) are insensitive, non-specific, and only detectable 
once severe, often irreversible, damage has occurred. Extensive research has 
therefore led to the identification of NAG and KIM-1 as potential biomarkers of 
acute kidney injury (AKI) that could facilitate earlier diagnosis. 132, 133 NAG and 
total protein were significantly elevated following gentamicin administration at 
either dosing time, relative to control levels, indicating that both are potentially 
useful markers of gentamicin-induced toxicity. Levels of KIM-1, NAG and total 
protein were elevated in the AM group relative to PM group, though of these only 
KIM-1 showed a statistically significant increase relative to PM levels. Therefore, 
NAG and total protein may be considered to lack sensitivity to differential 
gentamicin-induced nephrotoxicity in response to administration time. However, it 
should be noted that levels of all markers were highly variable in the AM group, 
the impact of which was exaggerated by the low animal number. 
The application of metabonomic techniques identified a number of 
metabolic consequences following gentamicin administration on the basis of O-
PLS-DA loadings coefficient plots, specifically perturbations in levels of amino 
acids, gut microbial co-metabolites, renal osmolytes and TCA cycle intermediates. 
AM administration of gentamicin was characterised by an increase in urinary 
levels of alanine, lactate and taurine, accompanied by a decrease in urinary levels 
of 3-IS, hippurate and PAG. A PM administration of gentamicin was characterised 
by elevated urinary levels of taurine, and a reduction in urinary levels of 3-IS, 
hippurate, citrate and succinate.  
The metabolic impact of gentamicin administration on kidney tissue was 
more marked following an AM administration with levels of choline, creatine, 
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fumarate, phosphocholine, glycine, and lactate all elevated in kidney tissue 
collected post treatment. Further, an AM administration of gentamicin resulted in 
lower tissue levels of a number of amino acids (alanine, leucine, isoleucine, 
phenylalanine, and valine), betaine and tyrosine in kidney tissue collected from 
treated animals. In the PM treatment group, elevated levels of choline, creatine 
and phosphocholine, and reduced levels of alanine and leucine were detected. 
Changes in urinary levels of compounds such as hippurate, 3-IS and PAG 
are suggestive of perturbations in gut microbial co-metabolism due to the 
antibiotic activity of gentamicin. Gut microbiota metabolise polyphenols to benzoic 
acid, which is detoxified via conjugation with glycine to form hippurate, which is 
secreted by renal tubular cells and subsequently excreted in the urine. 204 
Reductions in levels of hippurate are implicated in a number of pathophysiological 
states, including perturbation of the glycine pathway. However, 1H MAS-NMR of 
liver indicated that gentamicin administration had no significant impact on hepatic 
levels of glycine (results not shown). Therefore, reduced urinary levels of 
hippurate are likely due to disturbance in benzoic acid synthesis. Alternatively, a 
reduction in urinary levels of hippurate may indicate insufficient proximal 
secretion. 205 Numerous studies have reported reduced urinary levels of hippurate 
following aminoglycoside administration. 155, 156, 206, 207 Sieber et al. also noted a 
reduction in urinary levels of another microbial co-metabolite 3-IS. 156 3-IS is 
produced via bacterial mediated catabolism of tryptophan. Dietary tryptophan is 
metabolised to indole by the bacterial enzyme, tryptophanase. Indole is then 
hydroxylated in the liver by CYP2E1 to form indoxyl, which is subsequently 
sulphated by sulphotransferases forming 3-IS. 208, 209 Therefore a reduction in 
urinary 3-IS following gentamicin exposure is likely reflective of the antibiotic 
activity of gentamicin. Sieber et al. did however express concern about the 
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relative sensitivity of 3-IS as a potential biomarker of gentamicin exposure: a 
significant reduction in urinary levels of 3-IS was only observed following high 
dose administration (120 mg/kg). In comparison, 3-IS was significantly reduced 
following daily administration of gentamicin at 200 mg/kg in this current study.  
Sieber et al. also reported changes in urinary levels of PAG: a significant 
increase was noted on day 6. 156 In the current study, urinary levels of PAG were 
decreased following an AM administration of gentamicin, and unchanged in the 
PM treatment group. It should be noted however that the doses differ (200 mg/kg 
in present study compared to 120 mg/kg), as well as the dosing schedule (Sieber 
et al. dosed animals twice daily as opposed to once). PAG is derived from 
metabolism of phenylacetate as part of the putrefactive processes mediated by 
colonic bacteria. First, bacteria generate phenylacetate from phenylalanine, which 
is subsequently detoxified by the host via conjugation with glycine. 210 Reduced 
levels of PAG indicate disturbance to this pathway. PAG has previously been 
suggested as a potential biomarker of phospholipidosis, i.e. the accumulation of 
phospholipids within animal cells characterised by the presence of ‘onion bodies’. 
211-213 Again, this was inconsistent with the current study, though it should be 
noted that no microscopic signs of phospholipidosis were observed in the current 
work.  
 An increase in urinary amino acids (specifically alanine following AM 
administration), concomitant with a decrease in amino acids levels in kidney 
tissue (at both administration times, but more marked in the AM group) was 
observed following gentamicin administration, consistent with earlier work. 155, 156, 
206 Approximately 99% of amino acids are reabsorbed in the proximal tubule. 
Under nephrotoxic conditions, amino acid excretion is increased due to either 
increased membrane permeability, or impaired reabsorption. 214, 215 Boudonck et 
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al. reported a significant increase in urinary amino acid levels prior to the 
development of histopathological kidney damage, following exposure to a number 
of known nephrotoxins, including gentamicin. 155 Therefore, measurement of 
increased urinary amino acids may be a biomarker for early renal injury, though it 
lacks specificity for gentamicin-induced damage. In addition, reductions in levels 
of amino acids were observed in the kidneys at both administration times. While 
aminoaciduria can be explained by the known mechanism of gentamicin toxicity, 
i.e. impaired tubular re-absorption, the reasons for these apparently 
complementary observations in the kidney tissue are likely to be different, at least 
in part. Rather, this reduction in amino acid levels in the kidney of gentamicin-
treated rats is suggestive of perturbations in energy metabolism, a theory 
supported by perturbations in lactate levels. Further, tissue levels of leucine and 
isoleucine were reduced following gentamicin exposure suggestive of catabolism 
of branched-chain amino acids to produce acetyl CoA and glucose via 
gluconeogenesis. 216 An increase in urinary levels of 2-oxoglutarate, citrate and 
succinate was seen in the PM treatment group. All are considered non-specific 
markers, rather they indicate a generalised perturbation of mitochondrial energy 
metabolism.  
Kidneys respond to hypertonic stress, such as occurs with gentamicin 
toxicity, by accumulating osmolytes, such as MI, betaine and phosphocholine. 217 
Following gentamicin administration, levels of all three metabolites were 
significantly altered relative to control levels, reflective of gentamicin-induced 
nephrotoxicity. Taurine is also implicated in homeostatic control of renal 
osmolarity 140 and was elevated in urine following gentamicin exposure. Minor 
changes in urinary levels of a number of renal osmolytes were reported by Sieber 
et al. (i.e. TMAO, betaine, methylamine, dimethylglycine, dimethylamine). 156 
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Given that no urinary changes in levels of these metabolites were observed in this 
current study or in other studies of drug-induced renal stress, 155 combined with 
the knowledge that these metabolites are also implicated in choline metabolism 
200, 216 many of the changes may in fact be reflective of perturbations of gut 
microbial activity. Choline metabolism is the result of a complex host-symbiotic 
relationship, involving mammalian and gut microbial metabolism. 200 The first step 
in the metabolism of dietary choline involves conversion to trimethylamine (TMA), 
mediated by gut microbiota. 218 TMA is subsequently detoxified by oxidation to 
TMAO. In addition, the methylamines are subject to bacterial-mediated inter-
conversions; perturbations in urinary levels of these metabolites likely indicate 
disruption to one or other of the pathways. 
Many of the urinary metabolic perturbations observed following gentamicin 
exposure mirror those associated with Fanconi syndrome, specifically elevated 
urinary levels of lactate and amino acids. Associated with a wide variety of 
inherited and acquired conditions, Fanconi syndrome is a generalised dysfunction 
of the renal proximal tubules, characterised by a defect in transport mechanisms, 
resulting in renal loss of glucose, amino acids, uric acids, phosphate, and 
bicarbonate. 113 Primary Fanconi syndrome is associated with a number of inborn 
errors of amino acid and carbohydrate metabolism, all of which are inherited in an 
autosomal recessive pattern, including cystinosis (accumulation of cystine in 
lysosomes), 219 galactosaemia (deficiency in activity of galactose-1-phosphate 
uridyl transferase) and Wilson’s disease. 220 Primary Fanconi syndrome is 
generally observed in childhood. Fanconi syndrome can also be acquired (i.e. 
secondary) and a number of drugs, including aminoglycoside antibiotics, have 
been shown to cause renal tubular defects resulting in Fanconi syndrome. 221 The 
urinary metabolic profiles observed following gentamicin exposure in this current 
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study were consistent with the development of gentamicin-induced Fanconi 
syndrome.  
4.3.2 TIME-DEPENDENT METABOLIC RESPONSE TO 
GENTAMICIN 
The extent of aminoglycoside-induced toxicity is dependent on a number of 
factors, including dose, route of administration, duration of treatment, age and 
sex. 122 Administration time has also been identified as a contributing factor to the 
severity of toxic response, with an administration time corresponding to the rest 
period identified as resulting in a more toxic outcome. 122, 123  
NMR spectroscopic analysis identified clear urinary metabolic differences 
in response to administration of gentamicin at different times. An AM 
administration had a more marked impact on urinary levels of gut microbial co-
metabolites (hippurate, 3-IS, PAG). As previously stated, this is suggestive of the 
impact of gentamicin on gut microflora and is believed to be a marker of the 
pharmacological (antibiotic) activity of gentamicin, suggesting the presence of a 
differential impact on gut microbiota according to treatment time. Wang et al. 
noted a circadian variation in urinary levels of 3-IS in healthy male subjects, 222 
while diurnal variation in urinary levels of hippurate have been reported in the 
mouse model. 223 Therefore the observed temporal difference may be due to 
differences in gut microbiota activities during the day or differences in liver 
activity. This is further supported by the differences identified in kidney levels of 
phenylalanine and tyrosine: both metabolites were significantly elevated in the PM 
group, relative to the AM, based on the O-PLS-DA loadings plot. 
Gentamicin-induced nephrotoxicity is associated with an increase in 
urinary levels of alanine and lactate due to impaired reabsorption in the proximal 
155 
tubule. Both metabolites were identified as discriminatory between the treatment 
groups from the O-PLS-DA loadings plot, suggestive of increased toxicity in these 
individuals. This is consistent with both the microscopic observations made in this 
study and with earlier findings. 122, 123 Further, those individuals administered an 
AM dose of gentamicin experienced a significant increase in measured levels of 
renal osmolytes and a decrease in levels of amino acids in the kidney tissue, all 
considered biomarkers of nephrotoxicity. 155, 217  
PM administration of gentamicin resulted in significant reductions in urinary 
levels of succinate, citrate and 2-oxoglutarate; urinary levels of these metabolites 
were not significantly perturbed following an AM dose. These metabolites are 
TCA cycle intermediates, and are suggestive of mitochondrial metabolic 
perturbation. Perturbation of energy pathways was also identified in the kidney 
tissue following an AM dose of gentamicin (reduced levels of branched-chain 
amino acids), therefore the metabolic signature observed in the PM animals may 
be reflective of a less severe toxic response.  
Aminoglycoside-induced nephrotoxicity is dependent on accumulation of 
the drug within the renal cortex: urinary clearance of the drug is lower during the 
rest period, leading to increased accumulation and toxicity. 122, 224 However, 
temporal variation in glomerular filtration rate is unlikely to account for all the 
variation observed and a number of other mechanisms have been proposed, 
though the exact mechanism remain unclear. 124-129, 225-227 
4.3.3 L IMITATIONS AND COMPLICATIONS 
The conclusions drawn in this study are limited due to the low animal 
numbers and the high degree of inter-individual variation in response to treatment 
observed in the clinical chemistry and histopathological analysis. This has proved 
156 
to be a limiting factor for both conventional toxicological assessment and 
metabonomic analysis. Therefore, caution is urged when considering these 
results.  
A multivariate statistical approach was employed throughout this work to 
aid in the interpretation of the metabolic changes in response to gentamicin 
exposure. Multivariate methods, such as O-PLS-DA, can discover significant 
patterns of variables that contribute to separation between classes, none of which 
has any statistical significance when considered in isolation. In contrast, a 
univariate approach, which may be helpful in order to quantify the degree of 
metabolic perturbation in response to treatment, is not ideal as it involves 
univariate analysis of isolated metabolites identified from multivariate profiles. 
Further, the univariate approach will most likely obscure some of these significant 
changes as observed here. 
157 
4.4 CONCLUSION 
Based on metabonomic analysis, histopathological analysis and levels of 
KIM-1, administration of gentamicin was shown to be more toxic in the rat model 
following an AM administration. Gentamicin administration was characterised by 
an increase in urinary excretion of amino acids and lactate and reduced levels of 
gut microbial co-metabolites, including hippurate and 3-IS. 1H MAS-NMR analysis 
of intact kidney tissue detected a reduction in levels of amino acids and an 
increase in levels of lactate, MI and choline-related metabolites following 
gentamicin administration. The study identified a high degree of inter-individual 
variation in response to treatment, limiting the strength of these results. 
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Chapter 5 STATINS 
AIMS AND OBJECTIVES 
The primary purpose of this work was to investigate the potential to reduce 
gentamicin-induced nephrotoxicity through co-administration with a statin. This 
was done using a combination of traditional toxicity assessments and 
metabonomics, specifically high resolution (MAS) NMR spectroscopy of urine and 
intact kidney. Further, the metabolic impact of co-administration of gentamicin, 
statin and mevalonate on gentamicin-induced nephrotoxicity was investigated 
through the integration of traditional toxicity assessments with (MAS) NMR of 
urine and kidney. 
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5.1 METHODS  
The following study was carried out collaboratively with Dr Antoine and 
Prof Park at the MRC Centre for Drug Safety Science at the University of 
Liverpool, who designed the study. All animal manipulations were conducted by 
the MRC Centre for Drug Safety Science at the University of Liverpool. 
5.1.1 ANIMAL HANDLING AND SAMPLE COLLECTION 
All animal manipulations were conducted by the MRC Centre for Drug 
Safety Science at the University of Liverpool in full accordance with UK ethical 
legislation on animal experimentation. Male Sprague-Dawley (SD) rats 
(approximately 250-330g, n=24) were randomly allocated to six dose groups 
(n=4) as outlined in Table 5-1. Animals were dosed once daily for nine days via 
intra-peritoneal (i.p.) injection with control vehicle (0.9% saline), gentamicin (200 
mg/kg in 0.9% saline), mevalonate (100 mg/kg in 0.9% saline), atorvastatin (30 
mg/kg in 0.9% saline) or in combination, as described below. All injections were 
carried out at 10.00 a.m.  
 
Table 5-1 Dosing procedure and group assignments. 
Treatment Group Animal Numbers 
Control 1, 2, 3, 4 
Mevalonate 5, 6, 7, 8 
Gentamicin  9, 10, 11, 12 
Atorvastatin 13, 14, 15, 16 
Gentamicin + Atorvastatin 17, 18, 19, 20 
Gentamicin + Atorvastatin + Mevalonate 21, 22, 23, 24 
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Urine was collected over a period of 24 hours following administration of 
the final dose, and blood collected at termination via cardiac puncture. Kidney 
tissue samples were collected at termination. Three aliquots were snap frozen 
pending further analysis, and the remainder frozen in 10% formalin. 
5.1.2 CLINICAL CHEMISTRY AND HISTOPATHOLOGY 
Urine parameters (total volume, creatinine, kidney injury molecule 1 
(KIM1), and N-acetyl--glucosaminidase (NAG)) were recorded using standard 
methods, as outlined in Chapter 4. This work was conducted by Dr Antoine at the 
Vaidya/Bonventre laboratory, Harvard Medical School, Significant changes in 
these parameters from control levels were assessed using a Students two-tailed 
t-test. The kidney was sampled and fixed in a 10% formalin solution. 
Representative samples were processed routinely in an automatic tissue 
processor, embedded in paraffin, sectioned at 4-6 m, stained with haematoxylin 
and eosin, and examined histologically using light microscopy. This work was 
conducted in Professor Park’s laboratory at the University of Liverpool. 
5.1.3 NMR  SPECTROSCOPIC ANALYSIS OF URINE SAMPLES 
Urine samples were prepared and analysed by 1H NMR as described in 
Chapter 4, Section 4.1.3.  
5.1.4 1H MAS-NMR  SPECTROSCOPY OF INTACT K IDNEY 
SAMPLES 
Kidney samples were analysed by 1H MAS-NMR as described in Chapter 
4, Section 4.1.5.  
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5.1.5 NMR  SPECTRA DATA PROCESSING 
The 1H NMR spectra were processed as previously described (Chapter 4, 
Section 4.1.6) and subject to multivariate statistical analysis (PCA, PLS-DA, O-
PLS-DA). For further details, please refer to Chapter 4, Section 4.1.6. Relative 
concentrations of key metabolites (as identified using multivariate statistical 
methods) were calculated by integration of specific peaks. Correlation coefficient 
(R) heat maps were constructed from O-PLS-DA pair-wise models to summarise 
the metabolic variation observed in the urinary and kidney models in response to 
different treatment. 
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5.2 RESULTS  
5.2.1 CLINICAL CHEMISTRY AND HISTOPATHOLOGY 
Kidney tissue was examined microscopically and scored on a scale of 1 to 
4 according to severity of nephrotoxic damage (Figure 5-1c). There were no 
microscopic changes observed in the control or mevalonate treated group, while 
administration of atorvastatin resulted in mild changes in 2 out of 4 individuals 
(severity score of 1), characterised by the presence of tubular casts and cellular 
changes in the cortical tubules. Administration of gentamicin alone resulted in 
moderate damage in 3 out of 4 individuals (severity score of 2 or 3), characterised 
by the presence of necrotic cells in the cortical tubule and multi-focal mono-
nuclear interstitial infiltration. Co-administration of gentamicin + atorvastatin 
resulted in mild changes in 2 out of 4 individuals (severity score of 1), 
characterised as above. The remaining animals in this treatment group (2 out of 
4) exhibited no histopathological changes. Co-administration of gentamicin + 
atorvastatin + mevalonate resulted in a high degree of inter-individual variation 
across the treatment group with 2 individuals subject to moderate damage 
(severity score of 3), and 2 individuals exhibiting no macroscopic changes post 
treatment. Moderate damage was characterised as before. 
Urinary levels of KIM-1 and NAG were measured for all individuals at 
termination (Figure 5-1a, 1b). All levels were measured relative to creatinine, and 
are not absolute excretion values. There were no significant changes in levels of 
KIM-1 or NAG following administration of mevalonate or atorvastatin only, relative 
to control levels. There were no significant changes in measured levels of KIM-1 
and NAG in the gentamicin + atorvastatin co-administered group relative to the 
control individuals. KIM-1 and NAG were significantly elevated in the gentamicin 
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only and the gentamicin + atorvastatin + mevalonate co-administered animals 
relative to control animal levels, though levels of both parameters exhibited a high 
degree of inter-animal variation in both of these treatment groups.  
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Figure 5-1 Clinical chemistry parameters and histopathology scores following 
treatment with gentamicin, mevalonate, and atorvastatin for (a) KIM-1 
(ng/uCr/mg), (b) NAG (IU/uCr/mg), and (c) histopathology severity score of 
nephrotoxic damage.  
Individual values are identified with black dots and the bar represents the mean each 
group of samples. Error bars represent standard deviation. All kidneys were scored from 
0 (= no necrosis) to 4 (= severe necrosis). Urinary protein biomarker results were 
corrected for urinary creatinine levels. Analysis of KIM-1, and NAG was conducted by Dr 
Antoine at the Vaidya/Bonventre laboratory, Harvard Medical School, while 
histopathological assessment was conducted in Prof Park’s laboratory at the University of 
Liverpool. (**) p < 0.01. (***) p < 0.001.  
Key: KIM-1 – kidney injury molecule 1; NAG – N-acetyl--glucosaminidase. 
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5.2.2 METABOLIC IMPACT OF STATIN ADMINISTRATION 
The impact of statin (atorvastatin) administration on urinary and kidney 
metabolic profiles was assessed through the application of high resolution NMR 
spectroscopy. Representative 1H (MAS) NMR urinary and kidney spectra from 
control and atorvastatin treated individuals are shown in Figures 5-2 and 5-3. 
There were no statistically significant differences detected in metabolite levels in 
the urine or kidney tissue in response to atorvastatin administration, relative to 
control levels based on O-PLS-DA models (not shown).  
 
 
Figure 5-2 Representative 600 MHz 1H NMR spectra of urine from (a) control and 
(b) atorvastatin treated rats. 
Key: 2-OG – 2-oxoglutarate; 3-IS – 3-indoxylsulfate; DMG – dimethylglycine; NMNA – N-
methylnicotinic acid; NMND – N-methylnicotinamide; PAG – phenylacetylglycine; TMAO 
– trimethylamine-N-oxide. 
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Figure 5-3 Representative 600 MHz 1H MAS-NMR spectra of kidney from (a) 
control and (b) atorvastatin treated rats. 
Key: PC – phosphocholine; TMAO – trimethylamine-N-oxide. 
5.2.3 METABOLIC IMPACT OF MEVALONATE ADMINISTRATION 
The metabolic impact of mevalonate administration was explored through 
the use of high resolution NMR spectroscopy of urine, and intact kidney. 
Mevalonate was identified in urinary spectra by the presence of resonances at  
1.26 (s), 1.84 (t), 2.38 (d), and 3.87 (t), which were removed using STOCSYE 
prior to further analysis. 186 STOCSYE offers a highly efficient means of removing 
highly correlated peaks, i.e. peaks from the same compound such as mevalonate, 
thereby facilitating analysis using pattern recognition techniques without 
interference from drug metabolites. Representative 600 MHz 1H NMR urinary 
spectra from control and mevalonate treated individuals, before and after 
STOCSYE, are shown in Figure 5-5.  
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Figure 5-4 Representative 600 MHz 1H NMR spectra of urine from (a) mevalonate 
treated rats, (b) STOCSYE spectra showing mevalonate resonance only, (c) 
mevalonate treated rats post STOCSYE and (d) control rats. 
STOCSYE was applied to remove resonances associated with mevalonate at  1.26 (s), 
1.84 (t), 2.38 (d), and 3.87 (t).  
Key: 2-OG – 2-oxoglutarate; 3-IS – 3-indoxylsulfate; DMG – dimethylglycine; HIP – 
hippurate; NMNA – N-methylnicotinic acid; NMND – N-methylnicotinamide; PAG – 
phenylacetylglycine; TMAO – trimethylamine-N-oxide. 
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After the removal of the mevalonate-associated resonances, there was no 
statistically significant separation observed between the control and mevalonate-
treated urinary or kidney spectra (not shown).  
5.2.4 CO-ADMINISTRATION OF ATORVASTATIN REDUCES 
GENTAMICIN-INDUCED NEPHROTOXICITY 
The metabolic impact of co-administration of atorvastatin and gentamicin 
was assessed through the application of high resolution NMR spectroscopy to 
urine and kidney samples, following treatment. Representative 1H NMR urinary 
spectra from control, gentamicin and gentamicin + atorvastatin treated animals 
are shown in Figure 5-5. Gentamicin was detected in post-dose urine following 
administration of gentamicin + atorvastatin. Therefore, STOCSYE was again 
employed to remove the resonances due to gentamicin prior to statistical 
analysis. 186  
 
 
169 
 
Figure 5-5 Representative 600 MHz 1H NMR spectra of urine from (a) control (b) 
gentamicin, (c) STOCSYE spectra showing gentamicin resonances only and (d) 
gentamicin + atorvastatin treated animals. 
Key: 2-OG – 2-oxoglutarate; 3-IS – 3-indoxylsulfate; DMG – dimethylglycine; NMNA – N-
methylnicotinic acid; NMND – N-methylnicotinamide; PAG – phenylacetylglycine; TMAO 
– trimethylamine-N-oxide. 
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Representative 1H MAS-NMR spectra of kidney tissue from control, 
gentamicin and gentamicin + atorvastatin treated animals are presented in Figure 
5-6.  
 
 
Figure 5-6 Representative 600 MHz 1H MAS-NMR spectra of kidney from (a) 
control, (b) gentamicin, and (c) gentamicin + atorvastatin treated animals.  
Key: PC – phosphocholine; TMAO – trimethylamine-N-oxide. 
 
The metabolic impact of co-administration of atorvastatin on gentamicin 
activity was interrogated through multi-variate statistical modelling of urinary and 
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kidney spectra. The PCA scores plot (PC1 vs PC2 explaining 47% of the total 
variability) derived from the urinary spectra of control, gentamicin and gentamicin 
+ atorvastatin animals is presented in Figure 5-7. The gentamicin + atorvastatin 
individuals had an intermediate metabolic profile relative to the other groups. The 
PCA scores of gentamicin treated individuals were highly variable.  
 
 
Figure 5-7 PCA scores plot of PC1 vs PC2 obtained from 1H NMR urinary spectra 
of control and treated animals. 
Key: ( ) – control; ( ) – gentamicin; ( ) – gentamicin + atorvastatin. 
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PCA was insufficient to separate the kidney spectra of control, gentamicin 
and gentamicin + atorvastatin treated individuals (data not shown). The urinary 
spectra from subject 2 (control) contained high levels of betaine, compared to the 
other individuals in this treatment group. This subject was excluded from 
subsequent analysis; all control models (urinary and kidney) were therefore 
constructed with three individuals only. 
To obtain a greater insight into the metabolic impact of co-administration of 
atorvastatin on gentamicin activity, pair-wise O-PLS-DA models were constructed. 
An O-PLS-DA model showed clear separation between the gentamicin only and 
gentamicin + atorvastatin treated individuals (Figure 5-8). Interrogation of the 
corresponding loadings indicated that this separation was primarily due to low 
levels of gut microbial co-metabolites (i.e. hippurate, 3-indoxylsulfate (3-IS), 
phenylacetylglycine (PAG), 3-hydroxyphenylpropionate (3-HPPA), 
dimethylglycine, dimethylamine) and TCA cycle intermediates (i.e. citrate, 2-
oxoglutarate) in the urinary spectra of individuals administered gentamicin only.  
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Figure 5-8 O-PLS-DA model derived from 1H NMR urinary spectra of gentamicin 
(n=4) and gentamicin + atorvastatin (n=4) treated animals. 
(a) Cross validated scores (Tcv1) versus Y response. Gentamicin + atorvastatin ( ); 
gentamicin only ( ). (b) Loadings coefficients plot showing metabolites responsible for 
discrimination between gentamicin + atorvastatin (top) and gentamicin only (bottom) 
treated animals. Metabolites were assigned using standard spectra, literature values, and 
'spike-in' experiments (3-IS, PAG, 3-HPPA), while STOCSY was employed to identify 
correlated peaks. 
Model Statistics: Q2Y 0.68; R2Y 0.91; R2X 0.29; p = 0.03. 
Key: 2-OG – 2-oxoglutarate; 3-HPPA – 3-hydroxyphenylpropionate; 3-IS – 3-
indoxylsulfate; DMA – dimethylamine; DMG – dimethylglycine; PAG – 
phenylacetylglycine.  
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The metabolites responsible for discrimination between the gentamicin 
only and gentamicin + atorvastatin urinary spectra were comparable to those 
metabolites responsible for separation between the control and gentamicin 
animals in Chapter 4, i.e. hippurate, 3-IS, PAG, citrate, 2-oxoglutarate. Therefore, 
theorising that co-administration of gentamicin + atorvastatin had the potential to 
return the animals to their base metabolic state, the metabolic differences 
between the control and gentamicin + atorvastatin co-administered animals was 
explored. The PCA plot (Figure 4-8) showed metabolic separation between these 
groups, and the resulting O-PLS-DA model confirmed this (Figure 5-9). The 
statistically robust model identified the major metabolites contributing to the 
separation as hippurate, TCA cycle intermediates (i.e. 2-oxoglutarate, citrate, 
succinate), adipate and 2-aminoadipate which were all present at reduced levels 
in the gentamicin + atorvastatin urinary spectra, compared to levels in the control 
urine. In addition, the gentamicin + atorvastatin co-treated individuals also 
excreted higher urinary levels of glucose, dimethylglycine, 3-HPPA, lactate, and 
various amino acids (i.e. alanine, valine, leucine, isoleucine) compared to the 
control individuals. 
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Figure 5-9 O-PLS-DA model derived from 1H NMR urinary spectra of control (n=3) 
and gentamicin + atorvastatin (n=4) treated animals. 
(a) Cross validated scores (Tcv1) versus Y response. Control ( ); gentamicin + 
atorvastatin ( ). (b) Loadings coefficients plot showing metabolites responsible for 
discrimination between control (top) and gentamicin + atorvastatin (bottom) treated 
animals. Metabolites were assigned using standard spectra, and literature values, while 
STOCSY was employed to identify correlated peaks. 
Model Statistics: Q2Y 0.82; R2Y 0.97; p 0.02. 
Key: 2-AA – 2-aminoadipate; 2-OG – 2-oxoglutarate; 3-HPPA – 3-
hydroxyphenylpropionate; CIT – citrate; DMG – dimethylglycine; NMNA – N-
methylnicotinic acid.  
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O-PLS-DA pair-wise models were then constructed to investigate the 
impact of co-administration of gentamicin + atorvastatin on the kidney metabolic 
profile. A model was computed to assess the metabolic impact of gentamicin + 
atorvastatin co-administration relative to administration of gentamicin alone 
(Figure 5-10). Co-administration of gentamicin + atorvastatin resulted in higher 
levels of amino acids (i.e. tyrosine, phenylalanine, histidine, valine, leucine, 
isoleucine) in kidney tissue, relative to administration of gentamicin alone. The 
individuals exposed to gentamicin only had elevated levels of ethanol and glycine 
post dose.  
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Figure 5-10 O-PLS-DA model derived from 1H MAS-NMR kidney spectra of 
gentamicin (n=4) and gentamicin + atorvastatin (n=4) treated animals. 
(a) Cross validated scores (Tcv1) versus Y response. Gentamicin + atorvastatin ( ); 
gentamicin only ( ). (b) Loadings coefficients plot showing metabolites responsible for 
discrimination between gentamicin + atorvastatin (top) and gentamicin only (bottom) 
treated animals. Metabolites were assigned using standard spectra, and literature values, 
while STOCSY was employed to identify correlated peaks. 
Model Statistics: Q2Y 0.44; R2Y 0.86; p 0.07. 
 
 The O-PLS-DA model constructed to compare the kidney metabolic 
profiles of the control and gentamicin + atorvastatin treated animals was 
statistically valid, but identified only minor metabolic differences between these 
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groups, specifically lower levels of betaine and glycine in the kidney spectra from 
the gentamicin + atorvastatin treated individuals (Figure 5-11). 
 
 
Figure 5-11 O-PLS-DA model derived from 1H MAS-NMR kidney spectra of 
control (n=3) and gentamicin + atorvastatin (n=4) treated animals. 
(a) Cross validated scores (Tcv1) versus Y response. Control ( ); gentamicin + 
atorvastatin ( ). (b) Loadings coefficients plot showing metabolites responsible for 
discrimination between control (top) and gentamicin + atorvastatin (bottom) treated 
animals. Metabolites were assigned using standard spectra and literature values. 
Model Statistics: Q2Y 0.61; R2Y 0.99; p 0.05. 
5.2.5 MEVALONATE ADMINISTRATION REVERSES THE 
PROTECTIVE EFFECT OF ATORVASTATIN 
Finally, the metabolic impact of mevalonate on the urinary and kidney 
metabolic profiles was explored. While PCA analysis was insufficient to separate 
the urinary spectra of gentamicin and gentamicin + atorvastatin + mevalonate 
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treated individuals, it did show separation of these individuals from the control and 
gentamicin + atorvastatin co-administered animals (Figure 5-12).  
 
 
Figure 5-12 PCA scores plot of PC1 vs PC2 vs PC3 obtained from 1H NMR 
urinary spectra of control and treated animals. 
Key: ( ) – control; ( ) – gentamicin; ( ) – gentamicin + atorvastatin; ( ) – 
gentamicin + atorvastatin + mevalonate. 
 
Figure 5-13 shows the first three components (PC1 and PC2 and PC3 
accounting for 40% of the total variance) of the PCA analysis of kidney samples 
from control, gentamicin, gentamicin + atorvastatin, and gentamicin + atorvastatin 
+ mevalonate treated individuals. PCA analysis was unable to separate the 
kidney NMR spectra collected from the control and gentamicin + atorvastatin 
treated individuals, and from the gentamicin and gentamicin + atorvastatin + 
mevalonate treated individuals. 
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Figure 5-13 PCA scores plot of PC1 vs PC2 vs PC3 obtained from 1H MAS-NMR 
spectra of control and treated animals. 
Key: ( ) – control; ( ) – gentamicin; ( ) – gentamicin + atorvastatin; ( ) – 
gentamicin + atorvastatin + mevalonate. 
 
An O-PLS-DA model was constructed to assess the metabolic 
consequences of gentamicin + atorvastatin co-administration relative to co-
administration of gentamicin + atorvastatin + mevalonate (Figure 5-14). Again, the 
key metabolites contributing to separation were gut microbial co-metabolites, 
specifically hippurate, 3-IS, PAG, 3-HPPA and dimethylglycine which were all 
excreted at lower levels following co-administration of gentamicin + atorvastatin + 
mevalonate. 
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Figure 5-14 O-PLS-DA model derived from 1H NMR urinary spectra of gentamicin 
+ atorvastatin (n=4) and gentamicin + atorvastatin + mevalonate (n=4) treated 
animals. 
(a) Cross validated scores (Tcv1) versus Y response. Gentamicin + atorvastatin ( ); 
gentamicin + atorvastatin + mevalonate ( ). (b) Loadings coefficients plot showing 
metabolites responsible for discrimination between gentamicin + atorvastatin (top) and 
gentamicin + atorvastatin + mevalonate (bottom) treated animals. Metabolites were 
assigned using standard spectra, literature values, and 'spike-in' experiments (3-IS, PAG, 
3-HPPA_ while STOCSY was employed to identify correlated peaks. 
Model Statistics: Q2Y 0.72; R2Y 0.99; p 0.02. 
Key: 3-HPPA – 3-hydroxyphenylpropionate; 3-IS – 3-indoxylsulfate; DMG – 
dimethylglycine; PAG – phenylacetylglycine.  
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 O-PLS-DA showed clear discrimination between the kidney metabolic 
profiles of the gentamicin + atorvastatin and the gentamicin + atorvastatin + 
mevalonate treated individuals due to elevated levels of phenylalanine, tyrosine, 
histidine and betaine in the kidney spectra of those animals co-administered 
gentamicin + atorvastatin (Figure 5-15). Ethanol levels were higher in the kidney 
tissue from the gentamicin + atorvastatin + mevalonate co-administered 
individuals. 
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Figure 5-15 O-PLS-DA model derived from 1H MAS-NMR kidney spectra of 
gentamicin + atorvastatin (n=4) and gentamicin + atorvastatin + mevalonate (n=4) 
treated animals. 
(a) Cross validated scores (Tcv1) versus Y response. Gentamicin + atorvastatin ( ); 
gentamicin + atorvastatin + mevalonate ( ). (b) Loadings coefficients plot showing 
metabolites responsible for discrimination between gentamicin + atorvastatin (top) and 
gentamicin + atorvastatin + mevalonate (bottom) treated animals. Metabolites were 
assigned using standard spectra, and literature values, while STOCSY was employed to 
identify correlated peaks. 
Model Statistics: Q2Y 0.42; R2Y 0.93; p 0.07. 
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An O-PLS-DA model was constructed to identify urinary metabolic 
differences between the gentamicin only and gentamicin + atorvastatin + 
mevalonate treated animals: the resulting model had a negative Q2Y value (data 
not shown). Therefore, there was no statistically significant metabolic difference 
between these groups. Further, O-PLS-DA was unable to separate the MAS-NMR 
spectra of kidney obtained from those individuals treated with gentamicin alone 
and those co-administered gentamicin + atorvastatin + mevalonate: again, the O-
PLS-DA model constructed comparing these individuals had a low Q2Y and a 
high R2X, indicating the model was not reliable. 
Heat maps were constructed to summarise the results of the O-PLS-DA 
models computed from urinary and kidney NMR spectra, and identify similarities 
and differences in the metabolic response to difference treatment regimens 
(Figures 5-16 and-17). In columns 1 and 3, correlations were expressed relative 
to the control models, and in columns 2 and 4, to gentamicin + atorvastatin 
models. In all cases, blue indicated a positive correlation (i.e. elevated levels of 
this metabolite), while red represented a negative correlation (i.e. levels of the 
metabolite were decreased).  
The urinary and kidney metabolic perturbations in response to gentamicin 
administration, relative to control levels, were comparable to those identified 
following treatment with gentamicin + atorvastatin versus gentamicin + 
atorvastatin + mevalonate. Administration of gentamicin alone resulted in an 
decrease in urinary levels of TCA cycle intermediates (2-OG, citrate, succinate), 
gut microbial co-metabolites (3-IS, 3-HPPA, PAG and hippurate), and this 
metabolic pattern was replicated in the gentamicin treated animals, relative to the 
gentamicin + atorvastatin animals. Further, a comparable metabolic response 
was also noted in the kidney models, with gentamicin (relative to control) and 
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gentamicin (relative to gentamicin + atorvastatin) resulting in a significant 
decrease in levels of amino acids (alanine, valine, leucine), an increase in renal 
osmolytes (MI, phosphocholine). In addition, these heat maps also highlight the 
similarities between the metabolites responsible for separation between the 
gentamicin + atorvastatin animals relative to the gentamicin + atorvastatin + 
mevalonate, and those metabolites contributing to separation between the 
gentamicin only animals, relative to control (and to gentamicin + atorvastatin).  
Administration of gentamicin + atorvastatin relative to control resulted in 
unique metabolic signature in both the urine and kidney models. Urinary levels of 
amino acids were significantly increased following treatment, while levels of 2-
aminoadipate and adipate were elevated. Urinary levels of hippurate and TCA 
cycle intermediates (2-OG, citrate, succinate) were decreased in treated animals 
relative to control levels. The heat map derived from the kidney model of control 
versus gentamicin + atorvastatin showed less significant metabolites changes in 
response to treatment, although there was mild reductions in levels of kidney 
amino acids and mild elevations in levels of renal osmolytes in treated kidney 
relative to control. 
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Figure 5-16 Correlation coefficient heat map generated from four O-PLS-DA pair-
wise models, summarising urinary metabolic variation in response to therapeutic 
intervention. 
Metabolites coloured blue are increased relative to control levels (in columns 1 and 2), 
gentamicin levels (column 3) and gentamicin + atorvastatin (column 4); metabolites in red 
are decreased relative to these treatment groups.  
Key: 3-HPPA – 3-hydroxyphenylpropionic acid; NMNA – N-methylnicotinamide. 
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Figure 5-17 Correlation coefficient heat map generated from four O-PLS-DA pair-
wise models, summarising metabolic variation in kidney tissue in response to 
therapeutic intervention. 
Metabolites coloured blue are increased relative to control levels (in columns 1 and 2), 
gentamicin levels (column 3) and gentamicin + atorvastatin (column 4); metabolites in red 
are decreased relative to these treatment groups.  
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5.3 DISCUSSION 
Statins are among the most widely prescribed drugs worldwide. They are 
well-tolerated with limited adverse effects, though they can cause myopathy. 228, 
229 Also known as HMG-CoA reductase inhibitors, statins lower cholesterol levels 
by competitively inhibiting the rate-limiting step in cholesterol synthesis. The 
pathway responsible for synthesising cholesterol is called the mevalonate 
pathway, and it is also implicated in a number of other endogenous functions, 
including terpenoid synthesis, protein prenylation, cell membrane maintenance, 
hormone synthesis, protein anchoring and N-glycosylation. Further, the 
mevalonate pathway plays a key role in the internalisation of gentamicin into the 
kidney cell resulting in nephrotoxicity. It was therefore theorised by Professor 
Park of the University of Liverpool that statins have the potential to reduce 
gentamicin toxicity through the disruption of the mevalonate pathway. 121 This was 
assessed through the measurement of urinary biomarkers and high resolution 
NMR analysis of urine and intact kidney. 
5.3.1 ATORVASTATIN IS WELL-TOLERATED W ITH L IMITED 
METABOLIC IMPACT  
It has been previously shown that statin exposure in rats, specifically 
simvastatin, results in elevated urinary levels of 2-oxoglutarate, allantoin and 
TMAO following daily administration at 80 mg/kg. 230 It was theorised that statin 
administration had the potential to induce toxicity via oxidative stress related 
inflammation. The same study did however observe a high degree of inter-
individual variation with the statin-treated group. While these metabolic 
differences were reflective of differential levels of toxicity observed by Yang et al., 
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based on serum enzyme levels, the differential metabotypes reflective of the two 
populations were not explored in detail. 230 Kumar et al. looked specifically at the 
impact of atorvastatin, as used in this current study, and noted urinary 
perturbations in a number of amino acids through UPLC-MS metabolic profiling, 
though this study was carried out in hyperlipidaemic rats. 231 In this current study, 
administration of atorvastatin alone had no significant impact on urinary or kidney 
metabolic profiles. This was likely due to the differences in administered dose: the 
present study used 30 mg/kg compared to 80 mg/kg by Yang et al, and 70 and 
250 mg/kg by Kumar et al. Statins are well-tolerated and no atorvastatin-induced 
changes were detected in urinary levels of KIM1, NAG or in the microscopic 
appearance of the kidney tissue. 
5.3.2 ATORVASTATIN REDUCES GENTAMICIN-INDUCED 
NEPHROTOXICITY 
It was proposed that by disrupting the mevalonate pathway co-
administration of atorvastatin would prevent the accumulation of gentamicin and 
the subsequent development of drug-induced nephrotoxicity. This theory was 
supported by the results of conventional toxicity assessments (i.e. 
histopathological severity scores, KIM-1 and NAG) which indicated that 
gentamicin + atorvastatin co-administration was non-toxic in the rat model. 
It was established that administration of gentamicin resulted in elevated 
urinary levels of amino acids, lactate and glucose, due to impaired re-absorption, 
and reduced levels of a range of gut microbial co-metabolites, linked to the 
antibiotic action of gentamicin, relative to control levels (Chapter 4, 155, 156, 206, 232). 
In the present study, a number of the urinary metabolites responsible for 
separation between the gentamicin alone and gentamicin + atorvastatin animals 
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were all linked to gut microbial co-metabolism, specifically hippurate, 3-IS, 3-
HPPA and PAG 204, 208-210 which were all reduced following administration of 
gentamicin alone. Perturbations in these metabolites are likely reflective of the 
pharmacological, i.e. antibiotic, action of gentamicin. Analysis of the kidney 
spectra also identified perturbations in levels of phenylalanine and tyrosine, which 
were both elevated in the kidney collected from the animals co-administered 
gentamicin + atorvastatin. Again, both metabolites are implicated in bacterial 
mediated catabolism 233 and an increase in levels of these metabolites was 
considered suggestive of differential bacterial metabolism between these groups. 
Therefore, the impact observed on gut microbial co-metabolites in both the 
urinary and kidney spectra is likely a reflection of the systemic effect of 
gentamicin administration. 
There was no significant increase in urinary levels of amino acids, glucose 
and lactate following administration of gentamicin alone, relative to co-
administration of gentamicin + atorvastatin. If it is assumed that these metabolites 
are markers of gentamicin-induced nephrotoxicity due to impaired reabsorption, 
then it appears there was comparable levels of toxicity in both groups. However, it 
should be remembered that excretion rates are not known and all metabolic 
changes are expressed relative to control levels. Further, an increase in urinary 
levels of amino acids, lactate and glucose contributed to the separation observed 
between the control and the gentamicin + atorvastatin treated animals, also 
indicating that gentamicin retained a degree of nephrotoxicity when co-
administered with atorvastatin. While this suggested that co-administration of 
atorvastatin did not block gentamicin toxicity, analysis of the individual animal 
integral values identified a high degree of variability within the treatment groups, 
therefore reducing the significance of any observed changes. Although it is worth 
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noting that this variability in metabolic response was also reflected in the results 
of the conventional toxicity assessments, and is therefore not reflective of any 
shortcoming in the metabonomic approach. Reduced urinary levels of hippurate, 
as seen following administration of gentamicin alone and co-administration of 
gentamicin and atorvastatin, may also reflect gentamicin-induced toxicity. 
Hippurate is synthesised in renal and hepatic mitochondria from glycine and 
benzoic acid and secreted by renal tubular cells into the urine. 205 A decrease in 
urinary hippurate may therefore indicate perturbation in tubular excretion as a 
consequence of gentamicin-induced nephrotoxicity, in addition to its importance 
as a microbial co-metabolite. 
Analysis of the kidney spectra suggested that the toxicity experienced by 
the gentamicin + atorvastatin co-administered animals was less severe than that 
following administration of gentamicin alone: there were elevated levels of amino 
acids present in the tissue of those animals co-administered gentamicin + 
atorvastatin relative to gentamicin alone. Gentamicin administration alone results 
in a decrease in kidney amino acid levels due to impaired re-absorption and 
perturbation of energy metabolism (Chapter 4, 155). Therefore, the relative 
increase in levels of amino acids suggested that this renal impairment was 
significantly reduced following co-administration of atorvastatin. 
Given the small animal numbers and the high degree of variability in 
response to treatment, the true significance of the metabolic changes observed in 
this study in response to gentamicin are likely being masked. Allowing for these 
apparent shortcomings in experimental design, the metabonomic approach 
proved useful in the detection of subtle changes following gentamicin exposure. 
Therefore, when considered in conjunction with the conventional markers of 
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toxicity, the application of metabonomics may serve to offer a more complete 
picture than either technique in isolation.  
Co-administration of atorvastatin with gentamicin was found to reduce the 
toxicity of gentamicin. Of the animals treated with gentamicin alone or in 
combination, gentamicin was detected in the post dose urine collected from the 
gentamicin + atorvastatin individuals only. This suggests that atorvastatin resulted 
in increased excretion of gentamicin by blocking uptake and accumulation in the 
kidney, and reducing toxicity. However, metabonomic analysis suggested that co-
administration of atorvastatin impacted on the antibiotic action of gentamicin, 
albeit on a systemic level, likely due to the dose of atorvastatin administered: the 
dose used was 30 mg/kg compared to a therapeutic dose of between 10 and 80 
mg per day. While increasing the dose may result in a greater reduction in 
toxicity, it may also result in further undesired loss of antibiotic activity, though the 
extent is unclear based on current work. Clearly, from a clinical viewpoint, any 
impairment of the antibiotic action of gentamicin is unwanted. In addition, while 
statins are generally well-tolerated at therapeutic doses, administration of high 
doses can result in a broad range of adverse effects in a variety of tissue types, 
234 due to the importance of the mevalonate pathway and its products in many 
important endogenous functions. Therefore, complete blockage of the mevalonate 
pathway is undesirable.  
5.3.3 ADMINISTRATION OF MEVALONATE INDUCES MINOR 
METABOLIC CHANGES 
Mevalonate plays a key role in the internalisation of gentamicin into kidney 
cells and the subsequent development of gentamicin-induced nephrotoxicity, and 
administration of mevalonate alone was found to have no significant impact on 
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the urinary and kidney metabolic profiles or on any of the conventional markers of 
renal toxicity. 
5.3.4 CO-ADMINISTRATION OF MEVALONATE REVERSES THE 
PROTECTIVE EFFECT OF ATORVASTATIN  
It has been established that atorvastatin co-administration can reduce the 
nephrotoxic effect of gentamicin, due to interference with the mevalonate pathway 
via inhibition of HMG-CoA reductase. Mevalonate is the immediate product of 
HMG-CoA reductase, therefore it was further theorised that the combined 
administration of gentamicin, mevalonate and atorvastatin would have a toxic and 
metabolic impact comparable to that seen following administration of gentamicin 
alone. Further, co-administration of gentamicin, mevalonate and atorvastatin 
would provide proof of the importance of the mevalonate pathway in the 
development of gentamicin-induced nephrotoxicity. 
The ability of mevalonate to reverse the impact of statin administration was 
explored previously. 235, 236 Although this research focused on the potential for 
statin-induced hepatotoxicity, they observed a reduction in toxicity in the rat, on 
the basis of serum enzyme levels, following co-administration of lovastatin and 
mevalonate, relative to lovastatin alone. 235 Similar observations were made in the 
rabbit. 236 
Here, both KIM-1 and NAG were significantly elevated in the gentamicin + 
atorvastatin + mevalonate animals relative to control levels, and there was no 
significant difference between this group and the gentamicin only animals. Having 
established that atorvastatin could negate the toxic effect of gentamicin, this 
supported the theory that mevalonate could overcome this protective effect, and 
offered proof of the importance of the mevalonate pathway in the development of 
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gentamicin-induced nephrotoxicity, thereby supporting the hypothesis originally 
proposed by Antoine et al. 121 The histopathology scores for the co-administered 
group offered additional support for this hypothesis: moderate damage was 
observed in the gentamicin + atorvastatin + mevalonate group, comparable to that 
observed in the gentamicin only group. It was noted however that all three 
markers of toxicity showed a high degree of inter-individual variability in response 
to gentamicin + atorvastatin + mevalonate.  
Additional support was obtained through the application of metabolic 
profiling techniques: the urinary and kidney metabolic profiles of gentamicin only 
and gentamicin + atorvastatin + mevalonate treated individuals were 
indistinguishable. There were however clear metabolic differences between the 
gentamicin + atorvastatin + mevalonate and gentamicin + atorvastatin co-
administered individuals. The major urinary metabolites contributing to this 
separation were linked to gut microbial co-metabolism, specifically hippurate, 3-IS 
and PAG, which were all reduced in the gentamicin + atorvastatin + mevalonate 
animals. This was reflective of impaired antibiotic activity following administration 
of gentamicin + atorvastatin, an effect which was reversed with the addition of 
mevalonate. There were no significant differences in urinary levels of amino 
acids, lactate or glucose; given that elevated urinary levels of these metabolites 
are considered biomarkers of proximal tubule damage 156, 237 it was expected that 
the gentamicin + atorvastatin + mevalonate animals would excrete elevated levels 
of these metabolites. It was noted that levels of these metabolites showed a high 
degree of inter-individual variation in the gentamicin + atorvastatin + mevalonate 
group which may be obscuring the complete metabolic picture. 
Again, the interpretation of the metabolic impact of co-administration of 
gentamicin + atorvastatin + mevalonate was complicated by the experimental 
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design and the high degree of inter-individual variation within the treatment 
groups. Despite this, the combination of conventional urinary markers of toxicity 
and NMR-based metabonomic analysis of urine and kidney, indicated that the 
combined administration of gentamicin + atorvastatin + mevalonate resulted in a 
outcome comparable to administration of gentamicin alone. This further 
demonstrates the critical role of the mevalonate pathway in the development of 
gentamicin-induced nephrotoxicity. 
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5.4 CONCLUSION 
Co-administration of a statin was shown to reduce gentamicin-induced 
nephrotoxicity in the rat model, as measured using urinary levels of KIM-1 and 
NAG, histopathological examination and high resolution NMR of urine and intact 
kidney. However, the addition of a statin may potentially impact on the antibiotic 
effect of gentamicin to a degree, as indicated by perturbations in a number of gut 
microbial co-metabolites. Further exploration is necessary to quantify this effect. 
The protective effect of the statin was reversed via co-administration of 
mevalonate, thereby demonstrating the key role that the mevalonate pathway 
plays in the development of gentamicin-induced toxicity. Disruption to this 
pathway can prevent gentamicin uptake and subsequent nephrotoxicity. It is 
however important to note that inter-individual variation and low animal numbers 
limit the strength of any conclusions drawn from this study. Further, the 
experiments were designed to provide the maximum amount of information with 
the minimum number of animals, an aim that was clearly achieved. 
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Chapter 6 GENERAL DISCUSSION 
The purpose of this work was to increase the understanding of two widely 
prescribed therapeutic agents through the application of a high resolution NMR-
based metabonomic approach, enabling simultaneous identification of 
endogenous and exogenous metabolites in a range of biological matrices.  
A major problem with any treatment regimen is inter-individual variation in 
response, which can potentially result in pharmacological failure or adverse 
reactions. The INH study in Chapter 3 concluded that acetylator capacity was key 
to the development of INH-induced neurotoxicity, and that acetylator capacity 
could be predicted on the basis of pre-dose urinary metabolic profiles in rats. 
Further areas of research would include complete characterisation of these pre-
dose urinary metabolites and the investigation of the impact of the presence or 
absence of these metabolites on acetylation of other compounds. Identification of 
these metabolites has so far been unsuccessful despite the application of a range 
of 2D NMR experiments and the application of hyphenated techniques. 
Identification would hopefully enable a greater understanding of the role these 
metabolites play in INH-induced neurotoxicity. Acetylation is key to drug 
metabolism and detoxification, therefore, these metabolites may have implications 
for the efficacy or toxicity of other compounds. Ideally, this would involve a larger 
cohort of animals and would require urinary profiles to be obtained prior to dosing 
to enable classification of animals as strong, weak and intermediate responders, 
to ensure adequate numbers in each group. 
Ultimately, the hope is that this work would have a role in the provision of 
personalised or stratified health care. For this to happen, the findings need to be 
translatable to humans. Therefore, it would be necessary to analyse human urine 
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samples for the presence of these metabolites. If it is established as being 
present, further studies would be necessary to assess the relationship between 
this metabolite and patient acetylation capacity.  
Chapters 4 and 5 focused on the toxic impact of gentamicin and the ability 
to enhance or reduce its toxicity. This was a pilot study and therefore the animal 
numbers were small. The studies suggest that gentamicin-induced toxicity could 
be reduced via co-administration with atorvastatin, and while the results were 
promising it is clear that further work with a larger cohort is necessary to confirm 
the findings and account for the high degree of inter-individual variation observed. 
It would therefore be premature to talk about the future implications of this work 
on human healthcare, though the findings are potentially of great benefit. 
Gentamicin is widely prescribed due to its relative cost and high efficacy but 
development of nephrotoxicity is a dose-limiting factor. Reduction of toxicity 
without loss of pharmacological activity would greatly enhance the usefulness of 
gentamicin. 
Overall this work has provided further evidence of the benefits of a 
metabonomic-based approach in toxicity studies. Metabolic profiling identified 
clear endogenous and exogenous metabolic signatures reflective of INH and 
gentamicin therapy. The application of pharmacometabonomics enabled 
determination of a baseline, pre-treatment metabolic signature that was predictive 
of the differential metabolic fate of INH. The integrated metabonomic approach for 
the investigation of gentamicin toxicity demonstrated the combined use of 
conventional solution state NMR spectroscopy and MAS NMR spectroscopy for 
the analysis of biofluids and intact tissues, and the application of pattern 
recognition techniques in probing the biochemical response to a xenobiotic, in this 
case, gentamicin.  
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APPENDIX I – SUPPLEMENTAL DATA 
Chapter 3 – Isoniazid 
Table 7-1 Integral values for key INH-related urinary metabolites. 
All integral values have been divided by 106. 
Control, 0-7 Hours 
No. INH AcINH  INA INH-GLC INH-PA INH-KA 
001 33 70 1.6 112 69 26 
002 28 78 1.2 104 64 26 
003 25 79 1.3 108 71 28 
004 28 68 1.7 101 62 26 
005 26 61 1.6 110 55 28 
006 25 91 0.5 101 93 15 
007 18 79 7.9 110 81 21 
008 26 71 1.3 104 69 22 
009 21 82 1.5 101 79 27 
010 26 68 1.5 100 65 26 
Total 26 ± 4.1 75 ± 8.6 1.3 ± 0.4 105 ± 4.4 71 ± 11 25 ± 4.1 
Low Dose, 0-7 Hours 
No. INH AcINH  INA INH-GLC INH-PA INH-KA 
101 304 440 248 125 225 194 
102 921 443 347 151 353 198 
103 201 342 178 118 182 233 
104 151 301 166 115 126 166 
105 1150 409 375 146 486 264 
106 949 470 376 137 337 175 
107 570 279 207 128 255 187 
108 1270 441 377 149 584 311 
109 236 485 229 100 183 245 
110 959 298 262 163 369 265 
Total 292 ± 165 390 ± 78 206 ± 34 117 ± 11 194 ± 49 205 ± 3 
High Dose (CNS Non-Responders), 0-7 Hours 
No. INH AcINH  INA INH-GLC INH-PA INH-KA 
201 539 392 283 150 298 232 
202 866 461 364 127 309 250 
203 600 415 296 117 289 199 
208 762 560 332 188 404 221 
210 524 436 361 113 171 126 
Total 658 ± 150 452 ± 65 327 ± 37 139 ± 31 294 ± 83 206 ± 48 
High Dose (CNS Responders), 0-7 Hours 
No. INH AcINH  INA INH-GLC INH-PA INH-KA 
204 744 353 552 209 1010 294 
205 498 211 316 152 776 214 
207 957 210 301 871 679 308 
Total 733 ± 230 258 ± 82 390 ± 141 1490 ± 608 821 ± 170 272 ± 51 
221 
High Dose (CNS Non-Responder*), 0-7 Hours 
No. INH AcINH  INA INH-GLC INH-PA INH-KA 
206 671 379 478 1080 815 292 
Control, 7-24 Hours 
No. INH AcINH  INA INH-GLC  
001 31 68 0.7 89 
002 26 62 1.6 81 
003 22 68 1.3 77 
004 26 64 1.9 70 
005 23 64 1.7 86 
006 23 66 1.1 82 
007 19 73 1.7 76 
008 24 65 3.7 76 
009 20 65 1.8 75 
010 12 70 0.9 71 
Total 24 ± 3.5 66 ± 3.3 1.9 ± 0.5 78 ± 6.2 
Low Dose, 7-24 Hours 
No. INH AcINH  INA INH-GLC   
101 68 318 119 85   
102 44 238 73 101   
103 55 359 121 86   
104 64 259 124 85   
105 62 227 104 82   
106 27 193 95 76   
107 75 248 100 86   
108 62 273 99 83   
109 43 262 92 68   
110 55 209 77 88   
Total 55 ± 14 259 ± 5 100 ± 18 84 ± 8.3   
High Dose (CNS Non-Responders), 7-24 Hours 
No. INH AcINH  INA INH-GLC  
201 201 403 217 141 
202 171 395 200 128 
203 216 478 228 135 
208 168 477 245 92 
210 122 378 167 73 
Total 176 ± 36 418 ± 59 211 ± 29 114 ± 3 
High Dose (CNS Non-Responder*), 7-24 Hours 
No. INH AcINH  INA INH-GLC  
206 52 275 121 93 
Integrals were measured for resonances at  2.150 (AcINH), 2.194 (INH-PA), 4.263 (INH-
GLC), 7.705 (INH), 7.908 (INH-KA) and 8.619 (INA). 
Key: AcINH – acetylisoniazid; INA – isonicotinic acid; INH – isoniazid; INH-GLC – 
glucosyl isonicotinylhydrazide; INH-KA – 2-oxoglutarate isonicotinylhydrazone; INH-PA – 
pyruvate isonicotinylhydrazone. 
222 
(* This individual exhibited no overt clinical signs of adverse CNS effects but shared 
some of the metabolic features of the CNS responders) 
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Chapter 4 – Gentamicin 
To account for the low animal numbers used in this study, integrals were 
calculated for the metabolites responsible for separation between the groups. 
Individual values for each animal are listed; group values are expressed as mean 
± standard deviation. All integral values have been divided by 106. 
Table 7-2 Integral values for key urinary metabolites. 
Gentamicin, PM 
Metabolite 1 2 3 4 Total 
2-OG  850 1000 940 950 ± 110 
3-IS  56 50 41 49 ± 7.9 
Alanine  130 120 110 120 ± 8.8 
Citrate  1500 1500 1700 1600 ± 130 
Hippurate  81 110 81 90 ± 16 
Lactate  190 160 170 180 ± 16 
PAG  120 110 150 130 ± 19 
Succinate  290 310 350 320 ± 30 
Taurine  520 760 380 560 ± 190 
Gentamicin, AM 
Metabolite 5 6 7 8 Total 
2-OG 1100  1100 960 1100 ± 87 
3-IS 35  31 41 35 ± 5.3 
Alanine 150  140 140 140 ± 2.6 
Citrate 1600  1600 1600 1600 ± 20 
Hippurate 68  67 65 67 ± 1.1 
Lactate 200  190 190 190 ± 3.8 
PAG 90  950 72 86 ± 13 
Succinate 310  27 340 300 ± 35 
Taurine 590  610 510 570 ± 55 
Control, AM 
Metabolite 9 10 11 12 Total 
2-OG 1200 1500 1100  1300 ± 260 
3-IS 63 78 61  67 ± 9.3 
Alanine 120 120 120  120 ± 2.8 
Citrate 2000 2400 1600  2000 ± 410 
Hippurate 360 400 330  360 ± 33 
Lactate 160 160 160  160 ± 3.9 
PAG 150 150 120  140 ± 17 
Succinate 370 590 360  440 ± 130 
Taurine 270 260 340  290 ± 45 
Control, PM 
Metabolite 13 14 15 16 Total 
2-OG 1000 1300 1200 1200 1200 ± 8.8 
3-IS 74 80 81 79 78 ± 3.2 
Alanine 110 120 110 120 120 ± 4.6 
Citrate 2200 2000 1900 2300 2100 ± 180 
224 
Hippurate 370 220 300 370 310 ± 70 
Lactate 150 170 160 170 160 ± 9.9 
PAG 230 160 210 130 180 ± 43 
Succinate 410 480 410 450 440 ± 35 
Taurine 290 250 260 240 260 ± 234 
Subjects 1, 6, and 12 were excluded as outliers (see text for full details). 
Key: 2-OG – 2-oxoglutarate; 3-IS – 3-indoxylsulfate; DMG – dimethylglycine; PAG – 
phenylacetylglycine. 
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Table 7-3 Integral values for key metabolites in kidney MAS-NMR models. 
Gentamicin, PM 
Metabolite 1 2 3 4 Total 
Alanine  240 270 240 250 ± 17 
Betaine  740 700 680 710 ± 31 
Choline  150 140 160 150 ± 10 
Creatine  77 74 79 77 ± 2.3 
Fumarate  0.5 0.3 3.4 1.4 ± 1.8 
Glycine  160 130 170 150 ± 18 
Lactate  370 380 430 390 ± 29 
Leucine  270 310 240 270 ± 34 
MI  93 96 97 95 ± 1.8 
Phenylalanine  25 29 23 26 ± 2.9 
Phosphocholine  240 220 240 230 ± 9.5 
Tyrosine  26 29 25 26 ± 2.1 
Valine  100 120 91 100 ± 12 
Gentamicin, AM 
Metabolite 5 6 7 8 Total 
Alanine 110  150 160 140 ± 28 
Betaine 290  370 500 390 ± 110 
Choline 160  190 190 180 ± 17 
Creatine 100  89 74 88 ± 13 
Fumarate 8.1  6.3 5.1 6.5 ± 1.5 
Glycine 130  190 210 180 ± 41 
Lactate 670  990 620 760 ± 210 
Leucine 170  160 170 170 ± 1.4 
MI 70  92 97 86 ± 14 
Phenylalanine 15  12 15 14 ± 1.6 
Phosphocholine 250  360 280 300 ± 61 
Tyrosine 11  13 16 13 ± 2.6 
Valine 39  38 56 44 ± 10 
Control, AM 
Metabolite 9 10 11 12 Total 
Alanine 270 270 310  280 ± 22 
Betaine 550 630 440  540 ± 93 
Choline 180 160 110  150 ± 34 
Creatine 65 65 62  64 ± 1.6 
Fumarate 1.3 0.9 0.0  0.7 ± 0.7 
Glycine 160 150 120  140 ± 22 
Lactate 420 340 470  410 ± 64 
Leucine 300 270 360  310 ± 46 
MI 95 95 77  89 ± 11 
Phenylalanine 30 26 23  36 ± 3.5 
Phosphocholine 180 190 140  170 ± 23 
Tyrosine 29 24 19  24 ± 5.0 
Valine 110 110 140  120 ± 13 
Control, PM 
Metabolite 13 14 15 16 Total 
Alanine 300 290 350 310 310 ± 27 
Betaine 630 730 590 504 620 ± 83 
Choline 180 140 110 150 140 ± 28 
Creatine 71 68 65 67 68 ± 2.7 
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Fumarate 1.4 0.0 2.2 0.0 0.9 ± 1.0 
Glycine 140 160 130 150 150 ± 10 
Lactate 430 510 350 370 410 ± 72 
Leucine 320 350 360 340 340 ± 16 
MI 90 91 87 79 87 ± 0.6 
Phenylalanine 16 20 20 18 19 ± 2.1 
Phosphocholine 150 150 140 150 150 ± 7.9 
Tyrosine 17 14 20 21 18 ± 3.2 
Valine 100 120 120 110 110 ± 7.6 
Subjects 1, 6, and 12 were excluded as outliers (see text for full details). 
Key: MI – myo-inositol. 
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Chapter 5 – Statins 
To account for the low animal numbers used in this study, integrals were 
calculated for the metabolites responsible for separation between the groups. Individual 
values for each animal are listed; group values are expressed as mean ± standard 
deviation. Integral values have been divided by 106. 
Table 7-4 Integral values for key urinary metabolites. 
Control 
Metabolite 1 2 3 4 Total 
2-OG 490  450 710 550 ± 140 
3-IS 37  27 37 34 ± 5.9 
Alanine 32  31 28 30 ± 2.1 
Citrate 1800  1400 2300 1800 ± 450 
DMA 90  110 83 93 ± 12 
DMG 79  84 80 81 ± 2.5 
Glucose 96  120 77 98 ± 22 
Hippurate 310  270 220 260 ± 46 
Lactate 44  44 41 43 ± 1.8 
Leucine 78  71 78 76 ± 4.2 
NMNA 23  23 19 22 ± 2.2 
PAG 62  49 62 58 ± 7.6 
Succinate 100  98 160 120 ± 33 
Valine 9.9  9.5 10 9.9 ± 0.3 
Mevalonate 
Metabolite 5 6 7 8 Total 
2-OG 500 570 520 520 530 ± 31 
3-IS 32 37 43 38 38 ± 4.3 
Alanine 30 32 29 31 30 ± 1.2 
Citrate 2000 1700 1600 2000 1800 ± 170 
DMA 82 100 140 100 110 ± 24 
DMG 56 45 67 93 65 ± 21 
Glucose 130 100 98 110 110 ± 12 
Hippurate 320 180 260 300 270 ± 63 
Lactate 42 47 43 43 44 ± 2.5 
Leucine 76 79 74 75 76 ± 2.3 
NMNA 25 17 19 22 21 ± 3.4 
PAG 98 65 89 57 78 ± 20 
Succinate 120 140 120 120 130 ± 11 
Valine 10 11 11 10 11 ± 0.3 
Gentamicin 
Metabolite 9 10 11 12 Total 
2-OG 200 160 230 160 190 ± 36 
3-IS 17 12 13 15 14 ± 1.9 
Alanine 24 54 26 56 40 ± 17 
Citrate 800 480 760 580 660 ± 150 
DMA 43 47 67 74 58 ± 15 
DMG 47 29 74 40 48 ± 19 
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Glucose 120 470 98 510 300 ± 220 
Hippurate 60 57 59 50 56 ± 4.7 
Lactate 35 78 39 130 71 ± 45 
Leucine 140 110 65 74 98 ± 35 
NMNA 11 12 23 21 17 ± 6.2 
PAG 42 41 44 39 41 ± 2.1 
Succinate 73 66 75 62 68 ± 6.3 
Valine 15 13 8.1 9.0 13 ± 3.3 
Atorvastatin 
Metabolite 13 14 15 16 Total 
2-OG 370 500 490 440 45 ± 60 
3-IS 41 39 33 45 40 ± 5.1 
Alanine 30 28 29 27 28 ± 1.1 
Citrate 1600 1700 1800 1600 1700 ± 120 
DMA 76 87 96 77 84 ± 9.5 
DMG 67 43 57 58 56 ± 10 
Glucose 92 110 110 95 100 ± 7.6 
Hippurate 180 310 200 180 220 ± 61 
Lactate 39 33 38 34 36 ± 2.7 
Leucine 74 77 65 65 70 ± 6.0 
NMNA 16 16 23 19 18 ± 3.6 
PAG 94 63 58 53 68 ± 20 
Succinate 89 130 120 110 110 ± 16 
Valine 11 9.8 9.2 9.8 9.8 ± 0.6 
Gentamicin + Atorvastatin 
Metabolite 17 18 19 20 Total 
2-OG 340 330 310 300 320 ± 16 
3-IS 23 35 33 26 30 ± 5.7 
Alanine 63 60 47 55 56 ± 7.1 
Citrate 980 1300 940 680 980 ± 270 
DMA 140 140 230 170 170 ± 41 
DMG 180 150 130 170 160 ± 25 
Glucose 200 150 160 170 170 ± 26 
Hippurate 140 130 190 110 140 ± 32 
Lactate 130 100 93 110 110 ± 14 
Leucine 99 97 11 12 110 ± 8.9 
NMNA 17 16 15 15 16 ± 1.1 
PAG 60 65 61 59 61 ± 2.4 
Succinate 68 67 59 58 63 ± 5.6 
Valine 14 15 15 17 15 ± 1.2 
Gentamicin + Atorvastatin + Mevalonate 
Metabolite 21 22 23 24 Total 
2-OG 310 240 310 200 260 ± 54 
3-IS 17 15 13 14 15 ± 1.7 
Alanine 69 85 30 27 53 ± 26 
Citrate 540 790 970 710 750 ± 180 
DMA 82 62 37 78 65 ± 21 
DMG 36 46 40 45 42 ± 4.7 
Glucose 490 830 130 130 390 ± 340 
Hippurate 40 39 52 46 44 ± 6.0 
Lactate 190 220 53 41 130 ± 92 
Leucine 73 160 110 79 110 ± 39 
NMNA 21 16 11 79 16 ± 5.0 
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PAG 38 40 41 37 39 ± 2.0 
Succinate 35 110 78 63 71 ± 31 
Valine 8.7 19 16 11 14 ± 4.7 
Subject 2 was excluded as an outlier (see text for full details). 
Key: 2-OG – 2-oxoglutarate; 3-IS – 3-indoxylsulfate; DMA – dimethylamine; DMG – 
dimethylglycine; PAG – phenylacetylglycine. 
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Table 7-5 Integral values for key metabolites in kidney MAS-NMR models. 
Control 
Metabolite 1 2 3 4 Total 
Alanine 74  60 66 67 ± 7.4 
Betaine 65  68 88 74 ± 13 
Choline 16  17 22 18 ± 3.5 
Ethanol 28  17 8.4 18 ± 9.8 
Glycine 69  68 73 70 ± 2.4 
Histidine 8.6  5.4 6.0 6.7 ± 1.7 
Leucine 260  220 220 230 ± 22 
MI 88  85 92 88 ± 3.4 
Phenylalanine 12  11 6.4 9.7 ± 3.0 
Phosphocholine 25  25 37 29 ± 6.9 
Tyrosine 11  9.1 6.5 8.8 ± 2.2 
Valine 39  29 28 32 ± 5.9 
Mevalonate 
Metabolite 5 6 7 8 Total 
Alanine 69 63 70 57 65 ± 5.8 
Betaine 72 72 77 100 80 ± 14 
Choline 20 22 23 25 22 ± 1.8 
Ethanol 15 100 20 81 54 ± 43 
Glycine 74 72 77 83 76 ± 4.7 
Histidine 5.9 6.1 7.8 5.0 6.2 ± 1.2 
Leucine 250 230 240 190 230 ± 26 
MI 98 100 100 140 110 ± 22 
Phenylalanine 11 10 12 9.1 11 ± 1.1 
Phosphocholine 29 33 30 37 32 ± 3.3 
Tyrosine 9.4 8.6 9.6 8.0 8.9 ± 0.8 
Valine 32 30 32 24 30 ± 3.9 
Gentamicin 
Metabolite 9 10 11 12 Total 
Alanine 68 41 57 34 50 ± 15 
Betaine 66 39 74 42 55 ± 18 
Choline 22 19 26 19 21 ± 3.5 
Ethanol 19 23 27 25 24 ± 3.2 
Glycine 72 82 84 81 80 ± 4.9 
Histidine 6.1 4.2 6.8 2.7 5.0 ± 1.9 
Leucine 210 130 210 120 170 ± 50 
MI 100 120 120 120 110 ± 6.3 
Phenylalanine 5.6 5.7 7.6 3.6 5.6 ± 1.6 
Phosphocholine 31 40 45 44 40 ± 6.4 
Tyrosine 5.6 4.0 6.7 2.6 4.7 ± 1.8 
Valine 28 14 25 12 20 ± 8.3 
Atorvastatin 
Metabolite 13 14 15 16 Total 
Alanine 76 87 59 66 72 ± 12 
Betaine 71 67 65 75 69 ± 4.4 
Choline 23 8.5 20 23 18 ± 6.7 
Ethanol 13 5.9 9.7 6.9 8.8 ± 3.1 
Glycine 77 57 72 77 71 ± 9.8 
Histidine 7.7 11 6.0 7.9 8.1 ± 2.0 
Leucine 260 320 220 240 260 ± 43 
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MI 110 66 100 130 100 ± 26 
Phenylalanine 11 13 11 12 12 ± 1 
Phosphocholine 32 23 28 32 29 ± 4.5 
Tyrosine 9.9 13 9.1 9.5 10 ± 1.5 
Valine 34 52 30 33 37 ± 10 
Gentamicin + Atorvastatin 
Metabolite 17 18 19 20 Total 
Alanine 59 60 68 84 68 ± 12 
Betaine 70 79 73 61 70 ± 7.5 
Choline 19 19 20 29 21 ± 4.9 
Ethanol 16 16 8.0 12 13 ± 3.8 
Glycine 62 74 71 92 75 ± 12 
Histidine 6.8 6.5 7.3 11 7.9 ± 2.0 
Leucine 220 200 240 290 240 ± 38 
MI 98 94 96 120 100 ± 12 
Phenylalanine 10 8.9 12 15 12 ± 2.7 
Phosphocholine 28 29 29 33 30 ± 2.6 
Tyrosine 11 8.4 10 13 11 ± 2.0 
Valine 31 27 35 37 33 ± 4.5 
Gentamicin + Atorvastatin + Mevalonate 
Metabolite 21 22 23 24 Total 
Alanine 40 50 56 58 51 ± 7.7 
Betaine 43 43 73 68 57 ± 16 
Choline 25 21 15 21 20 ± 3.8 
Ethanol 52 30 31 12 32 ± 16 
Glycine 88 91 60 81 80 ± 14 
Histidine 7.8 4.6 5.3 6.7 6.1 ± 1.4 
Leucine 140 180 200 210 180 ± 33 
MI 130 130 100 120 120 ± 13 
Phenylalanine 5.0 8.2 8.2 9.0 7.6 ± 1.8 
Phosphocholine 39 41 33 39 38 ± 3.6 
Tyrosine 3.9 6.1 7.9 8.1 6.5 ± 2.0 
Valine 14 20 30 30 23 ± 7.9 
Subject 2 was excluded as an outlier (see text for full details). 
Key: MI – myo-inositol. 
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APPENDIX II – PUBLICATION 
Pharmacometabonomic characterization of xenobiotic and endogenous metabolic 
phenotypes that account for inter-individual variation in Isoniazid-induced 
toxicological response. 
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ABSTRACT: An NMR-based pharmacometabonomic approach was applied to 
investigate inter-animal variation in response to isoniazid (INH; 200 and 400 
mg/kg) in male Sprague−Dawley rats, alongside complementary clinical chemistry 
and histopathological analysis. Marked inter-animal variability in central nervous 
system (CNS) toxicity was identified following administration of a high dose of 
INH, which enabled characterization of CNS responders and CNS non-
responders. High-resolution post-dose urinary 1H NMR spectra were modelled 
both by their xenobiotic and endogenous metabolic information sets, enabling 
simultaneous identification of the differential metabolic fate of INH and its 
associated endogenous metabolic consequences in CNS responders and CNS 
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non-responders. A characteristic xenobiotic metabolic profile was observed for 
CNS responders, which revealed higher urinary levels of pyruvate 
isonicotinylhydrazone and β-glucosyl isonicotinylhydrazide and lower levels of 
acetylisoniazid compared to CNS non-responders. This suggested that the 
capacity for acetylation of INH was lower in CNS responders, leading to increased 
metabolism via conjugation with pyruvate and glucose. In addition, the 
endogenous metabolic profile of CNS responders revealed higher urinary levels 
of lactate and glucose, in comparison to CNS non-responders. 
Pharmacometabonomic analysis of the pre-dose 1H NMR urinary spectra 
identified a metabolic signature that correlated with the development of INH-
induced adverse CNS effects and may represent a means of predicting adverse 
events and acetylation capacity when challenged with high dose INH. Given the 
widespread use of INH for the treatment of tuberculosis, this 
pharmacometabonomic screening approach may have translational potential for 
patient stratification to minimize adverse events. 
